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ABSTRACT 
 
The prevalence of retinal dystrophies among people with European 
ancestry is 1 in 3500-4000. Large majority of these conditions are caused 
by mutations in single genes inherited in autosomal recessive, autosomal 
dominant, X-linked recessive or mitochondrial fashion. Identification of the 
genotype and elucidation of the phenotype of these disorders help in 
improving the understanding of the pathophysiology and eventually 
devising novel management strategies. This thesis concentrated on 
autosomal dominant retinal dystrophies caused by mono-allelic mutations. 
The overall prevalence of the different genotypes causing autosomal 
dominant retinitis pigmentosa in the British population was explored. The 
consequence on the retinal structure (fundus examination, spectral 
domain optical coherence tomography, fundus autofluorescence imaging) 
and visual function (visual acuity, perimetry, electrophysiology) of the 
patients with novel mutations in the RHO, PRPF31, PRPH2, NR2E3 and 
IMPDH1 genes were considered. The genotypes and the phenotypes of 
retinitis pigmentosa due to RP1 mutations were explored which provided 
insight into the understanding of the natural history of the disorder. Intra-
familial variability and reduced penetrance are phenomena observed in 
families with inherited retinal disorders. In families with PRPF8 mutations, 
these observations were identified and studied. All dominant alleles appear 
first in families as a de novo mutation. Families with de novo mutations 
within the dominant GUCY2D and semi-dominant CHM genes were 
examined which enhanced current knowledge on the counselling of 
patients with these conditions. In addition, families with mono-allelic 
mutations in the RPE65 gene were analysed and unique phenotypes 
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determined. Overall, results presented in this thesis contribute to an 
understanding of Mendelian dominant retinal disease that enhances our 
knowledge of the variability and natural history of the phenotypes. 
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1 INTRODUCTION 
 
1.1 THE RETINA 
 
“In the study of this membrane [the retina], I for the first time felt my 
faith in Darwinism (hypothesis of natural selection) weakened, being 
amazed and confounded by the supreme constructive ingenuity revealed 
not only in the retina and in the dioptric apparatus of the vertebrates but 
even in the meanest insect eye.” 
Santiago Ramón y Cajal 
 
The human eye is a highly specialised extension of the brain which acts as 
a sensory organ enabling the sensation of vision. The eye is comprised of 
three coats (tunics) from outside inwards, the corneoscleral coat, the uveal 
coat and the neural layer or the retina. 
The retina is the tissue where light from the object of interest forms an 
image after undergoing refractive changes in the various media of the 
eyeball. It extends from the optic nerve head posteriorly to the ora serrata, 
its anterior junction with the pars plana, a part of the ciliary body. Lying 
in between the temporal vascular arcades of the retina is an oval 
specialized region called the macula lutea, so called because of the yellow 
colouration of the region due to presence of macular pigment (Snodderly 
et al., 1984). Macular pigment is mainly composed of hydroxycarotenoids 
like lutein and zeaxanthin (Bone et al., 1997). The centre of macular lutea 
is exclusively formed of cone photoreceptors and is called the fovea 
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centralis which is responsible for colour vision and provides the highest 
visual acuity (Provis et al., 2005).  
Figure 1-1: Fundus photograph of the human retina showing the fovea 
and the macula lutea. 
 
Within the fovea centralis, a small central region is devoid of any capillaries 
called the foveal avascular zone. 
Figure 1-2: Fluorescein angiogram of the macula of a healthy subject 
demonstrating dark foveal avascular zone. (Laatikainen and Larinkari, 
1977) 
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Embryologically, the retina develops from two closely apposed 
neuroectodermal cell monolayers. The inner layer develops into a 
multilayer meshwork of the neurosensory retina while the outer layer stays 
as a single layer of the retinal pigment epithelium (Galli-Resta et al., 2008). 
In a cross section, the neurosensory retina has the following histologic 
layers from outside inwards: 
The rod and cone inner and outer segments 
External limiting membrane 
Outer nuclear layer 
Outer plexiform layer 
Inner nuclear layer 
Inner plexiform layer 
Ganglion cell layer 
Nerve fibre layer 
Internal limiting membrane 
Figure 1-3: Immunostaining of mouse retina. ONL – outer nuclear layer, 
OPL – Outer plexiform layer, INL – Inner nuclear layer, IPL – Inner 
plexiform layer, GCL – Ganglion cell layer. Modified from (Hoon et al., 
2014) 
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1.1.1 THE NEUROSENSORY RETINA 
 
The simplistic view of the neurosensory retina is that of an organisation 
consisting of three levels of neural cells arranged as a series electrical 
circuit. The light has to pass through all the layers of the retina to reach 
the outer most layer of the neurosensory retina, the photoreceptors. 
Stimulated photoreceptors pass the information as an hyperpolarisation 
event to the next level of neurons, the bipolar cells from where it is passed 
to the second level of neurons, the ganglion cells. The axons of the 
ganglion cells form the nerve fibre layer and eventually these neurons 
carry the information along the optic nerve into the brain. These three 
cells are the predominant participants in forming of the histological layers 
of the retina. These layers of the neurosensory retina are actually a 
meshwork of different specialised cells including photoreceptors, bipolar 
cells, ganglion cells, horizontal cells, amacrine cells and various glial cells.  
The cell bodies of the bipolar, horizontal and amacrine cells contribute to 
the inner nuclear layer of the retina while the photoreceptor cell bodies 
form the outer nuclear layer. The plexiform layers are formed by the 
dendrites, axons and the various ribbon synapses between different neural 
cells, with contributions from ganglion cells, bipolar cells, horizontal cells, 
amacrine cells and the photoreceptors. Ganglion cell bodies form the 
ganglion cell layer while the axons of these cells form the nerve fibre layer. 
 
Introduction 
25 
 
Figure 1-4: Simplified illustration of retinal anatomy. C-Cones, R-Rods, H-
Horizontal cell, MB, FB, RB-Different types of bipolar cells, A-Amacrine 
cell, MG, DG-Different types of ganglion cells. Modified from (Dowling 
and Boycott, 1966) 
 
1.1.1.1 The photoreceptors – rods and cones 
 
The photoreceptors are highly specialized neuro-epithelial cells which 
convert the energy from the incident photon into electrical energy. There 
are two types of photoreceptors, the rods and the cones. There are about 
120 million rods in the retina with rods outnumbering the cones by 20:1. 
Each photoreceptor cell has four distinct parts – the outer segment, the 
inner segment, the cell body and the synaptic terminal. (Nilsson, 1985) 
(Figure 1-5) 
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Figure 1-5: Basic organization of a vertebrate photoreceptor. Adapted 
from (Young, 1976) 
 
The outer segment of the rods contains discrete multiple laminated disks 
not attached to the cell membrane and a central connecting cilium which 
has a “9 plus 0” cross-sectional configuration. The cone outer segments 
are similar except that they are conical ellipsoids and the disks are 
attached to the cell membrane. Preservation of the structure of 
photoreceptor outer segments is important for the functioning of the retina 
as the visual pigments reside in the membranous disks. Disorganization of 
the outer segment structure can be an indicator of retinal degeneration as 
observed in patients with retinitis pigmentosa (RP). (Humphries et al., 
1997, Yamashita et al., 2009)  
As the outer segment of the photoreceptor does not have any significant 
organelles, it cannot synthesize the proteins and membranes that it 
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requires for its function, phototransduction. So, the proteins have to be 
transferred at high flow rates through the connecting cilium which acts as 
the conduit. The connecting cilium is a specialized structure trafficking 
protein from the inner segment containing the translational machinery to 
the outer segment. This non-motile structure is anchored to a basal body 
in the inner segment and also plays critical role in outer segment disk 
morphogenesis.(Ramamurthy and Cayouette, 2009)  
There are more than 1000 different proteins that have been identified in 
the connecting cilium making it one of the most complex structures. 
(Gherman et al., 2006) Mutations in genes encoding these proteins 
involved in ciliogenesis or protein transport to the outer segment lead to 
photoreceptor degeneration. This is evidenced in several disorders like RP 
(Gao et al., 2002, Liu et al., 2004, Connell et al., 1991, Adams et al., 2007, 
Moore et al., 2006), Usher syndrome (Williams, 2008, Reiners et al., 2006, 
Weil et al., 1995, Liu et al., 1999) and Bardet Biedl syndrome. (Blacque 
and Leroux, 2006, Tobin and Beales, 2007, Leroux, 2007, Nachury et al., 
2007, Hartong et al., 2006) 
Rod photoreceptors saturate at lower intensities of light and are 
responsible for vision in dim illumination while cones are 25-100 times less 
sensitive, do not saturate even at high light intensities and are responsible 
for colour and photopic vision (Rodieck, 1998). There are three varieties 
of cones – L (Long), M (Medium) and S (Short) classified on the basis of 
their maximum spectral sensitivity (λmax). Spectral sensitivity is the relative 
efficiency of detection of light as a function of its wavelength. The λmax for 
L-cones is 563 nm, M-cones is 532 nm and S-cones is between 417-420 
nm (Bowmaker and Hunt, 2006, Stockman et al., 1999). λmax for the more 
abundant rod opsin, also called rhodopsin is 495 nm. 
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Rhodopsin is a membrane protein present in the rod outer segment (ROS) 
discs which is attached to a vitamin A derived chromophore 11-cis retinal. 
Incidence of a single photon on 11-cis retinal results in its 
photoisomerization and generates activated rhodopsin (Metarhodopsin II). 
Metarhodopsin II activates a G-protein transducin, which in turn stimulates 
the activity of its effector enzyme phosphodiesterase (PDE). PDE catalyzes 
hydrolysis of cGMP to 5’-noncyclic GMP and decreases the concentration 
of cGMP. Low cGMP concentration closes the cGMP gated cationic channel 
hyperpolarizing the cell membrane. In dark, rhodopsin is inactivated by 
phosphorylation catalysed by rhodopsin kinase. Intrinsic GTPase 
inactivates transducin which in turn inactivates PDE. Guanylate cyclase 
(GC), stimulated by low Ca2+ ion concentration due to closure of the 
cationic channel, synthesizes cGMP from GTP increasing its concentration 
and opening the channel. Guanylate cyclase is assisted in this reaction by 
guanylate cyclase assisting proteins (GCAP). Opening of cationic channel 
depolarizes the membrane and releases neurotransmitter glutamate from 
rod synaptic terminals. This starts the neural signal for vision.(Arshavsky 
et al., 2002, Maeda et al., 2003) These series of reactions form the 
phototransduction cascade. (Figure 1-6)  
Qualitatively, cone phototransduction resembles that of rods. It is, 
however, comparatively insensitive to low intensities of light but is fast 
and capable of adapting to the ambient levels of illumination to a much 
higher degree. 
Mutations in the rod and cone phototransduction cascade can give rise to 
retinal disease. Within rod phototransduction pathway, mutations in 
rhodopsin, PDE and GC can cause RP while mutations in GCAP cause 
autosomal dominant cone dystrophy. Similarly, mutations in cone opsins 
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OPN1LW and OPN1MW express congenital red-green colour vision defects 
(Carroll et al., 2012). 
Figure 1-6: The phototransduction cascade. Adapted from (Zimmerman, 
1995). R-Rhodopsin, R*-Activated rhodopsin, GT-GDP-Transducin, GT-
GTP-Activated transducin, PDE-Phosphodiesterase, PDE*-Activated PDE, 
GC-Guanylate cyclise 
 
1.1.1.2 The inner nuclear layer 
 
The inner nuclear layer is formed by the cell bodies of three different types 
of cells – the bipolar cells, the horizontal cells and the amacrine cells.  
 
1.1.1.2.1 The bipolar cell 
 
The photoreceptors make synaptic connections with bipolar cells that in 
turn form synapses with ganglion cells. Functionally, there are at least two 
different types of bipolar cells, the ON-bipolar cell and the OFF-bipolar 
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cells. They are so called because of ON-bipolar cells are inhibited in 
response to glutamate release by cone synapses while the OFF-bipolars 
are stimulated. As light hyperpolarizes the cones and hence, inhibits 
glutamate release, ON-bipolars are stimulated (switched on) by light while 
the OFF-bipolars are inhibited (switched off). The cones synapse with both 
ON- and OFF-bipolar cells while the rods synapse only with ON-bipolar 
cells. In the fovea, a single cone synapses with single bipolar cell but in 
the periphery one cone can synapse with many different bipolar cells. 
However, this view might be too simplistic and it is believed that there are 
at least 9-11 different types of cone-driven bipolar cells in every 
mammalian retina (Masland, 2001b). 
Dysfunction in the bipolar cell function due to mutations in genes like 
TRPM1 can cause congenital stationary night blindness (CSNB) (Zeitz et 
al., 2015). 
 
1.1.1.2.2 The horizontal and the amacrine cells 
 
Horizontal cells receive stimulus from the photoreceptors and also provide 
inhibitory feedback. Once stimulated by a cone, the horizontal cell 
suppresses the feeder cone as well as the cones surrounding it. This 
‘centre-surround’ prevents spread of the stimulus as one cone can be 
connected to multiple ganglion cells through multiple bipolar cells 
(Masland, 2001a). 
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Figure 1-7: Different types of cells in the retina. Adapted from (Masland, 
2001b). From the top row to the bottom, photoreceptors, horizontal 
cells, bipolar cells, amacrine cells and ganglion cells. 
 
There are at least 29 different types of amacrine cells. Although the 
function of every amacrine cell is not known, they are believed to be 
performing specific functions like global adjustment of retinal response to 
bright light (Masland, 2001a). 
 
1.1.1.3 The ganglion cell 
 
The ganglion cell is the final common pathway for the retinal input to reach 
brain. Traditionally, classified as OFF- and ON-ganglion cells, it is now 
believed that there are about 10-15 types of ganglion cell types all of which 
receive input from bipolar cells.(Masland, 2001a) The axons of the 
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ganglion cells form the optic nerve which terminates in the lateral 
geniculate nucleus. 
 
1.1.1.4 The glia 
 
Müller cells form the main glial element in the retina. These cells extend 
from the inner segments of the photoreceptors to the internal limiting 
membrane, which is formed by their end feet. Besides playing a structural 
role, they form the external limiting membrane and participate in buffering 
the ionic concentrations in the extracellular space. The other glial cells 
observed in the retina are microglia and macroglia (astrocytes, 
oligodendroglia, Schwann’s cells). These cells respond to injury, provide 
physical support and maintain the ionic composition of extracellular space. 
 
1.1.2 THE RETINAL PIGMENT EPITHELIUM 
 
The retinal pigment epithelium (RPE) consists of single layer of polygonal 
cells resting on a basement membrane. These epithelial cells have a basal 
zone which contains the nucleus and an apical zone which is in connection 
with the photoreceptors' outer segments. In the apical zone, a series of 
cytoplasmic expansions start from the cell body and partially envelop the 
outer segment of the photoreceptors for about one-third of their length 
(Bairati and Orzalesi, 1963). This close interaction between the RPE and 
photoreceptors is critical for the maintenance of visual function. It 
facilitates the transfer of retinoids between photoreceptors and the RPE 
which is required for the visual cycle and the maintenance of 
photoreceptor excitability.  
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As discussed earlier, rhodopsin is activated on absorption of a photon. This 
is achieved by isomerization of 11-cis retinal to all-trans retinal. 
Restoration of photoexcitability of rhodopsin is accomplished by converting 
all-trans retinal back to 11-cis retinal. The multi-enzyme pathway 
performing this role is called the visual cycle (Palczewski and Saari, 1997). 
In photoreceptor outer segments, all-trans retinal is converted to all-trans 
retinol by all-trans retinal dehydrogenase. All-trans retinol is transported 
out of photoreceptors into the RPE with the help of inter-photoreceptor 
retinoid-binding protein (IRBP) present abundantly between the 
photoreceptor outer segments and the RPE apical cytoplasmic extensions 
(Jin et al., 2009). In the RPE, all-trans retinol is esterified by lecithin retinol 
acyltransferase (LRAT) and then hydrolysed and isomerised to 11-cis 
retinol by Rpe65 Isomerase. Finally, 11-cis retinol is oxidized to 11-cis 
retinal by 11-cis retinal dehydrogenase (RDH5) which is transported back 
to the photoreceptors assisted by IRBP. (Figure 1-8) 
Mutations in these proteins have been described to cause inherited retinal 
dystrophies like Leber’s congenital amaurosis (LCA) (Thompson et al., 
2001, Marlhens et al., 1997, Marlhens et al., 1998), autosomal recessive 
RP (den Hollander et al., 2009) and fundus albipunctatus (Yamamoto et 
al., 1999). For example, mutations in the gene ABCA4 cause Stargardt’s 
macular dystrophy, that in RDH12, LRAT and RPE65 cause LCA (Janecke 
et al., 2004, Thompson et al., 2001, Gu et al., 1997) while RGR mutations 
have been implicated in autosomal recessive RP (Morimura et al., 1999). 
Mutations in RLBP1 and RDH5, both genes participant in the visual cycle 
cause fundus albipunctatus phenotype. 
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Figure 1-8: The visual cycle. Adapted from (Jin et al., 2009). RAL-Retinal, 
ROL-Retinol, IRBP-Interphotoreceptor retinoid-binding protein, RE-
Retinol ester, IPM-Interphotoreceptor matrix, RDH-Retinal 
dehydrogenase 
 
Recently, as a therapeutic approach, gene therapy has been attempted to 
patients with LCA due to mutations in the RPE65 gene (Bainbridge et al., 
2008, Cideciyan et al., 2008, Maguire et al., 2008). The phenotype of the 
retinal dystrophy consequent upon deficiency of RPE65 protein has unique 
characteristics like retention of useful visual function and presence of non-
functioning photoreceptors early in childhood. Recombinant adeno-
associated virus (aav) vector was used to transfect the RPE with human 
RPE65 coding sequence. The results of these trials demonstrated gene 
therapy to be a safe procedure showing modest improvement in the visual 
status of the treated eyes. 
The cytoplasmic expansions of the RPE also assist in phagocytosis of the 
shed tips of the outer segments of photoreceptors, a process essential for 
photoreceptor survival. These phagocytosed products, once internalized 
form phagosome and are transported to the basal part of the RPE where 
they are degraded. (Kevany and Palczewski, 2010) Lipofuscin is formed 
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from the cellular debris, breakdown of which is difficult for the RPE 
machinery. In the retina, this autofluorescent material is formed as a result 
of incomplete digestion of the outer segment (OS) in the RPE (Wolf, 2003). 
Lipofuscin is converted to A2E, a retinoid toxic to the RPE cells due to its 
ability to produce free radicals. This mechanism has been hypothesized to 
be the underlying cause for disorders like macular degeneration. The 
inherent fluorescence of the lipofuscin can be utilized to document the 
general health of the RPE using confocal scanning laser ophthalmoscope 
(von Ruckmann et al., 1995b). 
The basal surface of the RPE lays on the Bruch’s membrane, which 
separates the RPE from the choriocapillaris, a layer of fenestrated 
capillaries. The RPE transports nutrients from the blood to the retina and 
transports ions, water and waste products from the sub-retinal space to 
the blood (Futter, 2006) 
The RPE is so called due to the presence of pigment granules in its 
cytoplasm. These granules contain melanin and are predominantly located 
in the apical and mid-portions of the cell. The exact role of melanin in the 
RPE is not clear. It plays the role of neutral density filter in scattering light. 
Melanin is also believed to play a role in retinal development as the albino 
mammals with disorders of melanin pathways have under-developed 
retinas. Similarly, in patients with ocular or oculo-cutaneous albinism 
reduced visual acuity is observed with associated foveal hypoplasia. 
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1.2 RELEVANT MOLECULAR BIOLOGY OF THE CELL 
 
“And now the announcement of Watson and Crick about DNA. This is for 
me the real proof of the existence of God.” 
Salvador Dali 
 
1.2.1 THE CENTRAL DOGMA OF MOLECULAR BIOLOGY 
 
In the year 1953, James D Watson and Francis H Crick elucidated the 
structure of deoxyribonucleic acid (DNA) which paved the way for 
significant developments in molecular biology thereafter (Watson and 
Crick, 1953). Once the structure of DNA was understood, an explanation 
was needed on its function. Francis Crick in 1958 argued that the sole 
function of DNA is to carry information for protein synthesis (Crick, 1958). 
He proposed that information, meaning precise determination of 
sequence, once passed onto proteins cannot get out. In other words, 
transfer of information from nucleic acid to nucleic acid or from nucleic 
acid to protein may be possible but transfer from protein to protein or 
protein to nucleic acid is not (Crick, 1958). This theory was called the 
central dogma. The theory was further refined later, on discoveries that 
DNA can be formed from ribonucleic acid (RNA) and that a single RNA 
molecule can rarely give rise to more RNA molecules (Crick, 1970). Recent 
discoveries have shown that this simplistic linear view of the central dogma 
does not fully explain the complexities of the higher eukaryotic biological 
systems. Large numbers of RNA molecules can be transcribed from the 
genomic DNA that does not carry any information for protein formation 
(Mattick, 2003). These ‘non-protein-coding RNAs’ derived from the introns 
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of protein coding genes or from the whole of non-protein-coding genes or 
from intergenic regions may play important roles regulating or modulating 
the functional processes undergoing in specific cells. In these cases at 
least, the information carried by the DNA is not meant solely for protein 
formation. 
 
1.2.2 TRANSCRIPTION 
 
The unit of heredity responsible for transferring a trait from individuals to 
their offspring is called a gene (Pearson, 2006). Genes were presumed to 
be pieces of DNA containing information to form a single protein. Recent 
advances in RNA biology have completely changed our understanding of 
a gene and it is proving difficult to impart a physical form to the abstract 
concept of a gene (Pearson, 2006). Not only that some RNA takes up 
infrastructural roles (e.g., ribosomal or transfer RNAs) which directly or 
indirectly facilitate protein coding; large amounts of RNA molecules are 
manufactured from the DNA template which have roles hitherto unknown 
(Mattick, 2003).  
In the protein coding scheme, the first step in which the double-stranded 
DNA molecule gives rise to a single-stranded RNA molecule is called the 
transcription. The catalyst for this reaction in humans is RNA polymerase 
II (Pol II) which is a globular protein having active sites for DNA template 
and channels for nucleotide access and RNA exit (Moore and Proudfoot, 
2009). This process involves initiation when Pol II binds to a site upstream 
to desired starting point of the gene. This region is called the promoter. 
In most eukaryotic genes, the promoter region consists of a TATA box 
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consisting of a consensus sequence of TATTAA about 25-35 bases 
upstream from the initiation site (Figure 1-9).  
 
1.2.2.1 Transcription factors 
 
Pol II utilises several co-factors, the transcription factors, during its 
function. These proteins bind to the cis-regulatory DNA sequences and 
thus, influence the expression of a gene positively or negatively. Besides 
promoter regions described above, transcription factors also bind to 
regions called the enhancers which can lie upstream, downstream or 
within the introns of a gene (Figure 1-9). The main mode of action of the 
transcription factors is to bind to specific DNA sequences and alter its own 
three-dimensional conformation. This change exposes or hides other 
functional domains within itself which recruits or binds other transcription 
factors. The function of whole transcription machinery is to modulate gene 
expression by enhancing or reducing the process of transcription. 
There are about 3000 transcription factors in humans (Phillips and Hoopes, 
2008). All transcription factors have at least two domains – a DNA-binding 
domain and a Trans-activating domain (Latchman, 1997). The 
transcription factors are classified into different families on the basis of the 
tertiary structure of its DNA-binding domain. The Trans-activating domain 
interacts with trans-elements like other transcription factors or co-factors. 
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Figure 1-9: Transcription machinery. Modified from (Levine and Tjian, 
2003) TATA-TATA box, INR-Initiator, DPE-Downstream promoter 
elements 
 
Nucleotide sequence and genomic organization of the transcription factors 
are relatively conserved through evolution (Coolen et al., 2005). Sequence 
alteration of the transcription factors hamper their functionality and can 
have profound phenotypic consequences. For example, amino acid 
substitution S50T in the trans-activating domain of transcription factor NRL 
results in autosomal dominant retinitis pigmentosa (Bessant et al., 1999). 
So far, at least three transcription factors, CRX, NRL and NR2E3 have been 
implicated in causation of autosomal dominant retinitis pigmentosa 
(Daiger et al., 1998).  
 
1.2.3 SPLICING 
 
At the end of transcription, the molecule that is generated is called the 
primary transcript, a faithful copy of the DNA template from which it is 
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formed. This molecule undergoes a series of processing reactions which 
result in the formation of the final mature mRNA. In most eukaryotes, the 
three major RNA processing reactions include splicing, capping and 
polyadenylation. Capping involves covalent bonding of 7-methylguanosine 
to the 5’ most nucleotide of the primary transcript by a 5’-5’ 
phosphodiester bond. Polyadenylation is the process of addition of around 
200 adenylate (AMP) residues at the 3’ end of the RNA transcript. 
However, the process which exerts the most profound influence in 
changing the primary transcript to the mature mRNA is splicing.  
Splicing is a series of reactions where the sections of the transcript carrying 
the genetic information, called exons are separated from the sequence 
carrying no coding information, called introns. The exons are identified, 
clipped out and finally re-joined to form the mature mRNA. The process of 
splicing involves cleavage of the 5’ end of an intron which usually begins 
with nucleotides GU. The cut end of the intron then attaches itself to a 
conserved adenylate (A) of another region called the branch point located 
between 18-40 nucleotides upstream from the 3’ end of the intron. This 
forms a loop called the lariat. The final step is cleavage of the 3’ end of 
the intron usually containing the dinucleotide AG and covalent bonding of 
the two exons (Clancy, 2008) (Figure 1-10). A protein-RNA complex called 
the spliceosome mediates the whole splicing machinery. 
A defect in the splicing machinery is responsible for several types of retinal 
dystrophies. For example, monoallelic mutations in PRPF3, PRPF4, PRPF6, 
PRPF8, PRPF31 and SNRNP200, all of which encode splicing factors are 
implicated in autosomal dominant retininitis pigmentosa (Chakarova et al., 
2002, Tanackovic et al., 2011a, McKie et al., 2001, Vithana et al., 2001, 
Benaglio et al., 2011, Chen et al., 2014). It is still not clear why defects in 
a ubiquitous process affect the retina predominantly. There can be few 
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possible explanations. The retinal protein machinery is high performing 
leading to high demands on splicing which results in splicing defects 
causing early dysfunction. Splicing factors may have to fulfil a completely 
unidentified function in the retina or splicing factors may produce retina 
specific transcripts which are critical to retinal function. (Faustino and 
Cooper, 2003) 
Figure 1-10: Lariat formation in splicing Modified from (Konarska et al., 
1985). L1 and L2 represent the exons while IVS (A) represents the spliced 
intron. 
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1.3 AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA 
 
1.3.1 HISTORY 
 
“To suppose that the eye with all its inimitable contrivances for adjusting 
the focus to different distances, for admitting different amounts of light, 
and for the correction of spherical and chromatic aberration, could have 
been formed by natural selection, seems, I freely confess, absurd in the 
highest degree.” 
Charles Darwin 
 
In 1857, Franciscus Cornelius Donders, a Dutch military doctor coined the 
term ‘Retinitis pigmentosa’ (RP) for a condition of progressive loss of visual 
fields (Donders, 1857). He believed this disorder was due to an 
inflammatory cause. Two years after the publication of Donders’ work, the 
seminal work of Charles Darwin, ‘The Origin of Species’ was published 
which changed the science of heredity and evolution forever. Around the 
same time (1856-1863), an Augustinian priest, Gregor Johann Mendel was 
experimenting on plant hybridization on nearly 30,000 pea plants at St. 
Thomas’ Abbey, Brno. Mendel read his paper at the meetings of Natural 
History Society of Brünn in 1865 where he laid down the two general laws 
of inheritance, the law of segregation and the law of independent 
assortment which are the basis of modern genetics (Mendel, 1866). Four 
years later, in 1869, a German ophthalmologist, Theodor Karl Gustav von 
Leber made an important observation whilst working at the Ilvesheim 
Institute for the blind. He reported an ‘intrauterine’ form of RP where 
affected children have nystagmus, photophobia and extremely poor visual 
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function (Leber, 1869). He called it ‘amaurosis congenita’ which later came 
to be known as Leber’s congenital amaurosis (LCA). 
While Mendel’s laws elucidated the modes of inheritance, the first 
description of a human disease with Mendelian inheritance pattern was 
reported by William Bateson and Sir Archibald Garrod in 1902 when they 
suggested recessive inheritance for alkaptonuria (Dunwell, 2007, Prasad 
and Galbraith, 2005, Garrod, 2002). William Bateson, a botanist with no 
medical qualifications is widely regarded as the person most responsible 
to spread the ideas of Mendel after they were rediscovered independently 
and almost simultaneously by three workers, Hugo De Vries, Carl Correns 
and Eric von Tschermak in the year 1900 (Harper, 2005, De Vries, 1900, 
Correns, 1900, Tschermak, 1900). Bateson collaborated with renowned 
ophthalmologist Edward Nettleship and together they described the 
genetics of many ophthalmic disorders for the first time (Harper, 2005, 
Rushton, 2000). In his book ‘Mendel's principles of heredity’, Bateson 
describes aniridia, congenital cataract, ectopia lentis and one family of 
stationary night blindness as autosomal dominant disorders while most 
families of stationary night blindness and colour blindness were called ‘sex-
limited’ (Bateson, 1909). Nettleship published large pedigrees of families 
with RP demonstrating Mendelian modes of inheritance in the disorder 
(Jay and Phil, 1983, Nettleship, 1907). 
RP is now believed to be heterogeneous group of progressive retinal 
disorders which can be transmitted in autosomal dominant (30-40%), 
autosomal recessive (50-60%) and X-linked (5-15%) fashion (Bunker et 
al., 1984, Grondahl, 1987). Rare cases of digenic inheritance have been 
reported (Kajiwara et al., 1994). Similarly, rare instances of mitochondrial 
DNA mutations causing RP have also been described (Mansergh et al., 
1999). 
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Linkage, a tendency of characters to be co-inherited through generations 
was first proposed by Morgan following his experiments with Drosophila 
in his famous ‘fly room’ (Morgan, 1910). In 1911, Wilson pointed out for 
the first time in humans that colour-blindness could be linked to the X 
chromosome (Wilson, 1911). In 1972, the complete sequence of a gene 
from bacteriophage was determined for the first time (Min Jou et al., 
1972). Within the next few years, complete nucleotide sequences of 
several human genes were identified (Kerem et al., 1989, Baralle, 1977, 
Spritz et al., 1980). Finally, in the year 1990, 133 years after the disease 
got its name; first disease causing mutation to cause autosomal dominant 
RP was identified in a large Irish family using linkage and candidate gene 
analysis (Dryja et al., 1990b). The gene, Rhodopsin is believed to be the 
commonest cause of autosomal dominant RP (Sullivan et al., 2006a, 
Hartong et al., 2006). 
 
1.3.2 MOLECULAR GENETICS 
 
Currently, mutations in 26 genes have been implicated to cause autosomal 
dominant RP (adRP) (RetNet) (Table 1-1). 
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Table 1-1: Genes encoding proteins mutation in which causes adRP 
Function Gene 
Membrane 
protein 
Rhodopsin (RHO) 
Peripherin 2 (retinal degeneration, slow) (RDS/PRPH2) 
Retinal outer segment membrane protein 1 (ROM1) 
Sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short cytoplasmic 
domain, (semaphorin) 4A (SEMA4A) 
Olfactory receptor, family 2, subfamily W, member 3 
(OR2W3) 
Structural protein Retinitis pigmentosa 1 (oxygen-regulated protein 1) 
(RP1) 
Fascin homolog 2, actin-bundling protein, retinal 
(Strongylocentrotus purpuratus) (FSCN2) 
Splicing factors Pre-mRNA processing factor 3 (PRPF3) 
Pre-mRNA processing factor 4 (PRPF4) 
Pre-mRNA processing factor 6 (PRPF6) 
Pre-mRNA processing factor 8 (PRPF8) 
Pre-mRNA processing factor 31 (PRPF31) 
Retinitis pigmentosa 9 (Pim-1 kinase associated protein) 
(RP9) 
Small nuclear ribonucleoprotein 200kDa (U5) 
(SNRNP200) 
Transcription 
factors 
Cone-rod homeobox (CRX) 
Neural retina leucine zipper (NRL) 
Nuclear receptor subfamily 2, group E, member 3 
(NR2E3) 
Enzymes Inosine 5'-monophosphate dehydrogenase 1 (IMPDH1) 
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Carbonic anhydrase IV (CA4) 
Retinol dehydrogenase 12 (all-trans/9-cis/11-cis) 
(RDH12) 
Hexokinase 1 (HK1) 
Nuclear protein Retinal pigment epithelium-specific protein 65kDa 
(RPE65) 
Ubiquitination Topoisomerase I binding, arginine/serine-rich (TOPORS) 
 Kelch-like 7 (Drosophila) (KLHL7) 
Signalling Guanylate cyclase activator 1B (retina) (GUCA1B) 
Voltage gated ion 
channels 
Bestrophin 1 (BEST1) 
 
Molecular genetics of the commonest causes of adRP is discussed below. 
Figure 1-11: Relative contribution of different genes to RP. Adapted from 
(Hartong et al., 2006) 
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1.3.2.1 RHO (MIM +180380) 
 
Locus – 3q21-q24 
This gene encodes Rhodopsin, the visual pigment present in rod outer 
segments. First cloned in 1984, the main function of Rhodopsin is to 
absorb light and to instigate the phototransduction cascade which results 
in the neural signal for vision (Nathans and Hogness, 1984). It is a 
membrane protein with 7 trans-membrane domains, 3 cytoplasmic and 3 
intradiscal loops (Figure 1-12). The chromophore retinal attaches itself to 
Lysine-296 of the seventh trans-membrane domain (Palczewski et al., 
2000). The RHO gene is expressed solely in rod photoreceptors. 
RHO was the first gene demonstrated to have a missense mutation 
segregating with adRP (Dryja et al., 1990b). Since then, more than 100 
different mutations have been identified in RHO contributing to the largest 
number of adRP patients. A classification of the missense mutations has 
been proposed on the basis of the behaviour of the mutant protein 
(Mendes et al., 2005). 
Figure 1-12: Schematic structure of Rhodopsin molecule showing seven 
trans-membrane domains and intradiscal and cytoplasmic loops. 
Introduction 
48 
 
Table 1-2: Classification of missense mutations in RHO. Adapted from 
(Mendes et al., 2005) 
 
The phenotype of the patients with RHO mutations can be grouped into 
three categories within limits of intra-familial and extra-familial variability. 
Cideciyan and colleagues classified these adRP families into Class A and 
Class B (Cideciyan et al., 1998). 
Patients in Class A present with night blindness and decreasing visual fields 
in early life. Ophthalmic examination shows progressive generalised retinal 
dystrophy with intraretinal pigmentation, narrowing of the arterioles and 
pale optic discs (Jacobson et al., 1991). These patients have severe 
generalised rod-cone dystrophy on electrophysiology.  
Class B patients have sectoral RP. The affected individuals are either 
asymptomatic or have very mild symptoms of night blindness. The 
intraretinal pigmentation and narrowing of arterioles are usually limited to 
inferior part of the retina. In the patients with true sector RP, the 
dystrophy does not progress to involve the rest of the healthy retina. 
These patients were classified as Class B1. The Class B2 families show 
progression and the dystrophy is characterised by generalised dysfunction 
on electrophysiology. Specific mutations in RHO, which may play a role in 
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glycosylation of the protein, have been implicated to cause true sector RP 
(Tam and Moritz, 2009).  
Recently, a third phenotype was described in a French family (Audo et al., 
2010b). The younger members showed focal photoreceptor or RPE 
abnormality in the posterior pole with patchy chorioretinal atrophy which 
were of larger size in the older members. Electrophysiological 
abnormalities consistent with generalised rod dysfunction were noted. 
RHO mutations have also been associated with other retinal dystrophies 
like congenital stationary night blindness (Dryja et al., 1993, Rao et al., 
1994, al-Jandal et al., 1999, Zeitz et al., 2008) and autosomal recessive 
RP (arRP) (Rosenfeld et al., 1992, Kumaramanickavel et al., 1994, Azam 
et al., 2009, Kartasasmita et al., 2011). Interestingly, all the families with 
arRP have homozygous mutations in RHO while the heterozygous carriers 
were unaffected. 
 
1.3.2.2 RP1 (MIM *603937) 
 
Locus – 8q11-q13 
In 1999, three groups working independently, identified the RP1 gene and 
associated it with adRP (Pierce et al., 1999, Sullivan et al., 1999, 
Guillonneau et al., 1999). Rp1 protein is expressed exclusively in the 
photoreceptors and is a microtubule-associated ciliary protein (Liu et al., 
2002, Liu et al., 2004). All the mutations causing adRP in this gene are 
truncating and limited to a hotspot in the terminal exon (Berson et al., 
2001). However, in families from China and Japan, stop mutation 
c.Arg1933Ter near the C-terminal of the RP1 protein causing truncation of 
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the protein had no deleterious effect (Baum et al., 2001, Kawamura et al., 
2004). In other words, haploinsufficiency of the C-terminal 224 amino 
acids of RP1 does not cause RP (Baum et al., 2001). 
Studies exploring the phenotype of families with RP1 mutations showed 
that reduction of rod photoreceptor function was much worse than that of 
cones. There was evidence of apparent non-penetrance within the families 
but even in these asymptomatic individuals, loss of photoreceptor function 
could be demonstrated on electrophysiology. Visual acuities remained near 
normal in most patients until late in life (Bowne et al., 1999, Jacobson et 
al., 2000, Payne et al., 2000). 
Homozygous frameshift mutations as well as biallelic mutations in the RP1 
gene have been shown to cause autosomal recessive (ar) RP in several 
families (Khaliq et al., 2005, Riazuddin et al., 2005, El Shamieh et al., 
2015). Although detailed phenotypic data is not available for these 
patients, they were night blind and lost central vision before 20 years of 
age. Electrophysiology showed a severe rod-cone dystrophy with early 
macular dysfunction (El Shamieh et al., 2015). 
 
1.3.2.3 PRPF31 (MIM *606419) 
 
Locus – 19q13.4 
This gene identified in 1996, encodes a protein with 20% homology with 
S. cerevisiae pre-mRNA splicing gene Prp31 (Weidenhammer et al., 1996). 
This level of sequence identity to the yeast genes suggested this highly 
conserved protein to be involved in pre-mRNA splicing. PRPF31 works as 
a part of the U4 complex of the spliceosome complex. 
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PRPF31 was associated with RP11 locus in 2001 when mutations were 
identified in four families and three individuals with adRP (Vithana et al., 
2001). The adRP families associated with RP11 locus were known to have 
incomplete penetrance in an ‘all or none’ manner, where gene carriers 
displayed either fully symptomatic phenotype or completely asymptomatic 
phenotype (McGee et al., 1997). It was demonstrated that the wild type 
allele can have high or low expressivity and dictate the phenotype in the 
individual with the mutation. Because most of the missense PRPF31 
mutations described so far are null alleles and wild type high expressing 
allele is identified in all the nonpenetrant mutation carriers, decreased 
gene dosage as a consequence of haploinsufficiency is likely to be the 
explanation for the nonpenetrance (Rivolta et al., 2006, Vithana et al., 
2003). Another group showed by linkage analysis that PRPF31 expression 
was significantly associated with one expression quantitative trait locus on 
chromosome 14q21-23 which might offer explanation of non-penetrance 
in some of these families (Rio Frio et al., 2008). 
 
1.3.2.4 PRPF8 (MIM *607300) 
 
Locus – 17p13.3 
Cloned in 1999, this gene encodes a protein with 86% homology with the 
nematode protein and 62% with the yeast protein (Luo et al., 1999). It is 
a component of both the major U2 and minor U12-dependent spliceosome. 
As with all the splicing factors, this gene is expressed ubiquitously. 
Mutations in this gene, the first splicing factor associated with adRP were 
identified in seven families in 2001 (McKie et al., 2001). Mutations in 
PRPF8 have been described as causing a severe form of adRP with most 
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of the affected subjects having onset of night blindness in the first or 
second decade of life (Towns et al., 2010). The phenotype caused by Prp8 
mutations in yeast correlates with the severity of RP caused by their 
human equivalent mutations. 
 
1.3.2.5 PRPF3 (MIM *607301) 
 
Locus – 1q21.2 
In 1997, PRPF3 gene was identified and it was described to be a splicing 
factor associated with U4/U6-U5 tri-snRNPs and U4/U6 snRNP (Lauber et 
al., 1997, Wang et al., 1997, Horowitz et al., 1997). 
The adRP RP18 locus was associated with the PRPF3 gene and mutations 
in the gene were identified in several families (Chakarova et al., 2002). 
Three mutations described so far (p.Thr494Met, p.Pro493Ser, and 
p.Ala489Asp) have been localized to a small region in exon 11 of the gene 
making it a mutational hotspot (Gamundi et al., 2008). 
Although variability in the adRP phenotype due to mutations in PRPF3 have 
been described (Vaclavik et al., 2010), the majority of the patients have 
an early onset of night blindness, severe visual field constriction, loss of 
central vision between the fourth and fifth decade, and a flat 
electroretinogram after the age of 30 (Wada et al., 2004, Inglehearn et 
al., 1998, Xu et al., 1996). 
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1.3.2.6 PRPF6 (MIM #613983) 
 
Locus – 20q13.33 
PRPF6 was identified as a splicing factor in the year 2000 as a protein with 
29% identity and 48% similarity at the amino acid level with the yeast 
equivalent splicing factor Prp6p (Makarov et al., 2000). During the 
formation of the spliceosome, this protein mediates the assembly of 
U4/U6.U5 complex (the tri-snRNP). PRPF6 acts as a molecular bridge 
between the U5 snRNP and U4/U6 snRNP (the di-snRNP) which helps is 
formation of the tri-snRNP (Tanackovic et al., 2011a). 
This splicing factor gene has recently been implicated in causing adRP on 
the basis of mutation screening (Tanackovic et al., 2011a). In the only 
family affected by the disorder, two brothers carried the mutation 
p.Arg729Trp in the PRPF6 gene. The phenotype described is identical to 
that of typical retinitis pigmentosa with loss of peripheral vision, night 
blindness, arteriolar attenuation and optic disc pallor. 
 
1.3.2.7 RP9 (MIM *607331) 
 
Locus – 7p14.2 
In the year 2000, Maita et al cloned the RP9 gene (Maita et al., 2000). 
RP9 was observed to localize in nuclear speckles containing the splicing 
factor SC35 and to interact with another splicing factor, U2AF35. Later, it 
was observed to be associated with PRPF3 in a tri-SNP spliceosome 
complex associating it with splicing. (Maita et al., 2004, Maita et al., 2005) 
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Only two mutations have been identified in this gene so far, both 
implicated in adRP (Keen et al., 2002). The disease expresses variably 
within these families with presence of asymptomatic obligate mutation 
carriers who showed mild phenotype only on electrophysiology (Kim et al., 
1995). 
 
1.3.2.8 SNRNP200 (MIM *601664) 
 
Locus – 2q11.2 
A U5-specific 200-kD protein was cloned in 1996 and was later shown to 
play a central role in pre-mRNA splicing (Lauber et al., 1996, Zhang et al., 
2009).  
Mutations in this gene were initially demonstrated to cause adRP in the 
Chinese families (Zhao et al., 2009, Li et al., 2010, Zhang et al., 2013, Liu 
et al., 2012). Recently, more families of North American descent were 
identified carrying mutations in the SNRNP200 gene (Benaglio et al., 
2011). The phenotype of the disorder is that of typical retinitis pigmentosa. 
The onset of disease is in early teen age years with progressive loss of rod 
and cone function. During the fourth decade, the patients have severe loss 
of visual function with undetectable cone or rod responses on 
electrophysiology.  
 
1.3.2.9 PRPF4 (MIM *607795) 
 
Locus – 9q32 
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First cloned in the year 1997, this splicing factor gene encodes one of 
several proteins that associate with U4 and U6 snRNPs (Lauber et al., 
1997). As with other splicing factors, this protein is ubiquitously expressed 
(Chen et al., 2014). 
Recently, mutations in PRPF4 have been implicated in autosomal dominant 
retinitis pigmentosa (Chen et al., 2014, Linder et al., 2014). The affected 
patients have shown variable expressivity but all showed intra-retinal 
pigment migration, pale optic discs and narrow retinal vessels. 
 
1.3.2.10 RDS/PRPH2 (MIM *179605) 
 
Locus – 6p21.1-cen 
In 1991, using a probe derived from the coding region of the mouse Rds 
cDNA, human RDS was cloned (Travis et al., 1991a). The encoded protein 
is a membrane-associated glycoprotein localized to photoreceptor outer 
segment discs. It plays a role in stabilization of the outer segment discs 
(Travis et al., 1991b). 
Mutation in RDS/PRPH2 gene was shown to cause adRP in a large Irish 
family for the first time in 1993 (Farrar et al., 1993). Other groups 
demonstrated a variety of phenotypes caused by RDS mutations like adRP, 
macular dystrophy, retinitis punctata albescens, pattern dystrophy, central 
areolar choroidal dystrophy, cone-rod dystrophy and adult-onset 
vitelliform macular dystrophy (Travis and Hepler, 1993, Nichols et al., 
1993a, Nichols et al., 1993b, Wells et al., 1993, Nakazawa et al., 1996). 
Most mutations are associated with a particular phenotype consistently, 
for example p.Cys118del causes adRP. However, multiple phenotypes 
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have also been described within the same family (Weleber et al., 1993, 
Aleman et al., 2009). 
 
1.3.2.11 IMPDH1 (MIM +146690) 
 
Locus – 7q31.3-q32 
Inosine monophosphate dehydrogenase (IMPDH) was cloned in 1988 
using a polyclonal antibody directed against the purified protein (Collart 
and Huberman, 1988). There are two IMPDH isozymes – I and II. Only 
IMPDH1 is expressed by the photoreceptors, although most mammalian 
cells express both the isozymes (Jain et al., 2004, Bowne et al., 2006a). 
IMPDH catalyses a key step in guanine nucleotide biosynthesis catalyzing 
the conversion of Insoine monophosphate to xanthosine monophosphate 
(Hedstrom, 1999). 
Several missense mutations have been demonstrated to be associated 
with the adRP phenotype (Kennan et al., 2002, Bowne et al., 2002). Bowne 
et al associated the locus LCA11 with IMPDH1 by demonstrating two 
families with missense changes (Bowne et al., 2006a). The enzymatic 
activity of IMPDH in retinal dystrophy patients is within normal range and 
it is proposed that an additional nucleic acid binding role is being played 
by the protein. Impairment of this binding may be the cause of 
photoreceptor degeneration in adRP (Hedstrom, 2008). 
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1.3.2.12 TOPORS (MIM *609507) 
 
Locus – 9p21 
Human TOPORS was cloned in 2001 when it was designated as LUN (Chu 
et al., 2001). Although the exact function of TOPORS protein is unknown, 
it binds to DNA topoisomerase I and p53 and plays a role in ubiquitination 
and sumoylation (Zhou et al., 1999, Rajendra et al., 2004). Recently, it 
has been demonstrated that TOPORS protein localizes to the basal body 
of the photoreceptor connecting cilium and may play a role in the 
regulation of the functioning of the primary cilium (Chakarova et al., 
2011). 
In 2007, mutations in TOPORS were associated with adRP (Chakarova et 
al., 2007). The phenotype was distinct in that the younger members had 
perivascular cuff of retinal pigment epithelial atrophy, surrounding the 
superior and inferior arcades. This progressed to diffuse pigmentary 
retinopathy in older subjects (Chakarova et al., 2007, Bowne et al., 2008, 
Selmer et al., 2009). 
 
1.3.2.13 KLHL7 (MIM *611119) 
 
Locus – 7p15.3 
This ubiquitously expressed gene was first cloned in humans in 2006 
although subsequently more transcripts have been identified (Bredholt et 
al., 2006, Friedman et al., 2009). Although the physiological function of 
the encoded protein Klhl7 is unknown, it is a member of BTB family 
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proteins that are associated with the ubiquitin-proteasome pathway of 
protein degradation (Perez-Torrado et al., 2006). 
Friedman et al linked KLHL7 to adRP by discovering four families of 
European descent with three mutations in the gene (Friedman et al., 
2009). The phenotype of one of these families showed progressive 
generalised rod-cone dystrophy with young members having milder 
involvement than the older individuals (Hugosson et al., 2010) 
 
1.3.2.14 CRX (MIM +602225) 
 
Locus – 19q13.3 
Cloned in 1997, CRX functions as a transcription factor for several retinal 
genes (Freund et al., 1997). CRX is expressed exclusively in the retina by 
the photoreceptors and the cells of the inner nuclear layer (Furukawa et 
al., 1999).  
Three different phenotypes have been associated with mutations in CRX, 
autosomal dominant cone-rod dystrophy, Leber’s congenital amaurosis 
and adRP (Sohocki et al., 1998, Sullivan et al., 2006a). After summarising 
all the mutations in CRX, Rivolta et al failed to find an association between 
the mutation and the phenotype. Interestingly, they observed relatively 
high proportion of CRX mutations being de novo (4/18). (Rivolta et al., 
2001) 
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1.3.2.15 NR2E3 (MIM *604485) 
 
Locus – 15q23 
NR2E3 is also a transcription factor mainly expressed in the retina that 
was cloned in 1999 (Kobayashi et al., 1999, Haider et al., 2000, Cheng et 
al., 2004). NR2E3 is believed to interact with NRL, another transcription 
factor, to suppress cone-specific gene expression and to activate a subset 
of rod-specific genes (Cheng et al., 2004). (Figure 1-13) 
Primarily implicated to cause enhanced S-cone syndrome, only one 
missense change (p.Gly56Arg) in this gene has been described to cause 
adRP (Haider et al., 2000, Coppieters et al., 2007). 
 
1.3.2.16 NRL (MIM +162080) 
 
Locus – 14q11.1-q11.2 
Another transcription factor implicated in adRP, NRL was first identified in 
1992 (Swaroop et al., 1992). The present understanding of the interaction 
between the transcription factors NRL and NR2E3 is such that NRL 
stimulates NR2E3 to suppress cone-specific gene expression and stimulate 
rod-specific gene expression (Figure 1-13). 
NRL was associated with adRP in 1999 when a missense change was 
identified at the highly conserved codon 50 (Bessant et al., 1999). Since 
then several missense changes have been identified in NRL which cause 
adRP, all limited to affecting three highly conserved codons 50, 51 and 
122 (Nishiguchi et al., 2004). Functional analysis of these amino-acids 
have shown that they lie within minimal transactivation domain (codon 50 
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and 51) or the hinge domain (codon 122) which interact with TATA-
binding protein at the promoter of target genes (Friedman et al., 2004, 
Kanda et al., 2007).  
The patients with these mutations have rod-cone dystrophy with severely 
reduced scotopic electroretinogram within the first two decades of life. 
They also have peri-papillary atrophy and may develop bull-eye macular 
atrophy later in life (Bessant et al., 2003). Interestingly, recessive NRL 
mutations are associated with a phenotype resembling enhanced S-cone 
syndrome (Nishiguchi et al., 2004).  
Figure 1-13: Photoreceptor differentiation. Retinal progenitor cells (RPC) 
develop into post-mitotic cells (PMC) which generate cone precursors or 
rod precursors. NRL stimulates NR2E3 to suppress cone generation and 
stimulate rod generation. Adapted from (Mears et al., 2001) 
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1.3.2.17 RDH12 (MIM *608830) 
 
Locus – 14q23.3 
Cloned in 2002 by Haeseleer at al, the exact role this retinol 
dehydrogenase plays in photoreceptor cells is not known (Haeseleer et al., 
2002). In the mouse retina, Rdh12 detoxifies 4-hydroxynonenal, a toxic 
product of lipid peroxidation and protects photoreceptors from light-
induced apoptosis (Marchette et al., 2010). 
Primarily implicated in Leber’s congenital amaurosis, the RDH12 gene has 
been associated with adRP in only one family (Fingert et al., 2008). 
 
1.3.2.18 RPE65 (MIM *180069) 
 
Locus – 1p31.3-p31.2 
This RPE65 protein was first characterised in 1993 by Hamel et al (Hamel 
et al., 1993) while the gene RPE65 was cloned two years later (Nicoletti 
et al., 1995). This was the first retinal pigment epithelium specific gene to 
be characterised.  
The expressed RPE65 protein acts as a molecular chaperone (Xue et al., 
2004). In its membrane-associated form, RPE65 acts as a chaperone for 
all-trans-retinyl esters and is palmitoylated. In its soluble form, it is not 
palmitoylated and acts as a chaperone for vitamin A.  
The predominant phenotype of patients with biallelic mutations in the 
RPE65 gene is that of early onset retinitis pigmentosa or Leber’s congenital 
amaurosis (Marlhens et al., 1997, Gu et al., 1997). Recently, a dominant 
Introduction 
62 
 
phenotype caused by monoallelic mutations in the RPE65 gene was 
described (Bowne et al., 2011). These patients had a distinct phenotype 
of extensive chorioretinal atrophy and variable intraretinal pigmentation. 
 
1.3.2.19 CA4 (MIM *114760) 
 
Locus – 17q23.1 
This gene was first implicated in adRP when the mutation p.R14W was 
identified in 2 South African families (Rebello et al., 2004). 2 other 
mutations, p.R69H and p.A12T in the same gene were identified by 
different groups in a selection of Chinese adRP families (Alvarez et al., 
2007, Tian et al., 2010). However, the original sequence variant p.R14W 
was identified in 6 of 143 normal Swedish controls casting doubt in its 
validity as a pathogenic variant (Kohn et al., 2008). 
 
1.3.2.20 ROM1 (MIM *180721) 
 
Locus – 11q12.3 
This gene has only been identified to be involved in causation of adRP in 
a digenic fashion in association with the PRPH2 gene (Kajiwara et al., 
1994). In patients of these families, existence of the sequence variant 
alone in either of the genes did not cause pathology although some of the 
patients did have reduction in the electroretinogram amplitudes. 
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1.3.2.21 SEMA4A (MIM *607292) 
 
Locus – 1q22 
This gene was implicated in adRP in 1 Pakistani family by direct mutation 
screening (Abid et al., 2006). In animal studies, it has been shown that 
point mutations in this gene cause retinal degeneration in homozygous 
conditions (Nojima et al., 2013). 
 
1.3.2.22 FSCN2 (MIM *607643) 
 
Locus – 17q25.3 
This gene was implicated in causing adRP in 4 unrelated Japanese families 
each showing presence of c.208delG mutation (Wada et al., 2001). 
However, in Chinese, Spanish, Italian and North American populations, 
this change has been identified as benign polymorphism casting doubt on 
the causation of adRP by the gene FSCN2 (Gamundi et al., 2005, Ziviello 
et al., 2005, Sullivan et al., 2006a, Zhang et al., 2007). 
 
1.3.2.23 GUCA1B (MIM *602275) 
 
Locus – 6p21.1 
This gene has been associated with adRP in 3 unrelated Japanese families 
all of whom exhibited p.G157R mutation (Sato et al., 2005b). However, in 
2 large screenings of retinal dystrophy families with European and North 
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American ancestry, no pathogenic variants could be identified (Payne et 
al., 1999, Kitiratschky et al., 2011). 
 
1.3.2.24 BEST 1 (MIM *607854) 
 
Locus – 11q12.3 
This gene has been associated with autosomal dominant infantile 
vitelliform macular dystrophy since 1998 (Petrukhin et al., 1998). More 
recently, other phenotypes have been identified with mono or biallelic 
mutations in the BEST1 gene (Kramer et al., 2000, Burgess et al., 2008). 
Davidson et al reported 5 adRP families, 4 of European descent and 1 of 
Pakistani origin with mutations in the BEST1 gene (Davidson et al., 2009). 
The phenotypes described were highly variable varying from 
predominantly macular involvement to advanced peripheral intraretinal 
pigmentation. 
 
1.3.2.25 HK1 (MIM *142600) 
 
Locus – 10q22.1 
Hexokinase (HK) is an enzyme participating in catalysis of the first step of 
glucose metabolism, phosphorylation of glucose to glucose-6-phosphate 
using ATP. Of the 4 different types, HK1, HK2, HK3 and HK4, HK1 is most 
ubiquitously expressed and is the predominant isozyme in brain, 
erythrocytes and lymphocytes (Bianchi et al., 1997). There is no clear cut 
explanation of why mutation in a ubiquitous enzyme causes dominant 
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retinitis pigmentosa. It is postulated that HK1 may possess unique, yet 
unidentified functions exclusively in the retina (Sullivan et al., 2014). 
Recently, one missense mutation in HK1, p.Glu847Lys, has been 
associated with adRP in six different families with four different ancestries 
(Wang et al., 2014, Sullivan et al., 2014). The affected individuals had 
variable phenotypes with some remaining asymptomatic until the fifth 
decade of life. Most showed signs of typical adRP with attenuated vessels, 
pale optic discs and intra-retinal pigment migration.  
 
1.3.2.26 OR2W3 (MIM *616729) 
 
Locus – 1q44 
Recently, OR2W3, an olfactory receptor gene has been associated with 
adRP in two independent families of Chinese origin. The single mutation 
p.Arg142Trp was identified using linkage and whole exome sequencing 
methods. OR2W3 expresses in retinal pigment epithelial cells and the 
encoded protein is believed to have multiple functions in addition to its 
role in olfaction (Ma et al., 2015). Interestingly, OR2W3 shares exons with 
a much larger gene TRIM58 with yet unknown function while the encoded 
protein shares sequence identity with JAG1, a gene associated with Alagille 
syndrome. 
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1.4 AIMS OF THE STUDY 
 
Retinal dystrophies are the most heterogeneous of the inherited eye 
disorders. Although all the modes of Mendelian and non-Mendelian 
inheritance patterns are observed, this study will mainly concentrate on 
the patients with autosomal dominant retinal dystrophies. Genotype and 
phenotype correlations continue to be observed, although accurate clinical 
data on large cohorts of molecularly characterised patients remains to be 
collected. 
Moorfields eye hospital (MEH) maintains a large inherited eye disorder 
database which contains molecular data of patients with known mutations. 
A significant number of families either have novel mutations in the known 
genes or mutations in genes that have not yet been identified. In the 
inherited retinal diseases clinic of MEH, new families are being examined 
regularly. The resource of families with dominantly inherited retinal 
degeneration is powerful, is growing and will form the basis of this thesis. 
The main aims of this project are: 
 To identify the families and individuals with known and unknown 
molecular diagnosis 
 To design an extended algorithm for the analysis of mutations in 
known genes so that changes that would be missed so far in 
standard clinical testing can be identified 
 To evaluate the phenotype of individuals and families with a known 
molecular diagnosis 
 To determine the longitudinal natural history of families for whom 
retrospective data is available 
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2 MATERIALS AND METHODS 
 
2.1 STUDY SUBJECTS 
 
2.1.1 ETHICAL APPROVAL AND CONSENT 
 
This study adhered to the tenets of the Declaration of Helsinki and was 
approved by the Moorfields and Whittington Hospitals Ethics Committee 
(WEBA1006; 05/Q0504/38). 
Fully informed consent was obtained from all the individuals involved in 
this study. 
 
2.1.2 CONTROL PANEL 
 
The control population screened for this study was 98 apparently normal, 
randomly selected British Caucasian donors (Human random control DNA 
panel 2, Health protection agency culture collections, Salisbury, UK)(Crick, 
1958). The RP1 gene was sequenced in the control panel in order to 
ascertain the pathogenicity of the variations identified. 
 
2.1.3 AFFECTED SUBJECTS 
 
A panel of all families carrying the diagnosis of adRP was collected by using 
an SQL query in the Inherited Eye Disease database maintained at 
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Moorfields eye hospital (MEH). Blood samples from one proband of each 
family were included in the study. Samples were ascertained from other 
family members for segregation studies, where deemed necessary. 
 
2.2 PHENOTYPING 
 
2.2.1 HISTORY AND CLINICAL EXAMINATION 
 
Patients were examined in the Genetics clinic, Medical retina firm, MEH 
under the supervision of Prof. Andrew Webster. Clinical information has 
also been collected retrospectively from MEH electronic databases and 
clinical and genetic notes. 
 
2.2.1.1 History 
 
A full clinical history was obtained including age of onset, symptoms at 
presentation like night blindness, difficulty in bright light or reduced 
peripheral vision, age of diagnosis, if any and progression of the 
symptoms. Particular visual difficulties in bright or dim illumination, 
symptoms of visual field impairment, difficulties in recognizing colours and 
presence of any refractive error were ascertained. Medical history was 
acquired and any other relevant drug history was noted. A family history 
was taken including a full pedigree with any history of consanguinity within 
the family and ethnicity. 
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2.2.1.2 Visual acuity 
 
The term ‘visual acuity’ was coined by Donders who defined it as a ratio 
between a subject’s performance and standard performance. In the year 
1862, Snellen published his famous letter chart, which was designed using 
special targets called optotypes. The Snellen visual acuity test is still the 
most commonly used test of visual acuity.  
The test involves a chart with rows of letters of diminishing size. Each row 
is accorded a number which indicates the distance at which a person with 
normal visual acuity should correctly identify the letters. The visual acuity 
is recorded as a fraction in which the numerator denotes the distance at 
which the subject is able to resolve the letters while the denominator 
indicates the distance at which a normal person should correctly identify 
the row. Normal vision is 6/6. 
The other chart used in this study was designed by Ian Bailey and Jan 
Lovie in 1976. The measure of visual acuity provided by this chart is known 
as LogMAR (Logarithm of the minimal angle of resolution). The range of 
visual acuity measurements in LogMAR charts is equivalent to Snellen 
acuities and vary from 0.0 (6/6) to 1.0 (6/60). 
In our study, patients underwent full ophthalmic examination including 
best–corrected visual acuities with Snellen chart which were converted to 
LogMAR values in some instances for ease of statistical analysis.  
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2.2.1.3 Colour vision 
 
In this study, colour vision was tested using the Ishihara 
pseudoisochromatic plates and/or the Hardy-Rand-Rittler plates (American 
Optical Co., New York, USA). 
 
2.2.1.3.1 Ishihara pseudoisochromatic plates 
 
These plates were designed to test red-green colour deficiency. There are 
24 pseudoisochromatic plates containing numerals and 1 test plate for 
demonstration of the visual task. 20 plates are for red-green screening 
which include 3 for subjects without numerical skills. The last 4 plates are 
for classification of red and green cone deficiencies (Figure 2-1). 
Figure 2-1: Ishihara colour test plates 
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2.2.1.3.2 Hardy-Rand-Rittler test (HRR) 
 
This test is designed to identify and to grade the severity of red (protan), 
green (deutan), and blue (tritan) colour vision defects. Its ability to detect 
tritan defects distinguishes it from the Ishihara test plates. There are 24 
plates which contain symbols of neutral colours increasing in saturation 
with successive plates of the test. There are 4 introductory plates, 6 plates 
for colour vision screening, and 14 plates for grading the severity of 
protan, deutan and tritan defects (Figure 2-2). 
Figure 2-2: HRR colour test plates. 
 
2.2.1.4 Fundoscopy  
 
Purkinje was probably the first to observe the pupillary ‘red reflex’ and 
wrote that when light was thrown at the eye “the whole pupil lit up in a 
beautiful orange colour” (Thau, 1942). Although Charles Babbage, an 
English mathematician was the first to invent an ophthalmoscope, 
Hermann von Helmholtz’s effort proved to be the more popular instrument 
(Keeler, 1997, Wade, 2007). Christian Theodor Georg Ruete invented 
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indirect ophthalmoscopy in 1852 and in 1911, Allvar Gullstrand, one of the 
few Ophthalmologists to receive a Nobel prize, developed the slit lamp 
(Simonsz, 2004, Nordenson, 1962). 
In all our patients, slit-lamp biomicroscopy and fundoscopy were carried 
out after dilating the pupils.  
 
2.2.2 VISUAL FIELDS 
 
Visual field data were collected from the patients using Goldmann visual 
field or Esterman binocular visual field.  
 
2.2.2.1 Kinetic perimetry 
 
Kinetic perimetry is a method of plotting the visual field by moving the 
target from the non-seeing area towards the seeing area. By varying the 
size, luminosity and colour of the stimulus, various isopters are drawn to 
describe the subject’s visual field in detail. The kinetic perimeter used in 
our study was the Goldmann perimeter. Wherever available, Goldmann 
visual field data was used for subsequent analysis.  
Patients underwent Goldmann perimetry only if their best-corrected visual 
acuity was better than counting fingers and if their measured visual field 
could be reliably replicated on repeat testing. The testing was performed 
unilaterally with spectacle correction. The largest and the brightest target, 
V4e was used for all patients. If the V4e isopter was completed without 
difficulty then the III4e target was used and the field recorded. 
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2.2.2.2 Static perimetry 
 
During static perimetry, the target is not mobile. It tests the threshold of 
individual points in the retina by varying the luminosity of the target at 
each point. We used Esterman suprathreshold visual field in some patients. 
This data was used only to assess the progression of the disorder. This 
visual field testing was performed by visual field technicians of MEH. 
The visual field area contained within the V4e isopter was used for 
subsequent analysis. The field area was scanned electronically. A two 
dimensional planimetry package ‘Retinal area analysis tool’ designed by Dr 
A.S. Halfyard and Prof. H.W. Fitzke (2002) was used to calculate the area 
in square degrees.  
 
2.2.3 RETINAL IMAGING 
 
In the majority of cases, imaging was performed by medical 
photographers (Moorfields Eye Hospital Medical Illustration Department). 
 
2.2.3.1 Fundus photography 
 
This principle of fundus photography is the same as that used for indirect 
ophthalmoscopy. The images from digital fundus CCD cameras are high 
resolution and are stored as a digital dataset. The photographs are taken 
with the subject 2-3 cm away from the camera imaging at an angle of 30° 
creating a photograph about 2.5 times the original life size. Colour fundus 
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photography was performed using a Topcon TRC 50IA retinal camera 
(Topcon Corporation, Tokyo, Japan). 
 
2.2.3.2 Fundus autofluorescence imaging (FAF) 
 
FAF was developed at UCL Institute of Ophthalmology, London, UK using 
a confocal scanning laser ophthalmoscope (von Ruckmann et al., 1995a). 
The principle of the device is to detect autofluorescence signal from the 
retinoid fluorophores which mainly reside in the retinal pigment 
epithelium. Using scanning laser ophthalmoscope, a spatially coherent, 
low-divergence, narrow beam from a laser is delivered to the retina and 
the reflectance is detected and is converted to an image. A mean image 
is constructed superimposing several images together.  
FAF was carried out using SPECTRALIS HRA2 (Heidelberg Engineering, 
Heidelberg, Germany). An excitation filter of wavelength 488 nm and a 
cut-off filter of 500 nm wavelength are used. Two different fields of view, 
35° or 55° are captured using different lenses.  
The big advantage of FAF is ease of evaluation of the retinal pigment 
epithelial health using naturally occurring fluorescence as an indicator. 
Several studies have indicated a correlation between distinct FAF patterns 
and types of retinal dystrophy (Robson et al., 2006, Robson et al., 2004). 
In a normal FAF image (Figure 2-3), the optic disc appears black due to 
absence of retinal pigment epithelium. The foveal autofluorescence is 
reduced due to presence of the macular pigment, lutein and zeaxanthin, 
increased amount of melanin in the foveal retinal pigment epithelium and 
presence of foveal “blue light filter” (Subczynski et al., 2010). 
Material and methods 
75 
 
Figure 2-3: Normal fundus autofluorescence images - 30° on the left and 
55° on the right. 
 
2.2.3.3 Optical coherence tomography (OCT) 
 
The principle of OCT is to measure time delay and the magnitude of 
reflected infrared light from the retina resulting in generation of cross-
sectional or even three-dimensional images. First in vivo study using OCT 
was published in 1993 (Swanson et al., 1993) and OCT became 
commercially available soon after. Use of infrared light with a wavelength 
of around 820 nm improved the resolution of the images and removed the 
need for tissue contact with the imaging probe. Current OCT models can 
resolve up to 2μm (axial resolution) and by using Fourier transformation, 
a mathematical concept, has improved image acquisition speed and 
resolution significantly. With a significant increase in imaging speed, 
current OCT models can acquire up to 312,000 A-scans per second, 
making three-dimensional reconstructions possible. OCT data was 
obtained using a SPECTRALIS® Spectral-domain OCT (Heidelberg 
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Engineering, Germany) and/or a STRATUSOCT Model 3000 scanner (Zeiss 
Humphrey Instruments, Dublin, California, USA). 
Figure 2-4: OCT layers – adapted from (Srinivasan et al., 2008). NFL – 
Nerve fibre layer, GCL – Ganglion cell layer, IPL – Inner plexiform layer, 
INL – Inner nuclear layer, OPL – Outer plexiform layer, ONL – Outer 
nuclear layer, ELM – External limiting membrane, IS – Inner segment, OS 
– Outer segment, COS – Cone outer segment, ROS – Rod outer segment, 
COST – Cone outer segment tip, ROST – Rod outer segment tip, RPE – 
Retinal pigment epithelium, BM – Bruch’s membrane, CC – Choriocapillaris. 
 
The precise interpretation of all the layers of an OCT image of the retina 
is still being resolved. Improvements in axial resolution and image 
acquisition speed are still being developed. Similar to FAF, several studies 
have pointed out specific OCT image patterns and their correlation with 
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retinal conditions (Huang et al., 2000, Gloesmann et al., 2003). In this 
study, the OCT layers have been interpreted as Figure 2-4. 
 
2.2.4 ELECTROPHYSIOLOGY 
 
Electrophysiological assessment involved obtaining a full-field 
electroretinogram (ERG), a pattern ERG (pERG), and an electro-oculogram 
(EOG). Electrophysiological testing was performed in the MEH 
Electrophysiology Department and the results were interpreted and 
reported by Professor Graham E Holder or Dr Anthony G Robson. 
Table 2-1: Origins of components of ERG and pERG (Heckenlively and 
Arden, 2006) 
ERG waveform Cellular origin 
a – wave 
Dark adapted a – wave is primarily driven by rod 
photoreceptors; Light adapted a – wave in rod 
saturating background is cone driven 
b – wave Primarily reflects the activity of ON – bipolar cells 
d – wave 
Partly produced by depolarization of OFF – bipolar 
cells 
Photopic fast flicker 
Probably driven by post-receptoral cells of the 
cone system 
pERG Retinal ganglion cells 
 
All electrophysiological analyses were performed incorporating the 
published standards of the International Society for Clinical 
Electrophysiology of Vision (ISCEV) (Marmor et al., 2009, Bach et al., 
2013, McCulloch et al., 2015). 
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After 20 minutes of dark adaptation, full-field Ganzfeld stimulation was 
provided in order to ensure uniformity, full-field extension and correct 
luminance of the stimulus. White flashes of increasing intensities between 
0.01 and 10.0 cd.s.m-2 were used to record dark adapted ERGs. The 
dimmest flash dark-adapted (DA) 0.01 ERG elicits rod-specific ERG 
response arising in the rod bipolar cells. 
The bright flash or DA 3.0 ERG is a mixed rod-cone response dominated 
by the rod system under scotopic conditions. The electronegative a-wave 
is generated by the photoreceptors and the positive b-wave dominated by 
the post-receptoral ON-bipolar cell activity. On the ascending limb of the 
b-wave, the small wavelets present are called the oscillatory potentials 
which are believed to arise from amacrine cells. 
A non-ISCEV standard additional red flash ERG was obtained to compare 
dark adapted cone and rod system function. In healthy individuals, the red 
flash ERG has an early cone component and later rod component.  
To record generalized photopic cone system function, 10 minutes light 
adaptation to a standard background (25 cd.s.m-2) was followed by 
recording the flicker ERG to a 30Hz flashing stimulus, the so called the 
Light adapted (LA) 3.0 flicker ERG. As temporal resolution of the rod 
system is lower than the cone system, this isolates the cone mediated 
activity. This response is dominated by the inner retinal cone-system 
activity. 
A stimulus of 3.0 cd.s.m-2 flash on a background illumination of 30 cd.m-2 
is used to elicit the single flash transient photopic ERG which was used to 
assess generalized light adapted cone function. The a-wave of this 
waveform partly represents the cone photoreceptor activity while the b-
wave reflects post phototransduction activity.  
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Non ISCEV standard ON–OFF ERGs were obtained using a long duration 
orange stimulus (560 cd.m-2, duration 200 ms) superimposed on a green 
light–adapting background (150 cd.m-2). This separates the cone ON-
bipolar cell activity from OFF-bipolar cell activity. The onset of the stimulus 
generates a positive polarity b-wave shaped largely by the cone ON 
pathway; the stimulus offset generates a positive polarity d-wave mainly 
arising from the cone OFF pathway (Table 2-1). 
Figure 2-5: ISCEV standard ERG. Adapted from (McCulloch et al., 2015) 
 
The normative data of the full-field ERGs have been published elsewhere 
(Robson et al., 2010) .  
The pERG is the response obtained by presenting an alternating black and 
white checkerboard of constant mean luminance to the central retina. 
Driven by the macular photoreceptors and other retinal cells, this response 
is largely generated at the ganglion cell level. This is a small response, 
typically about 2-8 µV in amplitude, which is largely influenced by the 
optics of the eye and also the integrity of photoreceptors, bipolar cells and 
retinal ganglion cells. It has a small initial negative component which peaks 
Material and methods 
80 
 
at about 35 ms (N35) followed by a larger positive component P50 at 
approximately 45 – 60 ms. This is followed by a large negative component 
N95 peaking at 90-100 ms.  
Table 2-2: Interpretation of the electrophysiological findings. Modified 
from (Sergouniotis, 2012) 
Electrophysiological changes Interpretation 
Reduced EOG light rise, normal 
ERG 
RPE dysfunction 
Reduced dark-adapted 0.01 ERG b-
wave and 11.0 ERG a-wave 
Rod photoreceptor dysfunction 
Reduced dark-adapted 0.01 ERG b-
wave, normal a-wave and markedly 
subnormal b-wave in dark-adapted 
11.0 ERG (electronegative) 
Postreceptoral (inner retinal) 
disease 
Normal dark-adapted 11.0 ERG, 
reduced light-adapted responses  
Cone photoreceptor dysfunction 
Normal full field ERG, abnormal 
pERG P50 or multifocal ERG 
Macular dysfunction 
Normal full field ERG, preserved 
pERG P50, abnormal pERG N95 
Ganglion cell dysfunction 
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2.3 MOLECULAR GENETIC METHODS 
 
2.3.1 STRATEGY FOR MUTATION DETECTION 
 
 
 
Initial screen for the most frequent alleles responsible for adRP was 
performed in the St. Mary's Hospital Academic Medicine Department, 
Manchester Academic Health Sciences Centre, University of Manchester, 
Manchester, UK as a service. The rest of the steps were performed by me 
in the laboratory of UCL Institute of Ophthalmology, London, UK. 
 
adRP family ascertained from the clinic
Initial screen of common alleles
No pathogenic mutation identified
Revisit pedigree and phenotype
Sequence mutational hotspot of RP1
MLPA for 
PRPF31
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2.3.2 STRATEGY FOR GENOTYPING 
 
 
 
2.3.3 DNA EXTRACTION 
 
Peripheral venous blood samples were collected in two 9ml sodium EDTA 
(Vacutainer) bottles and appropriately labelled. The samples were logged 
in the inherited eye disease database and stored at 4°C until DNA was 
extracted. The majority of blood samples were collected by Ms Genevieve 
Wright and Mrs Sophie Devery while most of DNA extraction was 
performed by Ms Bev Scott and Dr Naushin Waseem. 
 
 
DNA extraction
Primer design
Polymerase chain reaction (PCR)
Agarose gel electrophoresis
Purification of PCR products
Sequencing
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2.3.3.1 Principles of DNA extraction 
 
The cells in the blood sample were lysed with an anionic detergent. After 
lysis, RNase enzyme was used to digest the RNA in the sample. Proteins 
were salt precipitated and removed. Finally, the genomic DNA in the 
sample was recovered by precipitation with alcohol. The genomic DNA 
thus obtained was stored in -20°C for future use. Two different kits with 
the following protocols were used. 
 
2.3.3.2 Gentra® Puregene® blood kit (Qiagen, Hilden, Germany) 
 
The leukocyte-enriched buffy coat was prepared from the EDTA whole 
blood sample by centrifuging the sample at 2500 x g for 10 minutes at 
room temperature (15 – 25°C). The buffy coat was visible as the middle 
layer between the superficial clear plasma layer and the bottom layer of 
erythrocytes. 1 ml of buffy coat was extracted from 10 ml of centrifuged 
whole blood to harvest 10X enrichment. 3 ml of RBC lysis solution was 
mixed with 1 ml buffy coat and incubated for 10 minutes in room 
temperature. The mixture was centrifuged at 2000 x g for 5 minutes to 
pellet the leukocytes. Vortexing suspended the pellet in 200 µl solution to 
which 3 ml of cell lysis solution was added to lyse the cells. 15 µl of RNase 
A solution was added and the mixture was incubated for 15 minutes at 
37°C. It was incubated in ice for 3 minutes. 1 ml of protein precipitating 
solution was added and the mixture was centrifuged at 2000 x g for 5 
minutes. This precipitated the protein into a tight brown pellet. 3 ml of 
isopropanol was added to the supernatant, mixed and centrifuged at 2000 
x g for 3 minutes. Supernatant was discarded and 3 ml 70% ethanol was 
added and centrifuged for 1 min at 2000 x g. The supernatant was 
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discarded and the DNA pellet was air dried and finally dissolved in 300 µl 
DNA hydration solution and incubated for 1 hour at 65°C. 
 
2.3.3.3 Nucleon genomic DNA extraction kit (Tepnel 
Lifesciences, Manchester, UK) 
 
4 ml of Nucleon Reagent A was added to 1 ml of whole blood and vortexed 
for 4 minutes at room temperature. The mixture was centrifuged at 1300 
x g for 5 minutes. The supernatant was discarded and the pellet was 
suspended in 350 µl of Nucleon Reagent B to ensure that the detergent 
was fully dissolved. The mixture was incubated at 37°C for 10 minutes. 
2.5 µl of RNase A solution was added and the mixture was incubated at 
37°C for 30 minutes. To deproteinise the mixture, 100 µl of sodium 
perchlorate, 600 µl of chloroform and 150 µl of Nucleon resin was added. 
The mixture was centrifuged at 350 x g for 1 minute. 900 µl of absolute 
ethanol was added to 450 µl of the supernatant and centrifuged at 4000 
x g for 5 minutes. 1 ml of 70% alcohol was added to the DNA pellet and 
centrifuged. Finally, the DNA pellet was air dried and dissolved in TE 
buffer. 
 
2.3.4 PRIMER DESIGN 
 
The reference sequences were obtained from Ensembl genome database 
(Flicek et al., 2010). Primers were designed to anneal to the genomic 
sequence such that the coding region and the intron-exon boundaries are 
amplified within the DNA fragment. The primers had minimal secondary 
structure and no primer-dimer formation. The primers were limited to be 
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18-30 nucleotides length and the melting temperatures of the pair were 
matched as closely as possible. The properties of the primers were 
checked with OligoCalc (Kibbe, 2007) and the sequences were submitted 
to NCBI BLAST database (Altschul et al., 1997) to check specificity. The 
amplimer size was limited to 800 bp. 
 
2.3.5 POLYMERASE CHAIN REACTION 
 
Polymerase chain reaction (PCR) is method of amplifying small segments 
of DNA that has revolutionised molecular genetics (Kleppe et al., 1971, 
Mullis, 1990b, Mullis, 1990a). To permit such selective amplification, 
primers are designed complementary to specific regions either side of the 
area that requires amplification (amplimer). In the presence of a DNA 
polymerase, an enzyme that synthesizes DNA, and the four 
deoxynucleoside triphosphates, dATP, dCTP, dGTP and dTTP, the primers 
anneal to the denatured DNA and initiate the synthesis of new DNA strands 
complementary to the target sequence. This starts a chain reaction with 
newly synthesized DNA strands acting as templates for further DNA 
synthesis in subsequent cycles. The products of the PCR will include about 
105 copies of the desired amplimer after about 35 cycles of PCR. PCR was 
performed using MolTaq (Molzym, Bremen, Germany) DNA polymerase. 
The standard PCR cycling parameters used are described in Table 2-3. 
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Table 2-3: PCR cycling parameters 
Stage 
Temperature 
(°C) 
Time Cycle(s) 
Initial denaturation 94-95 3-5 minutes 1 
Denaturation 94-95 30-45seconds 
35 Annealing 50-70 30 seconds 
Extension 72 1 minute 
Final extension 72 5-7 minutes 1 
Hold 4 For ever 1 
 
The protocol used is elaborated in the manufacturer’s instructions (Table 
2-4). 
Occasionally, extra MgCl2 or DMSO up to 10% v/v was added to PCR 
reactions to enhance efficiency. For difficult or problematic PCR 
applications, different polymerases were used including BioTaq (Bioline) 
DNA polymerase, Platinum Taq DNA Polymerase High Fidelity (Invitrogen) 
or Platinum Pfx DNA Polymerase (Invitrogen), all according to the 
manufacturers’ instructions. 
 
Table 2-4: Molzym PCR protocol 
Component Volume Final concentration 
Buffer (1.5mM MgSO4) 3 µl 1X 
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Enhancer 0.3 µl (Molzym) 1.5 mM 
dNTP mixture 0.24 µl (Promega) 0.2 mM of dATP, dGTP, 
dCTP and dTTP 
Forward primer 1 µl 0.33 mM 
Reverse primer 1 µl 0.33 mM 
MolTaq polymerase 0.2 µl (5U/µl) 0.03 U/µl 
dH2O 23.26 µl  
DNA template 1 µl 10-50 ng/µl 
Total 30 µl  
 
2.3.6 AGAROSE GEL ELECTROPHORESIS 
 
Although it had been used to separate proteins earlier (Hammarlund and 
Rising, 1953), agarose gel electrophoresis was first used to separate, 
purify and isolate fragments of DNA in 1966 (Thorne, 1966). 2% w/v 
agarose gel was prepared by dissolving 2 gm of molecular grade agarose 
(Bio-Rad Laboratories, Berkeley, California, USA) in 100ml of 1X TBE buffer 
(Eppendorf, Hamburg, Germany). 5 µg of Ethidium bromide (Final 
concentration 0.5 µg/ml) (Flint and Harrington, 1972) was added to the 
mixture and the gel was set. To validate the amplified fragments of DNA 
following PCR, 3 µl of DNA was mixed with 2 µl of 1X loading dye (Bioline, 
London, UK) and placed in the wells of the agar gel along with standard 
size marker (Bioline, London, UK). The electrophoresis was performed at 
150mV for 30 minutes in 1X TBE buffer till the fragments were separate. 
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The separated fragments were visualized on a transilluminator (UV light 
of wavelength 210nm) and photographs were taken in a camera with 
orange filter (BioDoc-It 210, UVP, Upland, California, USA). 
 
2.3.7 PURIFICATION OF PCR PRODUCTS 
 
Once the correct size of the amplified PCR product was verified by agarose 
gel electrophoresis, the product was purified using vacuum-based 
Montage PCR96 cleanup kit (Millipore, Watford, UK). This used size 
exclusion separation method. 100 µl of PCR products were loaded into the 
wells of the MultiScreen96 PCR plate. Vacuum was applied at 24 inches Hg 
for 5-10 minutes till the wells had emptied. The samples were 
reconstituted with 100 µl of nuclease free water and vacuum was applied 
again. The samples were reconstituted with 100 µl of nuclease free water 
for the second time and mixed vigorously on a plate shaker for 5 minutes. 
The purified PCR products were pipetted out from each well and stored 
for future use. 
 
2.3.8 AUTOMATED DNA SEQUENCING 
 
Frederich Sanger’s method of dideoxy mediated chain-termination 
sequencing (Sanger et al., 1977a, Sanger et al., 1977b) was used to 
ascertain the nucleotide sequence of the PCR amplimer with BigDye® 
Terminator v3.1 (>500 bp) cycle sequencing kit (Applied Biosystems. 
Foster City, California, USA) bi-directionally. The protocol used for the 
sequencing reaction is described in Table 2-5.  
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Products following sequencing reaction were purified using Montage SEQ96 
Sequencing Reaction cleanup kit (Millipore, Watford, UK). 5 µl of the 
sequence reaction samples was diluted with 20 µl of Injection solution. 
The mixture was transferred into the wells of SEQ96 plate and vacuum of 
25 inches Hg was applied for 3-5 minutes until the solution was completely 
removed. 20 µl of Injection solution was added to each well again and the 
process was repeated. For the third time, 20 µl of Injection solution was 
used to suspend the sequence reaction samples by shaking them on a 
microplate shaker for 10 minutes. The purified products were transferred 
on to an injection plate. 
Table 2-5: PCR product sequencing reaction protocol 
Component Volume Concentration 
PCR product 1 µl 10-50 ng 
Primer 1 µl 1 µM 
Buffer (BigDye sequencing buffer) 2.5 µl 1X 
BigDye terminator 0.5 µl  
dH2O 5 µl  
Total 10 µl  
Table 2-6: Sequencing reaction cycle 
Temperature Time Cycles 
96°C 1 minute 1 
96°C 10 seconds 
25 50°C 5 seconds 
60°C 4 seconds 
4°C Hold For ever 
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The sequencing reaction cycle used is shown in Table 2-6. 48-capillary 
3730 DNA analyser (Applied Biosystems, Foster city, California, USA) was 
used to perform automated capillary electrophoresis.  
Seqman Pro software (Lasergene version 8.02 sequencing analysis 
software suite, DNAStar Inc., Madison, Wisconsin, USA) was used to 
compare electropherograms with those with the disease from control 
samples. Other softwares, Sequence Scanner Software v1.0 (Applied 
Biosystems, Foster city, California, USA) and Sequencher 4.10.1 (Gene 
Codes Corporation, Ann Arbor, USA) were also used for sequence analysis. 
 
2.3.9 MULTIPLEX LIGATION-DEPENDANT PROBE AMPLIFICATION (MLPA) 
 
Mainly used to detect copy number variations, this technique utilizes 
multiple probes of unique length that are hybridized to the target 
sequence. Each probe pair contains the same primer sequence at 3’ and 
5’ ends permitting their amplification in a single PCR reaction using a single 
primer pair. In MLPA, each probe pair hybridizes to the target close to one 
another permitting ligation. The ligated probe is then amplified. Amount 
of PCR product generated is dependent on successful ligation and reflects 
the number of target sequences (Schouten et al., 2002) (Figure 2-6) 
(http://www.applied-maths.com/applications/multiplex-ligation-
dependent-probe-amplification-mlpa-analysis)  
This technique was used to discover large deletions or insertions in the 
PRPF31 gene in families of adRP with incomplete penetrance where 
Sanger sequencing failed to find a mutation. The procedure was 
performed using the SALSA MLPA P235 Retinitis kit (MRC-Holland, 
Amsterdam, Netherlands).  
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Figure 2-6: Principles of MLPA 
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Table 2-7: Components in the SALSA MLPA Retinitis kit 
Component Ingredients 
SALSA MLPA 
Buffer 
KCl, Tris-HCl, EDTA, PEG-6000, oligonucleotides 
SALSA Ligase-
65 
Glycerol, BRIJ (0.05 %), EDTA, Beta-
Mercaptoethanol (0.1 %), KCl, Tris-HCl, Ligase-65 
enzyme (bacterial origin) 
Ligase Buffer A 
Nicotinamide Adenine Dinucleotide (NAD) 
(bacterial origin). 
Ligase Buffer B Tris-HCl, non-ionic detergents, MgCl2 
SALSA PCR 
Primer Mix 
Synthetic oligonucleotides with fluorescent dye 
(FAM, Cy5, IRD800, ROX or unlabeled), dNTPs, 
Tris-HCl, KCl, EDTA, BRIJ. 
SALSA 
Polymerase 
Glycerol, non-ionic detergents, EDTA, DTT (0.1 
%), KCl, Tris-HCl, 
Polymerase enzyme (bacterial origin). 
 
Table 2-8: Steps of MLPA and its protocol 
Reactions Temperature Time Steps 
DNA denaturation 98°C 
5 
minutes 
5 µl of DNA sample 
for denaturation 
 25°C pause 
Hybridisation 95°C 1 minute Mix 1.5 µl of MLPA 
buffer and 1.5 µl of 
probemix with 3 µl 
of denatured DNA 
for hybridisation 
 60°C 
16-20 
hours 
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Ligation 54°C pause Mix 25 µl of dH2O, 
3 µl of Ligase 
Buffer A, 3 µl of 
Ligase Buffer B and 
1 µl of Ligase-65 
enzyme to the 
hybridised DNA. 
 54°C 
15 
minutes 
 98°C 
5 
minutes 
 20°C pause 
PCR 95°C 
30 
seconds 
Add 4 µl of SALSA 
PCR buffer and 26 
µl of dH2O to 10 µl 
of ligation product. 
To it add 7.5 µl of 
dH2O, 2 µl of 
SALSA PCR primer 
mix and 0.5 µl of 
SALSA polymerase. 
Run the PCR for 35 
cycles. 
 60°C 
30 
seconds 
 72°C 
60 
seconds 
 72°C 
20 
minutes 
 15°C pause 
Capillary 
Electrophoresis 
86°C 
3 
minutes 
0.7 µl of PCR 
product, 0.3 µl of 
ROX or LIZ size 
standard and 9 µl 
of HiDi formamide 
is used in 3730 
DNA analyser (ABI, 
California, USA). 
 4°C 
2 
minutes 
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2.3.10 MICROSATELLITE MARKERS 
 
Microsatellites are di-, tri- or tetra-nucleotide repeats showing allelic 
polymorphisms that can be used to follow a chromosomal segment 
through a pedigree (Strachan and Read, 2004). First used in 1989, the 
commonest ones used are (CA) n repeats. They are highly informative and 
are distributed throughout the genome (Litt and Luty, 1989). 
Microsatellite markers for chromosome 17p (D17S799, D17S1876, 
D17S1791, D17S1828) were identified from Marshfield map (Broman et 
al., 1998) and the primers were obtained from ABI Prism Linkage Mapping 
Set version 2.5 (Applied Biosystems, Foster city, California, USA). PCR 
reactions were performed as follows (Table 2-9). 
Table 2-9: PCR reaction mix for microsatellites 
Component Volume 
Buffer (1.5mM MgSO4) 1.5 µl 
Enhancer (1.5 mM) 0.75 µl 
dNTP mixture (0.2 mM of dATP, dGTP, dCTP and 
dTTP) 
0.3 µl 
(Promega) 
Primer mix (5 µM of each primer) 0.6 µl 
Taq polymerase (5U/µl) 0.15 µl 
dH2O 10.7 µl 
DNA template (10-50 ng/µl) 1 µl 
Total 15 µl 
 
All four markers were multiplexed into a single reaction. The microsatellite 
markers labelled with dye FAM or VIC (D17S799, D17S1876 and 
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D17S1791) were diluted 1:20 while the marker labelled with dye NED 
(D17S1828) was diluted 1:10. 5 µl of diluted D17S799, D17S1791 and 
D17S1876 PCR products and 10 µl of diluted D17S1828 PCR product were 
pooled. 0.5 µl of pooled PCR products was mixed with 0.5 µl of LIZ as size 
standard and 9 µl of HiDi formamide. The mixture was incubated at 95°C 
for 5 minutes and then rapidly cooled in ice before loading for genotyping. 
3730 DNA analyser (Applied Biosystems, Foster city, California, USA) was 
used to genotype the region. Genotyping analysis was performed using 
GeneMapper software (version 4.1; Applied Biosystems, Foster city, 
California, USA). 
Table 2-10: PCR conditions for the microsatellite markers 
Stage Temperature Time Cycle(s) 
Initial 
denaturation 
94°C 2 minutes 1 
Denaturation 95°C 1 minute 
30 Annealing 55°C 45 seconds 
Extension 72°C 45 seconds 
Final extension 72°C 10 minutes 1 
Hold 4°C For ever 1 
 
2.3.11 BIOINFORMATICS 
 
In order to ascertain the pathogenicity of the single nucleotide variations 
identified by genetic analysis, an in-silico approach was adopted. An 
online tool CONDEL (Gonzalez-Perez and Lopez-Bigas, 2011) was 
utilised which combines the results of SIFT (Kumar et al., 2009), Polyphen-
2 (PPH2) (Adzhubei et al., 2010), Mutation assessor (MA) (Reva et al., 
2011) and Functional analysis of hidden Markov models (FATHMM) 
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(Shihab et al., 2015). SIFT algorithm estimates the conservation of an 
amino acid through evolution using sequence alignment. A SIFT value of 
<0.05 indicates changes damaging to the protein function. In addition to 
sequence alignment methods, PPH2 evaluates the effect of the mutation 
on protein structure and estimates the evolutionary role. A PPH2 value of 
≥1 indicates pathogenicity. MA uses a different algorithm to assess the 
evolutionary conservation of amino acids in a protein. FATHMM uses the 
mathematical concept of ‘Hidden Markov Model’ to add pathogenicity 
weights to protein sequences and domains. To further analyse the 
variations identified, presence of these missense changes were searched 
in two large databases – Exome Variant Server (EVS) and Exome 
Aggregation Consortium browser (ExAC). EVS contains whole exome 
analysis data from 2203 African-American and 4300 European American 
individuals (EVS, 2015). Similarly ExAC contained data obtained from 
large scale exome sequencing of 60706 individuals (ExAC, 2015). 
Absence of the missense changes in these databases decreased the 
changes of them being polymorphisms. 
 
Table 2-11: Experiments conducted and data collected by author 
Phenotyping 
History and clinical examination Author 
Goldmann visual fields Author 
Statistical analysis Author 
Genotyping 
Primer design for RP1, RPE65 and 
GUCY2D 
Author 
DNA extraction (3 patients) Author 
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PCR for RP1, RPE65, GUCY2D and 
CHM 
Author 
Gel electrophoresis Author 
DNA Sequencing Author 
MLPA for PRPF31 Author 
Microsatellite marker analysis Author 
Bioinformatics Author 
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3 RESULTS 
 
3.1 A SURVEY OF THE MOLECULAR PATHOLOGY OF 287 FAMILIES WITH 
AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA 
 
3.1.1 INTRODUCTION 
 
Retinitis Pigmentosa is a spectrum of inherited eye disorders with varied 
genotypes and phenotypes. It transmits within families in autosomal 
dominant, autosomal recessive, X-linked recessive or digenic fashion 
(Bunker et al., 1984, Grondahl, 1987, Kajiwara et al., 1994). Mutations 
in at least 26 different genes have been implicated in autosomal 
dominant retinitis pigmentosa (adRP) (RetNet) (Table 1-1). Although in 
some instances careful assessment of the phenotype may suggest 
which gene is likely to be causative and should be screened first, such 
cases are a minority. The gold standard strategy to ascertain the 
molecular diagnosis is to Sanger sequence all the genes implicated in 
adRP in their entirety. This is prohibitively time consuming and 
expensive. In this study, we propose an algorithm for screening the 
most common alleles in the genes causing adRP followed by phenotype-
directed gene sequencing. This strategy can be quick and a relatively 
inexpensive method of identifying the underlying molecular basis of 
disease in a large proportion of families and help finding potentially 
valuable families to identify novel disease-causing genes. 
We describe the result of genetic analysis of families with adRP 
presenting to a single UK tertiary referral hospital. The results provide 
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valuable insight into the predominant genetic causes of adRP in the 
British population. 
 
3.1.2 METHODS 
 
We ascertained families with the clinical diagnosis of adRP, based upon 
the phenotype and family history, from the inherited eye disease clinics 
at Moorfields Eye Hospital (MEH). After informed consent was obtained, 
one affected member from each family was screened for mutations in 
the known genes causing adRP.  
 
3.1.2.1 Genotyping 
 
An algorithm was constructed based on the observation that pathogenic 
alleles in the adRP genes are confined to specific regions of the gene 
(Bowne et al., 1999, Gamundi et al., 2008, DeAngelis et al., 2002, 
Towns et al., 2010, Wada et al., 2005b, Coppieters et al., 2007, Keen 
et al., 2002) (Table 3-1). Notable exceptions to this rule are the genes 
RHO, PRPH2 and PRPF31.  
This part of the study was conducted at St. Mary's Hospital Academic 
Medicine Department, Manchester Academic Health Sciences Centre, 
University of Manchester, Manchester, UK as a part of the National 
Health Service. 
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Table 3-1: The algorithm for screening the most common alleles and 
the mutational hotspots of genes causing adRP 
Gene Exon / Mutation Technique 
RHO Exons 1-5 
Bi-directional 
Sanger 
sequencing 
PRPH2/RDS Exons 1-3 
PRPF3 Exon 11 
PRPF8 Exon 42 
NR2E3 Exon 2-3 
IMPDH1 Exon 8-10 
NRL Exon 2 
RP9 c.410A>T, p.H137L 
Pyrosequencing PRPF31 
c.527+3A>G and c.1115_1125del11, 
p.Arg372GlnfsX99 
RP1 c.2029C>T, p.R677X 
 
If no positive result was obtained following the above-described 
algorithm, the mutational hotspot (codon 617-1081) of exon 4 of the 
RP1 gene was sequenced bi-directionally in two overlapping 
polymerase chain reactions (PCR). I performed this part of the 
genotyping at UCL Institute of Ophthalmology. 
Finally, in families where the pedigree structure / clinical findings 
indicated non-penetrance, all the exons and the intron-exon boundaries 
of PRPF31 were sequenced. In families with non-penetrance, which still 
did not yield a positive result, Multiplex Ligation-dependent Probe 
Amplification (MLPA) was performed to detect large copy-number 
variations in PRPF31 not detectable by PCR and sequencing. I 
performed the MLPA in the genetics laboratories of the UCL Institute of 
Ophthalmology.  
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After identifying a mutation in an individual, the segregation of the 
allele within the affected members of the family was verified by PCR 
and direct Sanger sequencing or MLPA. 
The pathogenicity of the novel missense changes identified were tested 
in-silico using the tool CONDEL (Gonzalez-Perez and Lopez-Bigas, 2011) 
which combines the results of SIFT (Kumar et al., 2009), Polyphen 
(PPH2) (Adzhubei et al., 2010), Mutation assessor (MA) (Reva et al., 
2011) and Functional analysis of hidden Markov models (FATHMM) 
(Shihab et al., 2015). The novel splice-site mutations were analysed 
using online tools like Human Splicing Finder (Desmet et al., 2009) and 
Spliceman web server (Lim et al., 2011). 
 
3.1.2.2 Phenotyping 
 
Phenotypic analysis of patients was limited to those with novel 
mutations. The aim of this strategy was to identify unique features in 
these patients that have not been described before to expand the 
current phenotype. 
Identification of a true autosomal dominant inheritance can sometimes 
be difficult based on phenotypic characteristics and family history. In 
some cases, notably in families with X-linked RPGR mutations, female 
carriers may present with variable phenotype including severe disease 
making identification of carriers difficult (Rozet et al., 2002). This, in 
absence of a male-to-male transmission, makes the pedigree structure 
similar to that of autosomal dominant inheritance. In order to identify 
presence of such families, we compared the number of affected females 
in our families with known and unknown molecular diagnosis.  
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3.1.3 RESULTS 
 
Two hundred and eighty-seven families with adRP were included in this 
survey. One family harboured two mutations – one branch carrying 
RHO p.G106R while the other branch had the PRPF31 variant 
p.E183_M193dup. This family has been included as both RHO and 
PRPF31 mutation carrier for calculations. All the mutations identified in 
this study are listed in Table 5-1 in Appendix.  
The initial screen of the common alleles was performed in 265 families 
at the St. Mary's Hospital Academic Medicine Department, Manchester 
Academic Health Sciences Centre, University of Manchester, 
Manchester, UK. This identified mutations in 143/265 (53.9%) families. 
Among the rest 122 families with no molecular diagnosis, mutational 
hotspot of the RP1 gene was screened. In addition, another group of 
22 families who did not undergo Manchester screening were sequenced 
for the RP1 hotspot. This identified mutations in the RP1 gene in 38 
additional families. 10 families with no molecular diagnosis from the 
screening described above but clear evidence of non-penetrance had 
further sequencing and MLPA of the whole of the PRPF31 gene. This 
identified 3 more families with PRPF31 mutations.  
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Figure 3-1: The strategy of mutation screening adopted in this  
 
In total, our strategy identified mutations in 183 (63.1%) adRP families. 
The relative contribution of each gene towards adRP in our cohort is 
depicted in Figure 3-2. Variants in RHO, RP1 and PRPF31 together 
accounted for 51.6% of our families. No pathogenic mutation was 
found in 36.9% (106/287) of adRP families.  
 
3.1.3.1 Rhodopsin 
 
A mutation in RHO was the most common (22.6%) molecular diagnosis 
in our cohort (Figure 3-2). The initial screening of the whole of the RHO 
gene identified 25 different mutations in RHO, 2 of which were novel 
265 families screened using Manchester algorithm
143/265 families with positive 
molecular diagnosis
122/265 families with no mutation 
identified
122 + 22 = 144 families were 
screened for RP1 hotspot
38 families were identified 
with RP1 mutations
10 families were 
screened for PRPF31 
3 families were PRPF31
mutation positive
22 additional families with 
no Manchester screen
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(Table 5-1). The mutations in our cohort were distributed throughout 
all the exons of the gene. Specifically, 22/25 (88%) of the mutations 
were missenses, while two mutations produced in-frame deletions. One 
mutation was identified as a splice site mutation. Except for the 
mutation c.937-1G>T (splice site mutation) which may produce a null 
allele, in all other cases the protein was predicted to be expressed. 
Figure 3-2: A – The pie chart showing the relative contributions of 
different genes in the causation of adRP in our cohort B – The adRP 
genotypes as described by previous authors (Hartong et al., 2006) 
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2 families were identified with novel RHO mutations –family GC16058 
with c.511C>A, p.P171T and family GC19225 with c.512C>G, p.171R. 
In order to identify the impact of these missense changes on the protein 
structure and function, in-silico analysis of the mutations were 
performed (Table 3-2). Both the substitutions were absent from EVS or 
ExAC databases (ExAC, 2015, EVS, 2015). 
Table 3-2: Analysis of the novel RHO mutations 
Mutation SIFT PPH2 MA FATHMM CONDEL Conclusion 
c.511C>A, 
p.P171T 0 1 4.72 1.06 0.7441108 
Likely 
deleterious 
c.512C>G, 
p.P171R 0 1 4.72 1.02 0.7471266 
Likely 
deleterious 
 
Both the novel mutations affect Prolene 171 in the fourth 
transmembrane region of rhodopsin. Other substitutions of this amino 
acid have been described in different families with adRP suggesting that 
P171 is vital for the function of the protein (Dryja et al., 1991, Antinolo 
et al., 1994, Vaithinathan et al., 1994). It has been proposed that 
substitutions in this amino acid is likely to cause misfolding of the 
rhodopsin protein causing retention of the mutant protein in the 
endoplasmic reticulum and impairing reconstitution with 11-cis-retinal 
(Mendes et al., 2005). 
 
3.1.3.1.1 Phenotype of the patients with novel mutations in RHO 
 
Phenotyping was performed on 3 affected members of the families 
GC16058 and GC19225 who harboured novel RHO mutations  
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The proband of the family GC16058 is of Indian origin, who presented 
at the age of 50 years with dimness of vision, night blindness and 
reduced peripheral vision. She experienced difficulty in peripheral vision 
in her early teens and night vision problems when she was 16 years of 
age. The central vision deteriorated since. The visual acuities were 6/24 
in both eyes.  
She was identified to have intra-retinal pigmentation in the mid-
peripheral retina, attenuated arterioles, optic disc pallor and atrophic 
changes in the posterior pole (Figure 3-3). In addition, there were 
bilateral posterior sub-capsular cataracts which were operated. She 
demonstrated steady decline of her visual function since and at the age 
of 61 years, she had visual acuities of 6/24 in both eyes and severely 
restricted visual fields of less than 5 degrees. Serial OCT evaluation 
failed to identify any macular oedema although there was 
photoreceptor drop-out in the foveal region.  
The other affected individual was the son of the proband of family 
GC16058. He presented at 23-years of age with mild symptoms of night 
blindness. His visual acuities were 6/9 both eyes and his visual fields to 
confrontation was full. On examination at 27-years of age, his visual 
acuities were 6/6 both eyes with correction. Ophthalmic evaluation 
showed mid-peripheral intraretinal pigment migration, constricted 
visual fields but no evidence of macular oedema or cataracts (Figure 
3-4). A ring of hyperautofluorescence in the posterior pole was evident 
on autofluorescence imaging surrounding the fovea. On OCT evaluation 
of the retina, the perifoveal zone was healthy although there was 
disturbance in the photoreceptor- retinal pigment epithelium layers in 
the retinal periphery. 
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Figure 3-3: Phenotype of 61-year-old female with p.P171T mutation in 
RHO 
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Figure 3-4: Phenotype of 27-year-old male with p.P171T mutation in 
RHO  
 
The proband of family GC19225 presented with night vision problems 
at the age of 15. He was diagnosed with retinitis pigmentosa at the age 
of 33. When examined at the age of 39, his visual acuities were 6/9 in 
each eye.  
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Figure 3-5: Phenotype of 39-year old male with p.P171R mutation in 
RHO  
 
Results 
110 
 
He had constricted visual fields, mid-peripheral intraretinal pigment, 
attenuated arterioles and pale optic discs. No cataract or macular 
oedema could be identified (Figure 3-5). Although there was no 
evidence of OCT abnormality of the central posterior pole, 
autofluorescence could not identify a well-demarcated high-density 
ring. The peripheral retina on OCT showed disruption and discontinuity 
of the outer retinal layers. 
These three individuals with novel RHO mutations noticed night vision 
problems between 15-23 years age and were diagnosed as RP between 
23-50 years of age. Patients had visual acuity better than 6/9 until 39 
years of age but at age 50-years, it deteriorated to 6/24. All three 
showed intraretinal pigment migration, dystrophic retinal architecture, 
attenuated retinal arterioles and optic disc pallor. Hyperautofluorescent 
ring in the perifoveal region could only be identified in the FAF region 
in the youngest at age 27 years. None of these three showed any 
macular oedema.  
It is well-known that the RHO mutations cause a variable phenotype 
which has been variously classified (Cideciyan et al., 1998). In general, 
the three major phenotypes are diffuse retinal involement from early 
age, mild retinal disease at early age which may remain sectoral or may 
become diffuse. The phenotypic data from a mutation in P171 has 
shown a phenotype of diffuse retinal pathology (Antinolo et al., 1994). 
In one Spanish family, affected members showed onset of the disease 
by the middle of the second decade resulting in severe loss of visual 
field by the age of 40. This is similar to the phenotype described in our 
study. 
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3.1.3.2 RP1 
 
RP1 was the second most common gene (19.9%) in our cohort (Figure 
3-2). 19 families were identified by the initial screen of the allele 
c.2029C>T. 38 additional families were identified during the second 
RP1 screen. Five of the thirteen mutations identified were novel (Table 
5-1). All the mutations were predicted to cause a frameshift or were 
nonsense. However, as all the mutations were downstream to the 
terminal intron, the alleles would be predicted to be expressed resulting 
in a faulty protein, and not undergo nonsense-mediated decay 
(Holbrook et al., 2004). The phenotype of the patients with mutations 
in the RP1 gene has been described in the next section. 
 
3.1.3.3 Splicing factors 
 
The splicing factors PRPF31, PRPF8, PRPF3 and RP9 formed the next 
most common group of genes with 40/287 (13.9%) families harbouring 
mutations in one of these genes (Figure 3-2). 37/40 mutations in these 
genes were identified by the initial screen at Manchester. Subsequent 
PRPF31 screen with sequencing and MLPA found mutations in 3 
additional families. All the mutations identified in PRPF3 or PRPF8 were 
missense changes. There was only one missense mutation in the RP9 
gene.  
8 novel mutations were identified in this group, all in the PRPF31 gene 
(Table 5-1). Sixteen out of twenty (80%) mutations found in PRPF31 
were either nonsense or splice site mutations, all of which would be 
predicted to produce a null allele as none of them reside in the terminal 
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exon. We also identified 3 missense mutations and 1 in-frame insertion. 
The mutations in PRPF31 were not limited to one particular domain of 
the protein.  
Of the novel mutations identified in the PRPF31, 2 were splice-site 
mutations, 1 was a missense change while the rest were stop mutations 
or frameshifts. In-silico analysis of the missense mutation c.584T>A, 
p.L195P in PRPF31 is shown in the Table 3-3. This mutation was not 
present in EVS or ExAC databases (EVS, 2015) 
The novel mutation likely to affect the splice site, c.238+2T>C was 
analysed in-silico using tools like Human Splicing Finder (Desmet et al., 
2009) and Spliceman web server (Lim et al., 2011). Both the tools 
concluded that this change is likely to disrupt the splice donor site which 
might result in interruption of splicing of PRPF31 mRNA. Similar analysis 
was performed on the second novel intronic substitution, 
c.1146+2T>C. Using the same analysis tools Human Splicing Finder 
and Spliceman web server, this missense change was also predicted to 
disrupt the donor splice site affecting correct splicing of the PRPF31 
mRNA. 
Table 3-3: In-silico analysis of novel PRPF31 substitution 
Mutation SIFT PPH2 MA FATHMM CONDEL Conclusion 
c.584T>A, 
p.L195P 0.08 0.522 
2.39
5 -1.19 0.616788 
Likely 
deleterious 
 
3.1.3.3.1 Phenotype of the patients with novel mutations in PRPF31 
 
11 affected individuals from 8 families were phenotyped for the study. 
The phenotypic characteristics are described in the Table 3-4 and 
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Figure 3-7, Figure 3-8, Figure 3-9, Figure 3-10, Figure 3-11, Figure 
3-12, Figure 3-13, Figure 3-14, Figure 3-15, Figure 3-16 and Figure 
3-17. 
These patients were divided into three groups on the basis of their 
mutations – stops or frameshifts, splice-site mutations and 
substitutions. No clear differentiation could be made on the phenotypes 
of each group. There was wide variation among different affected 
members in each group and even within the same family.  
Table 3-4: Phenotypic characteristics of patients with novel PRPF31 
mutations. Pt – Patient, PSC – Posterior sub-capsular cataract, CMO – 
Cystoid macular oedema, IOL – Pseudophakia, HM – Hand movements, 
CNV – Choroidal neovascularisation, CVS - Confrontation visual field, 
A/S - Asymptomatic 
Family (Mutation) Pt Onset Age at 
exam  
BCVA 
in 
better 
eye 
Visual 
field 
in 
better 
eye 
Comment 
Frameshift 
or stop 
mutations 
GC16468 
(p.Glu68*) 
01 19 
years 
30 
years 
6/24 20° CMO 
  02 48 
years 
59 
years 
6/24 15° CMO 
  03 17 
years 
32 
years 
6/36 5° PSC, CMO 
 GC3031 
(p.Gln177*) 
01 Mid-
teens 
45 
years 
6/24 5° IOL 
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 GC19105 
(p.His270Thrfs
*51) 
01 Early 
teens 
36 
years 
6/18  CMO, 
Myopia 
 GC107 
(p.Arg293Glyfs
*28) 
01  68 
years 
HM  CMO, IOL, 
Glaucoma 
 GC19272 
(p.Lys363*) 
01 9 
years 
17 
years 
6/6 Full 
CVS 
CMO 
Splice site 
mutations 
GC21373 
(c.238+2 T>C) 
01 <10 
years 
36 
years 
6/6 10°  
 GC16220 
(c.1146+2 
T>C) 
01 12 
years 
23 
years 
6/5 20° CMO 
Missense 
mutation 
GC1485 
(p.Leu195Pro) 
01 Early 
teens 
71 
years 
HM  CMO, CNV 
  02 A/S 48 
years 
6/6 Full  
 
The symptomatic individuals began to experience night blindness 
with/without peripheral vision problems in late first decade or early 
second decade of life. One individual was asymptomatic (GC1485-02) 
and one started experiencing night vision problems (GC16468-02) in 
late forties. The pedigrees of two of the families showed non-
penetrance from history (Figure 3-6) although we could examine only 
one unaffected mutation carrier (GC1485-02). Visual acuities were 
affected variably and were influenced by cataract, cystoid macular 
oedema (CMO) and foveal involvement by the disease process.  
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Figure 3-6: Pedigree of family GC107 showing non-penetrant individual 
in a red square. 
Figure 3-7: GC16468-01 at 27-years of age 
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Figure 3-8: GC16468-02 at 55-years-age 
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Figure 3-9: GC16468-03 at 30 years of age 
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Figure 3-10: GC3031-01 at 43-years-age 
 
Visual fields were reduced to less than 20° in all individuals over 23 
years of age although a 17-year-old female (GC19272-01) had full field 
to confrontation. Fundus examination of the affected individuals 
showed typical features of attenuated arterioles, pale atrophic optic 
discs and bone spicule intraretinal pigment migration in the mid-
peripheral retina. 8/11 (72.72%) individuals had documented CMO, one 
of whom went on to develop choroidal neovascularisation (CNV) in the 
left eye (GC1485-01) (Figure 3-16). 
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Figure 3-11: GC19105-01 at 34-years-age 
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Figure 3-12: GC107-01 at 69 years of age 
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Figure 3-13: GC19272-01 at 18 years of age 
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Figure 3-14:GC21373-01 at 36-years-age 
 
Similar to the observations in this study, the literature describes the 
variable nature of the phenotype in patients with PRPF31 mutations 
(Audo et al., 2010a). Incidence of non-penetrance have been observed 
in several families and it has been suggested that high penetrance is 
an exception rather than rule (Audo et al., 2010a). In patients who 
show the disease phenotype, disease onset is within the first two 
decades of life in the majority (Pan et al., 2014, Xu et al., 2012, Sato 
et al., 2005a, Audo et al., 2010a), similar to that observed in our novel 
mutation families. Variable involvement of the macula later in the 
disease have been observed by other groups as well (Audo et al., 
2010a). We observed a relatively high percentage of patients with 
cystoid macular oedema (72.72%). This might be due to ages of the 
patients in our cohort as 9/11 patients were above 30-years-age. 
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Figure 3-15: GC16220-01 at age 23 years 
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Figure 3-16: GC1485-01 – OCT and FAF showing CNV in the left eye 
 
Choroidal neovascularisation following RP is not common (1.7%) (Triolo 
et al., 2013) and has not been described in any patients who have been 
molecularly diagnosed. Our patient refused any treatment due to his 
advanced RP. 
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Figure 3-17: GC1485-02 at 46 years of age – an unaffected mutation 
carrier of PRPF31 
 
3.1.3.4 RDS/PRPH2 
 
Seven mutations were identified in PRPH2, with two being in-frame 
deletions and the rest substitutions. These mutations were not limited 
to one particular region of the gene. We identified one novel mutation 
c.653C>T, p.S218L which was analysed in-silico and was found likely 
to have deleterious effect on the functions of the protein (Table 3-5). 
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This substitution was also absent from the ExAC and EVS servers (EVS, 
2015, ExAC, 2015).  
Table 3-5: In-silico analysis of novel PRPH2 mutation 
Mutation SIFT PPH2 MA FATHMM CONDEL Conclusion 
c.653C>T, 
p.S218L 0.08 0.983 2.45 -2.34 0.604356 
Likely 
deleterious 
 
3.1.3.4.1 Phenotype of the family with novel PRPH2 mutation 
 
One member of this family GC18899 could be phenotyped for this study 
(Figure 3-18). This affected female started noticing dimness of vision 
in dim lighting conditions at early teen age years and was diagnosed to 
have adRP at the age of 16 years. At 34-years-age, she had corrected 
visual acuities of 6/12 OD and 6/18 OS. She had reduced inferior visual 
fields to confrontation. Colour vision was affected as she could not 
identify the universal plate on Ishihara pseudo-isochromatic testing. 
Ocular examination showed symmetrical wide-spread degenerative 
changes of both the retina with foveal involvement. There were optic 
disc pallor, retinal pigment epithelial atrophic changes, attenuated 
arterioles and intra-retinal pigment migration in both eyes.  
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Figure 3-18: GC18899-01 at 34-years-age with novel p.S218L PRPH2 
mutation 
 
Autofluorescence imaging revealed foveal hyper-autofluorescence with 
surrounding ring of hypo-autofluorescence. There was absence of high 
density ring around the fovea. OCT evaluation showed patchy demise 
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of the outer retinal layers and generalised loss of retinal architecture. 
Electrodiagnostic tests at the age of 31 years showed undetectable 
pattern ERG and minimal residual photopic and scotopic activity. This 
implied very severe generalised loss of retinal function involving both 
rod and cone systems along with loss of macular function.  
Various different phenotypes have been associated with PRPH2 
mutations varying from several descriptions of macular dystrophies like 
pattern dystrophy and central areolar choroidal dystrophy, cone or 
cone-rod dystrophy and RP (Boon et al., 2008). Combination of the 
above phenotypes within a single family has also been noted (Leroy et 
al., 2007). From the phenotypic analysis of the proband in our novel 
S218L mutation, it is likely that this patient had an RP phenotype with 
macular involvement. The mutation is located in the D2 loop of the 
PRPH2 protein, a common locus for mutations for RP phenotype. This 
missense mutation adds evidence to the assertion that most of the 
patients with missense PRPH2 mutations result in the RP phenotype 
(Boon et al., 2008). 
 
3.1.3.5 Transcription factors – NRL and NR2E3 
 
We identified a previously known mutation, p.S50T in NRL in 2 adRP 
families (Bessant et al., 1999). 2 different mutations were found in 
NR2E3, p.G56R and p.K57R in 3 separate families (Coppieters et al., 
2007). The substitution c.170A>G, p.K57R is a novel mutation not 
previously associated with adRP. In-silico analysis for the missense 
change is shown in Table 3-6. This mutation has not been evident in 
EVS or ExAC mutation databases (EVS, 2015, ExAC, 2015).  
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Table 3-6: In-silico analysis of the mutation p.K57R in NR2E3 
Mutation SIFT PPH2 MA FATHMM CONDEL Conclusion 
c.170A>G, 
p.K57R 0.02 0.889 1.15  0.57292 
Likely 
deleterious 
 
3.1.3.5.1 Phenotype of the novel NR2E3 mutation 
 
Only one affected individual in the family GC17172 could be phenotyped 
(Figure 3-19). The affected female noticed difficulty in night vision from 
early childhood. At 16 years of age, she had visual acuities of 6/6 in 
both eyes. The visual field was less than 5° with Humphrey’s visual field 
analyser. Ocular examination showed thin retinal vessels and extensive 
white dots at the level of the retinal pigment epithelium.  
Autofluorescence imaging showed hyper-autofluorescent ring 
surrounding the foveal region. Electrodiagnostic evaluation showed 
rod-cone dystrophy.  
Bi-allelic mutations in NR2E3 are predominantly associated with 
Enhanced S-cone syndrome, a recessive retinal dystrophy characterised 
by nummular intra-retinal pigment and supernormal S-cone ERG 
(Jacobson et al., 1990, Marmor et al., 1990). Only one allele p.G56R 
has been causative of adRP so far. These patients have a rod-cone 
dystrophy with three concentric rings of hyperautofluorescence on FAF 
imaging (Coppieters et al., 2007). Presence of a mixture of nummular 
and spicular type of intraretinal pigmentation has also been noted. With 
the limited phenotypic data that we could acquire from our patient, we 
could not identify either nummular pigmentation or multiple concentric 
rings on FAF. However, given the young age of the patient, we could 
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not exclude subsequent development of a phenotype similar to that 
noted above.  
Figure 3-19: Affected female at 16-years of age with NR2E3 p.K57R 
mutation 
 
3.1.3.6 IMPDH1 
 
We identified 6 different IMPDH1 mutations, all of which were missense 
changes. 3/6 (50%) mutations were novel. The following table shows 
the predicted changes to the function of IMPDH1 protein due to the 
novel substitutions using in-silico analysis (Table 3-7). 
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Table 3-7: In-silico analysis of the novel IMPDH1 mutations 
Mutation SIFT PPH2 MA FATHMM CONDEL Conclusion 
c.928A>C, 
p.T310P 0 0.944 3.57 -3.32 0.695493 
Likely 
deleterious 
c.952T>G, 
p.Y318D 0 0.812 2.05 -1.31 0.573651 
Likely 
deleterious 
c.968A>G, 
p.K323R 0.02 0.129 2.12 -1.3 0.581156 
Likely 
deleterious 
 
These changes were not found in either EVS or ExAC databases (ExAC, 
2015, EVS, 2015). 
 
3.1.3.6.1 Phenotype of the families with novel IMPDH1 mutations 
 
7 affected individuals from three families were examined for this study. 
The examination findings are shown in the following table (Table 3-8) 
and the following figures (Figure 3-20, Figure 3-21, Figure 3-22, Figure 
3-23). 
6/7 (85.7%) affected individuals noted difficulty in seeing in dim light 
and reduced peripheral vision in early childhood. 2 individuals 
phenotyped in the third decade of life had visual acuity as poor as legal 
blindness. 
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Table 3-8: Phenotypic characteristics of patients affected by novel 
IMPDH1 mutations. Pt – Patient, CMO – Cystoid macular oedema, PSC 
– Posterior subcapsular cataract, ERG – Electrodiagnostics  
Family 
(mutation) 
Pt Age of 
onset 
Age at 
exam 
BCVA 
in 
better 
eye 
Visual 
field 
in 
better 
eye 
Comments 
GC1296 
(p.K323R) 
01 Early 
childhood 
13 
years 
  CMO 
 02 Early 
childhood 
14 
years 
  CMO 
GC3776 
(p.T310P) 
01 Early 
childhood 
9 years 6/9  ERG – rod cone 
photoreceptor 
dystrophy 
 02 Early 
childhood 
14 
years 
6/6  ERG – rod cone 
photoreceptor 
dystrophy 
 03 Early 
childhood 
37 
years 
PL  PSC 
GC5256 
(p.Y318D) 
01 6 years 35 
years 
3/60 < 5° CMO 
 02 13 years 16 
years 
6/36  ERG – rod-cone 
photoreceptor 
dystrophy 
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Figure 3-20: GC1296-01 at 13-years-age 
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Figure 3-21: GC1296-02 at 14 years of age 
 
Subjects in the paediatric group were examined between 9-16 years of 
age. There was variability in the signs from normal looking retina 
(GC5256-02) to optic disc pallor, attenuation of retinal vessels and 
intra-retinal pigment migration (GC3776-01). Similar variability in the 
autofluorescence imaging was noted with presence of hyper-
autofluorescent peri-foveal ring in GC1296-01 while GC5256-02 had 
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normal 30° autofluorescence. 3/7 (42.86%) individuals had OCT 
confirmed cystoid macular oedema. 
Figure 3-22: GC5256-01 female at 35-years-age 
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Figure 3-23: GC5256-02 at 16-years-age 
 
Proband of family GC3776, GC3776-03 presented with no history of 
retinitis pigmentosa in her antecedents of at least 2 generations. The 
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pedigree structure was amenable to a diagnosis of autosomal recessive 
retinitis pigmentosa. However, the disease was evident in her 2 sons 
early in life and the diagnosis was revised to autosomal dominant 
retinitis pigmentosa. 
This high variability in the IMPDH1 RP phenotype has been described 
by other groups as well. Patients with T116M and H372P alleles have 
been noted to present in their thirties with night vision problems while 
those with R105W and N198K presented at early childhood with severe 
retinal dystrophy similar to LCA (Bowne et al., 2006b). The commonest 
mutation D226N usually resulted in a severe RP with onset in early 
childhood and subsequent decline in visual function with age although 
intra-familial variability have been noted (Kozma et al., 2005, Schatz et 
al., 2005). Interestingly in one Pakistani family, this allele produces 
disease only in homozygous state (Ali et al., 2015). All the alleles in our 
cohort of novel mutations behaved broadly similar to D226N phenotype 
although intra-familial variability is clearly evident. de novo mutations 
have  not been described in IMPDH1 before. We could not genotype 
the parents of the individual GC3776-03 in order to verify the de novo 
nature of her mutation.  
 
In order to determine the probability of X-linked inheritance in the 
unresolved families, we compared the number of affected females 
among families with known and unknown molecular diagnosis. Within 
the families with unknown molecular diagnosis, 61% of the affected 
individuals were females whereas within a sample of 77 families with 
known molecular diagnosis, 52% of the affected were females. 
(p=0.2). The difference in the number of females being non-significant 
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implies that there were few families with X-linked inheritance in the 
unknown molecular diagnosis group, if any. 
3.1.4 DISCUSSION 
 
With 26 genes implicated in the causation of adRP (Table 1-1), 
identifying the correct molecular diagnosis can be an arduous task, 
particularly if Sanger sequencing of all the known genes is performed. 
Most dominant alleles in the genes such as RP1, PRPF3, PRPF8, RP9, 
IMPDH1, NR2E3 and NRL are found within single exons (Chakarova et 
al., 2002, Martinez-Gimeno et al., 2003, Bowne et al., 1999) which 
allowed us to develop an algorithm for initial screen of the adRP 
families. The algorithm involved the complete Sanger screening of two 
genes, RHO and PRPH2, with targeted screening of key exons in the 
remaining genes.  
Our study identified mutations in 64% of the families with adRP. This 
is higher than studies previously reported, where the detection rate 
varied between 28-54% (Ziviello et al., 2005, Hartong et al., 2006, 
Sullivan et al., 2006a). Our strategy of focussing the sequencing efforts 
on the mutational hotspots makes the screening procedure more 
efficient while retaining the probability of detecting novel mutations.  
Sequence variants in RHO, RP1 and PRPF31 were the most common 
underlying cause of disease in our cohort. As the families were drawn 
from a database of varied racial background, this result may represent 
the true genetic distribution of the adRP families in the population. The 
contribution of RP1 (23.3%) is significantly higher than the largest 
previous study of this kind (3.5%) (Sullivan et al., 2006a), which may 
be a British phenomenon. 
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The contribution of RHO to the genetics of adRP was similar to that 
found in a previous study (Sullivan et al., 2006a). All but one of the 
RHO mutations in our cohort was amino acid substitutions or in-frame 
deletions making it likely that the mutant protein is expressed. RHO 
mutations have been classified into different classes depending on the 
behaviour of the mutant protein (Mendes et al., 2005) (Table 1-2). Two 
novel mutations identified (p.P171T and p.P171R) affect the same 
amino acid and would be classified as Class II mutations which cause 
misfolding of the mutant protein. Functional experiments need to be 
conducted in order to elucidate the true effect of these alleles. 
Interestingly, the allele P23H which is one of the commonest causes of 
adRP (Sullivan et al., 2006a) in North America and has a widely 
experimented mouse model was not identified in our cohort. 
It was evident from the mutations identified in our cohort and that from 
other databases that there are no mutational hotspots within the RHO 
gene (Stenson et al., 2009). So far, functional experiments have not 
been conducted to elucidate the pathogenesis of all the mutations 
identified in RHO. Although splice site mutations have been identified, 
haploinsufficiency has not been put forward as the mechanism of 
disease. This is supported by the fact that heterozygous rhodopsin 
knockout mice show little photoreceptor degeneration (Lem et al., 
1999).  
In spite of limiting the screening of RP1 to the presumed mutational 
hotspot in exon 4 (Berson et al., 2001), we identified eight new 
mutations. All the adRP families harbouring RP1 mutations were of 
European descent. It is possible that dominant alleles in this gene is 
especially prevalent in the European British population as such large 
incidence has not been noted in patients from South-East Asia, China 
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or the United States (Sullivan et al., 2006a, Gandra et al., 2008, Zhang 
et al., 2010). The prevalence of the p.R677X allele in our adRP cohort 
was 6.7%, making it the commonest adRP allele by far; this suggests 
that this allele should be screened specifically in the early stages of any 
screening strategy in the British population. 
All the RP1 mutations identified so far associated with adRP are 
confined to exon 4 (Audo et al., 2012). In all cases, the mutations result 
in a truncated protein, which is expressed, at least in cultured 
lymphocytes (Liu et al., 2003). This makes it likely that the mechanism 
of disease in these cases is dominant negative or gain-of-function. 
Furthermore, the presence of null alleles in phenotypically unaffected 
carriers of autosomal recessive RP (Chen et al., 2010, Aldahmesh et al., 
2009) caused by mutations in RP1 makes haploinsufficiency unlikely. 
Interestingly, Chinese and Japanese patients with alleles producing 
stop codons beyond p.D1922 do not have disease (Kawamura et al., 
2004, Baum et al., 2001). Thus, the protein domain between p.M500 
to p.D1922 performs a hitherto unknown function, alteration in which 
imparts gain-of-function or a dominant negative property to the mutant 
RP1 protein. 
PRPF31 was the third most common molecular diagnosis in our adRP 
families. We screened the whole of the gene using Sanger sequencing 
and/or MLPA in families with demonstrable non-penetrance. Several 
groups have discovered large deletions involving this gene (Sullivan et 
al., 2006b, Abu-Safieh et al., 2006, Rose et al., 2011). As these 
deletions are not easily detected using conventional Sanger 
sequencing, techniques such as MLPA is essential in screening PRPF31.  
The predominant mechanism for PRPF31 related adRP is believed to be 
haploinsufficiency (Rivolta et al., 2006, Abu-Safieh et al., 2006). This 
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hypothesis is further supported by the fact that out of 59 mutations 
reported in this gene so far including those in our cohort (Audo et al., 
2010a, Saini et al., 2012, Xu et al., 2012, Rose et al., 2011, Utz et al., 
2013), only a few (p.L107V, p.T138K, p.A194E, p.L195P, p.A216P, 
p.A291P, and p.C299R) are missense mutations. We also identified in-
frame duplication (p.E183_M193dup). The p.L107V and p.T138K 
changes are predicted to create donor splice-sites and frameshift 
(Rivolta et al., 2006, Waseem et al., 2007). The p.A216P allele has been 
functionally characterised and it is believed that a dominant negative 
mechanism may be responsible for disease with this allele (Huranova 
et al., 2009). Further experimental evidence needs to be obtained to 
identify the mechanism of disease in other alleles. Thus, although there 
is overwhelming evidence that haploinsufficiency may be the primary 
mechanism in PRPF31 mutations, there may be a dominant negative 
effect in a minority of alleles. In these cases, however, the disease may 
not be amenable to gene replacement therapy alone.  
Many groups have commented on the propensity of non-penetrance in 
adRP families associated with PRPF31 mutations (Moore et al., 1993, 
Al-Maghtheh et al., 1996, Audo et al., 2010a). One explanation for non-
penetrance is differential expression of the wild type allele (Vithana et 
al., 2003). This expression was determined to be associated with an 
expression quantitative trait locus (eQTL) on chromosome 14q21-23 
(Rio Frio et al., 2008). Recently, it has been demonstrated that high 
levels of CNOT3 gene expression on 19q13.4 correlate with low 
expression of PRPF31 (Venturini et al., 2012). Hence, multiple 
influences on the expression of the PRPF31 wild type allele may 
determine the phenotypic expression of the disease in mutation 
carriers. 
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We investigated other splicing factors in our mutation screening. PRPF8 
was responsible for 2.8% of adRP families in our cohort. This is similar 
to that observed in other studies (Daiger et al., 2007, Hartong et al., 
2006, Martinez-Gimeno et al., 2003, Sullivan et al., 2006a). All the 
mutations identified in this gene have been in exon 42 of this gene 
except in one family where it was identified in exon 39 (Towns et al., 
2010). In a 43-exon-gene, this region would be the C-terminal end of 
the protein, which contains the MPN domain whose function may be 
affected by the observed mutations. Unlike in PRPF31 mutations, in 
lymphoblast cell lines, the mutant protein is expressed and probably 
affects binding to hSnu114 and hBrr2 proteins, which play a role in 
U4/U6 and U4atac/U6atac snRNA unwinding (Tanackovic et al., 2011b). 
There is evidence of incomplete penetrance in some of these families 
as well, although the mechanism remains to be explored (Maubaret et 
al., 2011).  
There have been only three mutations identified in PRPF3 to date – 
p.A489D, p.P493S and the commonest, p.T494M (Gamundi et al., 2008, 
Chakarova et al., 2002). All three mutations are very close to each other 
in exon 11. As expected, this mutant protein is expressed and these 
mutations in the C-terminal region of the protein are believed to 
partially destabilize the assembly of the U4/U6 snRNP complex, which 
could affect spliceosome assembly (Gonzalez-Santos et al., 2008). 
There has been only one mutation identified in the RP9 gene so far 
(Keen et al., 2002). We identified this variant in 3 families in our cohort. 
Identification of mutations in PRPH2 causing adRP is dependent on 
strict phenotypic criteria. We have excluded patients from dominant 
families with predominant macular involvement in whom PRPH2 is a 
significant cause of disease. In our cohort, only 2.4% of the families 
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harbour mutations in this gene. This is in agreement with the findings 
of some groups (Hartong et al., 2006) and not with others (Sullivan et 
al., 2006b). One explanation may be variable phenotypic criteria as 
several phenotypes have been attributed to this gene (Nichols et al., 
1993b, Wells et al., 1993, Weleber et al., 1993). We screened the whole 
gene to identify mutations in all three exons and identified 1 nonsense 
mutation, 2 in-frame deletions and 4 missense mutations.  
There has previously been only one allele (p.G56R) reported in NR2E3 
associated with adRP (Coppieters et al., 2007). We identified a second 
dominant allele (p.K57R) in NR2E3. This mutation lies next to the 
previously reported change within the first zinc finger of the DNA-
binding domain of the protein (Coppieters et al., 2007). This finding 
supports the pathogenicity of NR2E3 in causing adRP. 
We identified just one mutation in NRL in our adRP cohort. Although 
this gene has been implicated in cone dysfunction and recessive retinitis 
pigmentosa (Nishiguchi et al., 2004), mutations in only 4 amino acids 
– p.S50, p.P51, p.P67 and p.M96 have been associated with adRP 
(DeAngelis et al., 2002, Ziviello et al., 2005, Hernan et al., 2012). It has 
been demonstrated that some of these mutations impart a gain-of-
function to the mutant protein, which alone and/or together with CRX, 
increased RHO transcription by influencing the promoter (Bessant et 
al., 1999, Hernan et al., 2012).  
IMPDH1 analysis in our cohort revealed 6 missense mutations in 7 
families, 3 of which were novel. All the mutations identified in this gene 
are present in or near the CBS domain of the protein. Several 
hypotheses have been put forward to explain a retina specific 
phenotype due to mutations in a ubiquitous enzyme. One group 
identified a unique nucleic acid binding property of IMPDH1 which is 
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impaired by the observed mutations (Hedstrom, 2008). Another group 
identified several retina-specific IMPDH1 transcripts and suggested that 
these may have singular properties, which are impaired by the 
mutations (Bowne et al., 2006a). A third group suggested that some of 
the mutant proteins have faulty tertiary structures that interferes with 
folding and thus, the function of wild-type IMPDH1 (Wang et al., 2011). 
It is probable that a combination of the above mechanisms play a role 
in the pathogenesis of this disease. 
We failed to identify the underlying genetic cause in a third of families 
using our algorithm. One explanation may be the presence of mutations 
in exons which were not included in the screen. There may also be large 
copy number variations that can be missed by Sanger sequencing. It 
may also be possible that the mode of inheritance in some of these 
families is not autosomal dominant. However, the number of affected 
females in families with unknown molecular diagnosis was not 
significantly lower than that of confirmed adRP families making X-linked 
inheritance unlikely.  
Finally, it is plausible that some of these families with unknown 
molecular diagnosis harbour rare or novel mutations in the known 
genes or mutations in genes that have not yet been identified. The 
advent of next generation sequencing should allow many of these 
currently undiagnosed cases to be solved and is likely to lead to the 
identification of novel genes causing adRP (Daiger et al., 2010). 
In conclusion, we describe a strategy concentrating on specific exons 
and variants where most mutations have been reported, which allowed 
us to identify the causative mutation in two-thirds of families. Our 
report provides useful information about the relative contributions 
made by different genes in adRP within a British cohort.  
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3.2  A MOLECULAR AND CLINICAL ANALYSIS OF PATIENTS WITH RETINAL 
DEGENERATION DUE TO DOMINANT ALLELES OF THE RP1 GENE  
 
3.2.1 INTRODUCTION 
 
RP1 is a four-exon gene located in chromosome 8q12.1 (Pierce et al., 
1999). The expressed protein is photoreceptor specific and has been 
demonstrated in both rods and cones (Sullivan et al., 1999). RP1 is a 
microtubule-associated protein that forms an integral part of the 
axoneme of the connecting cilium in the outer segment of the 
photoreceptors (Liu et al., 2002, Liu et al., 2004). 
47 mutations have been described in the RP1 gene so far. These are 
associated with both autosomal recessive (ar) and adRP (Audo et al., 
2012). All the mutations observed in the RP1 gene associated with adRP 
group within a small region in the exon 4 of the gene (Audo et al., 
2012). All of these mutations cause premature truncation of the RP1 
protein. This is unlike the ones that cause arRP, which include missense 
mutations and are distributed all along the coding segment of the RP1 
gene including the mutational hotspot (Audo et al., 2012).  
In this section, we survey the mutations in RP1 in families with adRP, 
determine the detailed phenotype, and assess the degree of variability. 
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3.2.2 METHODS 
 
All the families with adRP registered to Moorfields Eye Hospital (MEH) 
Inherited Eye Disease Database were explored to identify families with 
unknown molecular diagnosis. One affected individual from each family 
was ascertained for this study. After obtaining informed consent, blood 
samples were obtained and leukocyte DNA extracted. Polymerase chain 
reactions (PCR) were set up to amplify the mutational hotspot (c.1847 
– c.3245) in exon 4 of the RP1 gene (MIM *603937, RefSeq 
NM_006269.1) as two overlapping amplimers. The primers used in the 
study are illustrated in Table 3-9. The PCR products were sequenced 
bi-directionally by Sanger sequencing. 
 
Table 3-9: Primer sequences for RP1 PCR reactions 
 Forward primer (5’-3’) Reverse primer (5’-3’) 
First 
amplimer 
AGCAGATGCAACCCATTTTT GCCCTGGTTGTAGCATGTTGT 
Second 
amplimer 
GCACCGCAATCTCAAGCAGAAGT GTGAAGCATCAGGACTGGTAAG 
 
Affected individuals from the adRP families with a RP1 mutation were 
invited for phenotyping. Retrospective evaluation of clinical notes was 
also made and relevant data were included in the study. The data 
obtained included colour fundus photography, fundus autofluorescence 
imaging, perimetry, optical coherence tomography (OCT) and ISCEV 
standard pattern and full-field electroretinography (PERG/ERG). 20 
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patients underwent ISCEV standard ERGs while 5 patients had non-
Ganzfeld ERGs in the past. 
Kinetic perimetry with Goldmann perimeter was performed in the 
affected patients. The visual field obtained by moving the V4e stimulus 
from the non-seeing area to the seeing area was plotted. The areas of 
the Goldmann V4e visual fields were measured in square degrees using 
custom software called Retinal area analysis tool designed by Dr. 
Anthony Halfyard and Prof. Fred Fitzke, Institute of Ophthalmology, 
London, 2002.  
 
3.2.2.1 Statistical Analysis 
 
The Spearman’s rank correlation coefficient was used to measure the 
association between the average visual acuity from both eyes at the 
last visit and age. Survival analysis was conducted using the visual 
acuity and the visual field of better-seeing eye. The following failure 
criteria were applied: Visual acuity 0.3 logMAR (i.e., vision compatible 
with driving) and visual field area 293 deg2 (corresponds with visual 
field of 10° diameter, i.e., criterion for legal blindness). As a control, 
similar analysis was performed for affected adRP patients with 
mutations in the PRPF8 gene using published data (Towns et al., 2010). 
Statistical analysis was performed using GraphPad Prism 4.00 
(GraphPad Software, San Diego, CA). 
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3.2.2.2 Genotyping 
 
As illustrated in the previous section, 57 out of 287 (19.7%) adRP 
families showed presence of a mutation in the RP1 gene. The mutations 
identified have been listed in Table 3-10. 
All the mutations caused premature termination of the protein and 
resulted in a shortened C-terminal. Depending on the nature of the new 
C-terminal, the mutations can be -1 frameshifts where the reading 
frame shifts one base ahead (for example, resulting from deletion of a 
single base or insertion of two bases), +1 frameshifts where the reading 
frame shifts one base backwards (by insertion of one base or deletion 
of two bases) and non-sense (Table 3-11).  
 
Table 3-10: Mutations in RP1 causing adRP in MEH cohort 
Mutation 
Number 
of 
families 
Reference 
c. p.Lys673Argfs*9 1 Novel 
c.2029C>T, p.Arg677* 19 (Pierce et al., 1999, 
Sullivan et al., 1999, 
Guillonneau et al., 
1999) 
c.2035C>T, p.Gln679* 3 (Berson et al., 2001, 
Sullivan et al., 1999) 
c.2055T>A, p.Tyr685* 1 Novel 
c.2098G>T, p.Glu700* 3 (Bowne et al., 1999) 
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c.2115delA, p.Gly706Valfs*7 1 (Gamundi et al., 
2006) 
c.2143C>T, p.Gln715* 1 Novel 
c.2168_2181delGAGGGATACTTTGT 
or 
c.2172_2185delGATACTTTGTGAGG, 
p.Ile725Argfs*6 
11 (Payne et al., 2000) 
c.2205_2206insA, p.Thr736Asnfs*4 3 Novel 
c.2232C>A, p.Cys744* 1 (Payne et al., 2000) 
c.2285_2289delTAAAT, 
p.Leu762Tyrfs*17 
2 (Payne et al., 2000) 
c.2596_2597delTT, 
p.Leu866Lysfs*7 
8 Novel 
c.2607_2608insA, p.Arg872Thrfs*2 3 (Payne et al., 2000) 
Total 57  
 
Table 3-11: Types of RP1 mutations identified in MEH cohort 
-1 Frameshift 
mutation 
+1 Frameshift 
mutation 
Non-sense 
mutation 
p.Lys673Argfs*9 p.Ile725Argfs*6 p.Arg677* 
p.Gly706Valfs*7 p.Thr736Asnfs*4 p.Gln679* 
 p.Leu762Tyrfs*17 p.Tyr685* 
 p.Leu866Lysfs*7 p.Glu700* 
 p.Arg872Thrfs*2 p.Gln715* 
  p.Cys744* 
2 families 27 families 28 families 
 
Results 
150 
 
Table 3-12: Variations identified in 98 controls 
Missense changes Frequency Reference 
c.2763G>A 43/196 rs444772 
c.2783G>C 1/196 rs753472023 
c.3101A>T 69/196 rs2293869 
 
3.2.3 RESULTS 
 
3.2.3.1 Clinical features 
 
The clinical features of all the patients are described in the appendix 
(Table 5-2). 
There were 384 affected individuals in 57 families. 98 mutation-carrier 
individuals from 54/57 (94.7%) of these families were included in the 
clinical analysis. 62/98 patients were examined while retrospective 
evaluation of medical notes was performed for the rest of the patients. 
166/384 (43.23%) individuals were females. All 56 families were of 
white European ancestry. There was no evidence of consanguinity in 
any of the families. In 6 families, there was evidence of non-penetrance 
by history (Figure 3-24). 
Among the 98 patients phenotyped, 21 individuals were examined only 
once. Among the rest (77 subjects), the follow up varied from 1 year 
to 34 years (Median=6 years, Mean=8.65 years, Standard deviation 
8.46 years). 
The average age at which the patients first noticed symptoms was 
34.76 years (Median 32 years, Range 15-72 years). Night blindness was 
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the most common primary symptom at onset. Only 51% of patients 
complained about problems in dim light as their sole primary symptom 
at onset, although no patient reported night blindness in the first 
decade of life. Flashing lights were reported as the primary symptom 
by 8% patients, 6% complained of loss of peripheral visual field and 
8% had multiple symptoms.  
Figure 3-24: GC754 showing 2 generations of non-penetrance – IV:16 
and V:23 being obligate carriers 
 
Among the 62 examined patients, 16 (25.8%) were completely 
asymptomatic and were diagnosed on the basis of genetic test and/or 
ophthalmic examination. The mean age of these patients was 42.76 
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years with a median of 40 years. The range varied from 24 years to 63 
years of age.  
Best Corrected Visual acuity (BCVA) in logMAR correlated with age 
(Spearman’s rank correlation coefficient r = 0.6126, p<0.0001) (Figure 
3-25). On performing the survival analysis, the median age at which 
BCVA deteriorated to worse than 6/9 in RP1 patients was 77 years 
which was 20 years later than that observed in PRPF8 patients (57 
years) (Log rank Mantel-Cox test p<0.0001) (Figure 3-26). 
Figure 3-25: Correlation of best-corrected visual acuity with age 
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Figure 3-26: Survival analysis of visual acuity of patients with RP1 
mutations and patients with PRPF8 mutations 
 
Reliable Goldmann visual field data could be obtained from 48 eyes of 
24 patients. Some patients had visual fields done multiple times 
resulting in more data points (57) than eyes (48). The median age at 
which the visual field in the larger field eye deteriorated to 10° or worse 
in RP1 patients was 83 years which was 19 years later than that 
observed in PRPF8 patients (64 years) (Log rank Mantel-Cox test 
p<0.0001) (Figure 3-28).  
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Figure 3-27: Variability of visual fields in RP1 mutation carriers. A-73-
year-old female with p.R677X , B-64-year-old male with p.R677X , C- 
36-year-old female with p.R677X, D-75-year-old female with p.R677X , 
E- 52-year-old man with p.L866KfsX7, F- 64-year-old man with 
p.L866KfsX7. 
 
 
 
 
Results 
155 
 
Figure 3-28: Survival analysis of visual field deterioration of patients 
with RP1 mutations compared with those with PRPF8 mutations 
 
 
56 patients underwent AF imaging while 46 underwent OCT. FAF 
images in 32/56 (57.14%) cases delineated the area of retinal 
dystrophy and showed a ring of high autofluorescence around the 
fovea. Among the rest 18/56 (32.14%) patients had normal 30° 
autofluorescence. 6/56 (10.71%) patients had widespread hypo-
autofluorescence involving the macular region in a patchy distribution.  
The spectral domain OCT in patients with RP1 retinal dystrophy showed 
preserved photoreceptor-RPE complex at the posterior pole within the 
hyper-autofluorescent FAF ring in 33/46 (71.7%) patients. Among the 
rest of the patients (12/46), there were patchy disruptions of the 
photoreceptor layer which corresponded to the absence of normal 
autofluorescence pattern. In 1 patient, there was a lamellar macular 
hole at the fovea. 
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Figure 3-29: Variability of fundus phenotype in RP1 patients. A - 35-
year-old asymptomatic male with p.L866KfsX7 showing absence of 
pigment, B - 36-year-old female with p.R677X, C – 45-year-old female 
with perifoveal atrophy having p.I725RfsX6 mutation, D – 64-year-old 
female with p.K673RfsX9, E - 49-year-old female with p.I725RfsX6 
mutation with very little pigment migration, F – 51-year-old female with 
sectoral pigment distribution. 
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Figure 3-30: Variability of autofluorescence and OCT phenotype in the 
same family GC903. A and B are images from two sisters carrying the 
RP1 mutation p.K673RfsX9; A (72 years) is 3 years older than B (69 
years) and has macular involvement while B has perimacular 
hyperautofluorescent ring and retained macular OCT morphology. 
 
18/98 (18.37%) patients developed macular oedema. The BCVA of eyes 
with macular oedema varied from 0 (6/6) to 1 (6/60) [Median=0.301 
(6/12)]. The ages of the patients who developed macular oedema 
ranged from 34 years to 72 years.  
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3.2.3.1.1 Electrophysiology 
 
ERG findings on 33 patients are presented in Figure 3-31. Full-field 
ERGs of patients with RP1 mutations were consistent with rod-cone 
dystrophy. The amplitude of dark-adapted bright flash ERG a-waves 
varied greatly, consistent with differing degrees of rod photoreceptor 
involvement. Patients with RP1 dystrophy showed wide variation in the 
function of their rods and cones. Retinas with similar rod photoreceptor 
degeneration demonstrated by dark adapted bright flash a-wave 
showed wide variation in cone system function (Figure 3-31A). 
Transient cone ERG b-wave amplitude showed milder or no reduction 
in our cohort. 30Hz flicker ERGs were delayed in 16 cases by 1-16ms 
(median 6ms) indicating variable extent of the degeneration. The major 
scotopic and photopic ERG amplitude parameters correlated weakly 
with age (Figure 3-31B). 
The macular function as measured by pERG P50 was compared with 
age (Figure 3-31C). In 3/33 patients (9%) cases the amplitude of p50 
was lower than 1µV. Thus, in 91% patients, even those with age more 
than 60 years, macular function as measured by pERG p50 amplitude 
were preserved.  
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Figure 3-31: A – ERG amplitude as a percentage of lower limit of normal 
values in ascending order of dark adapted bright flash a-wave in all 
patients showing the spread of the cone function. B – ERG amplitude 
as a percentage of lower limits of normal values compared to age. C – 
pERG p50 amplitudes compared to age 
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3.2.4 DISCUSSION 
 
This section describes the phenotype of adRP caused by heterozygous 
mutations in the RP1 gene and attempts to establish the genotype-
phenotype correlations.  
About 20% of adRP in MEH is caused by RP1 mutations. This figure is 
significantly larger than similar studies conducted previously (3.5%) 
(Sullivan et al., 2006a). One possible explanation of such a large 
difference can be racial. Unlike previous studies which were conducted 
in North America with possible mix of African, Hispanic and Caucasian 
haplotypes, all families with RP1 mutations in our cohort belonged to 
White European population. Thus, RP1 may be an important cause of 
adRP in Caucasians in general and White British population in particular. 
The screening for mutations in the RP1 gene was limited to the 
mutational hotspot (c.617-c.1081). This was based on the available 
evidence that all the adRP causing mutations are located within this 
region. Further supporting this hypothesis is the fact that several 
groups have attempted to screen the whole RP1 gene including the un-
translated regions but have failed to identify a pathogenic change 
(Jacobson et al., 2000, Audo et al., 2012, Zhang et al., 2010). 
All the mutations associated with adRP cause premature truncation of 
the C-terminal end of the protein due to formation of a stop codon 
either by frameshift or by alteration of a single base. This study has 
identified 5 novel mutations all of which cause premature stop codon 
formation. The main conserved domains in the RP1 protein are the two 
doublecortin domains near the N-terminal of the protein. However, it is 
the C-terminal end of the protein, which contains the mutational 
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hotspot where all the adRP mutations conglomerate. So far the function 
of this region of the protein is unknown. As the hotspot is in the terminal 
fourth exon of the gene, it is predicted to survive nonsense-mediated 
decay. This has been established by Liu et al who demonstrated the 
presence of truncated protein in human cultured lymphoblasts in a 
patient with RP1 p.Arg677* mutation (Liu et al., 2003). Thus, 
haploinsufficiency is an unlikely mechanism for disease in heterozygous 
RP1 mutations while dominant negative effect is more plausible. 
Interestingly, non-sense mutations near the 3’ end of the gene have 
been shown to be non-pathogenic in Chinese and Japanese populations 
(Baum et al., 2001, Kawamura et al., 2004). Thus, it can be concluded 
that a relatively small region near the C-terminus of RP1 performs an 
unknown important function, alteration of which impairs the working of 
the normal allele.  
Most of the examinations were conducted in patients aged between 20-
80 years. This is indicative of the fact that symptoms for RP1 retinal 
dystrophy appears rarely in the first two decades of life. Corroborating 
with this observation is that the median onset of symptoms was 32 
years. This agrees with observations from previous studies (Audo et al., 
2012, Berson et al., 2001). As expected for an autosomal dominant 
disease, there was no influence of gender on the onset of the disease. 
A quarter of the patients were asymptomatic who were detected by 
ophthalmic examinations or genetic testing. It can be concluded that 
similar patients with minimal symptoms can be diagnosed as unaffected 
or non-penetrant as has been observed in previous studies (Audo et 
al., 2012, Berson et al., 2001, Jacobson et al., 2000). However, the 
retinas of all the asymptomatic individuals could be identified as 
carrying the mutation by fundus photography, autofluorescence or 
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electrophysiology. Hence, the RP1 dystrophy can be described as highly 
variable and with some individuals being non-penetrant for symptoms. 
Visual acuity in a patient with retinitis pigmentosa can be influenced by 
various factors like cataract, macular oedema, keratoconus, amblyopia 
etc. Overall, when plotted against age, there was a gradual reduction 
of visual acuity. The Kaplan-Meier survival curve using outcome as the 
age when visual acuity worsens beyond 6/9, showed that the patients 
with RP1 mutations generally retained their visual acuity longer than 
their counterparts with PRPF8 mutations. This difference was more 
marked during early life but tended to persist even in advanced years 
of life. However, there are limitations to such an analysis like other 
confounding factors, variability within observations and reliability of 
subjective testing. The survival analysis also assumed that all patients 
had better or equal to 6/9 visual acuity at birth and the vision got worse 
with age and disease. Even with these limitations, the pattern ERG, 
autofluorescence and OCT data supported the conclusion that patients 
with RP1 retinal dystrophy tended to retain their central macular 
function longer. 
Similar survival analysis was performed for visual field with 10° visual 
field as the outcome. The visual field deteriorated for most patients 
slowly till the sixth decade following which the rate of decline 
accelerated. Although this analysis had fewer confounding factors, 
more data is required to improve the confidence and draw better 
conclusions. 
As observed in previous studies the retinal fundus imaging revealed a 
variable phenotype (Jacobson et al., 2000, Audo et al., 2012, Berson et 
al., 2001). Although most patients showed circumferential mid-
peripheral disease, several young patients showed evidence of 
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involvement of nasal and inferior sector only. However, 
electrophysiology failed to reveal a limited phenotype and these 
patients had a mild generalised rod-cone dystrophy even though the 
intra-retinal pigment migration was limited to infero-nasal sectors. In 
one female, the retinal involvement was completely unilateral 
(Mukhopadhyay et al., 2011). The complete unilaterality of the disease 
due to environmental influences or genetic modifiers is difficult to 
explain. One possible explanation could be a somatic genetic change 
appearing in the progenitor cells of the unaffected eye ameliorating the 
effect of pathogenic mutation. 
18% patients with RP1 mutations developed macular oedema which 
was similar to that observed in other studies (Fishman et al., 1977, 
Pruett, 1983). However, Hajali et al described a significantly higher 
incidence of macular oedema (52%) among a genetically 
heterogeneous group of adRP patients (Hajali et al., 2008). It is 
probable that RP1 adRP causes fewer cases of macular oedema. Further 
studies are required to substantiate or refute the above conclusion. 
Electrophysiological analysis was performed in about a quarter of the 
patients. As observed in other studies, all cases were that of rod-cone 
dystrophy with rod-system involvement at the photoreceptor level 
being more pronounced than cone-system involvement (Jacobson et 
al., 2000). The patients maintained macular function even during their 
sixth decade of life. This agrees with the previous observations 
regarding visual acuity, FAF and OCT. 
No genotype-phenotype correlations were observed for visual acuity. 
However, in the case of non-sense mutations, the loss of visual field 
seemed to progress faster than in case of the frameshift mutations. 
More data is required to substantiate this observation. 
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Overall, heterozygosity for the RP1 mutations generally causes a mild 
adult onset rod-cone retinal degeneration. Macular function remained 
normal or relatively preserved until the late stages in most cases. 
Unilateral disease and sectoral distribution of the pigment have been 
observed. 
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3.3 AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA WITH INTRAFAMILIAL 
VARIABILITY AND INCOMPLETE PENETRANCE IN TWO FAMILIES CARRYING 
MUTATIONS IN PRPF8 
 
3.3.1 INTRODUCTION 
 
Seven genes, PRPF3, PRPF4, PRPF6, PRPF8, PRFP31, RP9 and 
SNRNP200 encode splicing factors which together account for 
approximately 15% of families with adRP in the United Kingdom (Figure 
3-2). There are few detailed descriptions of the clinical phenotype 
associated with PRPF8 mutations (Towns et al., 2010). This section 
describes the detailed clinical phenotype in two British families with 
adRP associated with mutations in PRPF8 (Maubaret et al., 2011). 
 
3.3.2 METHODS 
 
3.3.2.1 Clinical Assessment 
 
Two families, a six-generation (GC171) and another three-generation 
(GC16352), were ascertained from the inherited eye disease clinic of 
the Moorfields Eye Hospital (Figure 3-32). Eight members of GC171, 
seven affected and one mildly symptomatic underwent ophthalmic 
examination. Colour fundus photography was performed in five out of 
eight patients; three had autofluorescence imaging (FAF) and spectral-
domain optical coherence tomography (SD-OCT) and four had 
Goldmann visual field examination (VF). Four affected members of 
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GC16352 were examined and underwent colour fundus photography 
and three had FAF and SD-OCT.  
 
Figure 3-32: Pedigrees of GC171 and GC16352 
 
Full field electroretinography (ERG) was performed using the 
International Society for Clinical Electrophysiology of Vision (ISCEV) 
standards (McCulloch et al., 2015) in two of the milder affected 
members of GC171 (IV.8 and V.12) and a young (6-year-old) affected 
(III.2) from GC16352 who underwent a modified paediatric ERG 
protocol (Marmor et al., 2009) (Figure 3-32). 
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3.3.2.2 Molecular genetic analysis 
 
Molecular genetic analysis and mutation screening was performed by 
Dr Cecilia Maubaret at UCL Institute of Ophthalmology, London, UK. 
After obtaining written consent, blood samples from affected and 
unaffected family members were collected for DNA and RNA 
extractions. RNA was isolated from lymphocytes of one affected 
member from each family (Trizol; Invitrogen, Paisley, UK). 
Microsatellite markers flanking known genes for adRP were selected 
from a linkage mapping set (ABI Prism Linkage Mapping Set v 2.5; 
Applied Biosystems, Foster City, CA) and additional FAM-labeled 
microsatellite markers were selected from the Ensembl database. 8 
PCRs were done (Absolute QPCR; Thermo-Fisher, Epsom, UK) 
according to manufacturer’s instructions. The resultant PCR products 
were loaded in a DNA sequencer (ABI model 3730; Applied Biosystems) 
and the genotyping calls and Mendelian error checks were performed 
with commercial software (GeneMarker, version 1.70; Biogene, 
Cambridgeshire, UK) for linkage analysis.  
 
3.3.2.2.1 Mutation Screening 
 
cDNA was synthesized from leukocyte RNA (patient IV.2 in GC171 and 
II.2 in GC16352) using reverse transcriptase (Superscript III Reverse 
Transcriptase; Invitrogen) according to manufacturer’s instructions. 
Mutation analysis was performed by Sanger sequencing of the cDNA 
using a terminator sequencing kit (BigDye ver 3.1; Life Technologies, 
Paisley, UK) on the ABI 3730 machine (Applied Biosystems). cDNA 
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sequences obtained for patient IV.2 and II.2 were compared with the 
reference sequence of PRPF8 from the Ensembl database. 8 Primers 
used for PCR and sequencing are described in Table 2 of Towns et al 
(Towns et al., 2010). Exons and nucleotides were numbered according 
to OMIM (Online Mendelian Inheritance in Man; 
http://www.ncbi.nlm.nih.gov/Omim/ provided in the public domain by 
the National Center for Biotechnology Information, Bethesda, MD) ID 
607300. For the other members of the families, genomic DNA was 
sequenced using primers e38F/e39R in GC171 and e42F/e42R in 
GC16352. DNA from 130 healthy Caucasian controls (Sigma-Aldrich, 
Dorset, UK) was sequenced for the two identified mutations from 
GC171 and GC16352.  
 
3.3.3 RESULTS 
 
3.3.3.1 Clinical Assessment 
 
3.3.3.1.1 GC171 
 
Seven clinically affected members aged between 37 and 82 years and 
one mildly symptomatic, obligate carrier (68 years) were assessed. Six 
affected subjects complained of night blindness as the first symptom. 
The age of onset of the night blindness varied within family members 
from early childhood (patients V.10, V.11, V.12) to mid-thirties (IV.12). 
Visual field constriction was reported in late teens in patients III.2 and 
V.11 and after the age of forty in patient IV.12. Patient IV.8, an obligate 
carrier, reported no problems driving at night or looking at stars in the 
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night sky although had confessed to mild difficulty in different lighting 
conditions previously. He did not complain of any visual field 
constriction. Best corrected visual acuity (BCVA) in the better eye was 
6/12 or better in five out of seven symptomatic patients. In the 82-
year-old female (III.2), BCVA was 6/18 in the right and 6/36 in the left 
eye while in a 59-year-old male (IV.2), it was hand movements right 
and 6/18 left eye. Bilateral sub-capsular cataract was observed in 
patients III.2 at a young age, IV.2 (age 34 years), and V.11 (age 33 
years).  
In all patients fundoscopy revealed attenuated retinal vessels, pale 
optic nerve head and variable degrees of diffuse bone spicule like 
pigment clumping within the neurosensory retina (Figure 3-33A).  
Asteroid hyalosis was observed in the left eye of patient IV.12. Patient 
V.11 had bilateral optic nerve drusen. Patient IV.2 developed Coats-like 
retinal telangiectasia in his right retinal periphery resulting in a vitreous 
haemorrhage when aged 34 years. Patient IV.12 had an episode of 
angle closure glaucoma at 41 years of age. Cystoid macular oedema of 
various degrees was observed in four symptomatic patients (IV.2, V.10, 
V.11, and V.12). Individual IV.8 had a normal retinal appearance 
(Figure 3-33C).  
Extensive peripheral atrophy was present in two affected individuals in 
FAF images with a small peri-foveal ring of increased autofluorescence 
(Figure 3-33A). OCT showed preserved outer retinal structure in the 
area delineated by the ring of hyperautofluorescence (Figure 3-33A). 
In another patient (IV.2), OCT showed disruption of the outer retinal 
structure in the fovea (Figure 3-33A). FAF and OCT of the only mildly 
symptomatic obligate carrier (IV.8) (Figure 3-33C) were normal.  
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Figure 3-33: Variability of phenotype of PRPF8 retinitis pigmentosa. (A) 
GC171 – (A1)-Right fundus of 60-year-old male with OCT of the right 
(A2) and left eye (A3), (A4, A5)-Right fundus and FAF of a 51-year-old 
female, (A6, A7) Right fundus of a 38-year-old male with FAF. (B) 
GC16352 – (B1, B2) show the fundus and AF of a 49-year-old male. 
Fundus photographs (B3, B5) and FAF (B4, B6) at age 15 and 11 years 
of age respectively of a female subject (C) Fundus photographs, 
autofluorescence, spectral-domain OCT, and Goldmann visual fields of 
asymptomatic individual IV.8 of GC171 showing relative preservation of 
normal structure and function at 63 years of age. 
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Goldman perimetry showed a variable degree of visual field loss with 
patient V.12 retaining approximately 50° of horizontal visual field in the 
better eye with the biggest and brightest target (V4e) at 34 years of 
age while V.10 had near normal fields at 37 years of age. Subject IV.2 
had a small central field of approximately 15° at 38 years of age with 
retention of a temporal island of preserved field. Individual IV.8 had 
normal visual fields at 63 years of age (Figure 3-33C). 
Electrophysiological testing of the patient (IV.8) who complained of 
only mild contrast adjustment showed mildly abnormal rod 
photoreceptor function (rod specific ERGs were normal but bright flash 
[DA 11.0] a-wave was mildly reduced). Cone ERGs were normal (Figure 
3-34A). Subjects V.10 and V.12 had only residual detectable rod and 
cone ERGs in keeping with a severe rod-cone dystrophy. 
 
3.3.3.1.2 GC16352: 
 
The proband, a 35-year-old man (Figure 3-32, lower panel, II.2), had 
night vision problems from early childhood and was diagnosed with RP 
in his late teens. He later developed deterioration of central vision and 
when examined aged 35 years, right eye BCVA was 6/24 with hand 
movements in the left eye. At that time his Esterman supra-threshold 
bilateral visual fields were reduced to 5°. He developed bilateral 
subcapsular cataracts in his mid-twenties. His half-brother (II.1), 
sharing the same mother, was also affected and had early onset of 
subcapsular cataracts for which he underwent bilateral cataract 
surgery. His BCVA at 48 years of age was 3/60 right and left. His older 
daughter (III.2) developed night blindness in early childhood. BCVA at 
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age 15 years was 6/10 right eye; 6/5 left eye. The youngest daughter 
(III.3) was noted to be night blind in the first decade and at age 11 
years had BCVA of 6/15 in both right and left eyes. According to reports 
from her sons, the deceased grandmother of the two affected females 
(I.2) had no visual symptoms when she died at the age of 69 years. All 
symptomatic family members examined showed severe attenuation of 
arterioles, pale optic discs, and sparse intraretinal pigment migration 
(Figure 3-33B).  
Figure 3-34: Electrophysiology of affected individuals. (A) ISCEV 
standard ERGs of patient IV.8 of GC171 (see Figure 3-33C 63 years of 
age, asymptomatic) show subnormal DA 11.0 a-wave amplitude. (B) 
ERGs of patient III.2 of GC16352 (6 years of age, symptomatic) show 
severe generalized loss of both rod and cone photoreceptor function 
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FAF in patient II.1 showed peripheral and central macular atrophy, 
while there was preservation of central macula with perifoveal 
hyperautofluorescent ring in the two young females (III.2 and III.3) 
(Figure 3-33B). FAF and OCT revealed bilateral macular oedema in both 
III.2 and III.3 with the younger more affected (Figure 3-33B). OCT of 
II.1 showed central macular atrophy.  
Electrophysiological assessment of III.2 at 6 years of age using 
paediatric protocols revealed severe photoreceptor dysfunction with 
undetectable waveforms (Figure 3-34B).  
 
3.3.3.2 Mutational Screening: 
 
3.3.3.2.1 GC171:  
 
Linkage analysis with flanking microsatellite markers to all known adRP 
loci showed strong evidence for linkage at the RP13 locus (markers 
D17S849, D17S831, D17S1840, D17S1574, and D17S525). Because 
PRPF8 is the gene implicated in RP13, it was initially decided to directly 
sequence exon 42 as all published mutations have been found in this 
exon. No variant was found by direct sequencing of the proband IV.2. 
Therefore, RNA from IV.2 was extracted, reverse transcribed, and 
PRPF8 cDNA was directly sequenced allowing for a quick investigation 
of possible splicing defect and/or exonic mutation. The variant c.6353 
C>T, was identified in exon 38 in a heterozygous state (Figure 3-35, 
upper panel). Direct sequencing of the PRPF8 exon 38 from the 
genomic DNA of the whole family revealed that all the affected patients, 
and the one mildly symptomatic carrier harboured this change, which 
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was not present in unaffected family members. The mutation c.6353 
C>T (p.S2118F) was not found in 130 unrelated controls from the same 
ethnic origin indicating that this change is likely to be causative of the 
disorder in this family. 
Figure 3-35: Electropherograms of the mutations identified. 
 
3.3.3.2.2 GC16352: 
 
The entire cDNA of affected proband (II.2) was sequenced and the 
mutation c.6930G>C (Figure 3-35, lower panel) leading to p.R2310S 
missense change in the protein was identified in exon 42. The same 
variant was present in all affected family members and was not found 
in 130 control individuals.  
 
3.3.4 DISCUSSION 
 
This section describes the detailed phenotype of affected members of 
a large British family carrying the missense PRPF8 mutation c.6353 C>T 
(p.S2118F) in exon 38 reported by Towns et al (Towns et al., 2010). 
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All previous PRPF8 mutations had been reported to occur in exon 42 of 
the gene (McKie et al., 2001, Martinez-Gimeno et al., 2003, van Lith-
Verhoeven et al., 2002, Tarttelin et al., 1996, Testa et al., 2006). 
Mutations in PRPF8 gene are rare, accounting for 2%–3% of patients 
with adRP in Spanish and American studies,(Daiger et al., 2007, 
Hartong et al., 2006, Martinez-Gimeno et al., 2003, Sullivan et al., 
2006a) and 2.79% in a large United Kingdom cohort (Figure 3-2). These 
percentages are likely to be underestimates given the current restriction 
of screening to exon 42 of the gene. 
Previous reports have documented a severe form of RP in British, 
Spanish, Dutch, and African American families, with mutations in exon 
42 of PRPF8 (Martinez-Gimeno et al., 2003, van Lith-Verhoeven et al., 
2002, Tarttelin et al., 1996, Testa et al., 2006, Walia et al., 2008). The 
previous phenotype descriptions were consistent with an infantile onset 
of night blindness, followed by visual field loss a few years later. All the 
published adult patients have unrecordable ERG values and the rod 
function in affected paediatric population is severely abnormal 
(Martinez-Gimeno et al., 2003, Testa et al., 2006, Walia et al., 2008). 
The phenotype is relatively uniform and there is no evidence of 
variability or incomplete penetrance. 
The present study reveals a high degree of intrafamilial phenotypic 
variability. The age of onset of night blindness varied from early 
childhood to late thirties. One 67-year-old individual heterozygous for 
the c.6353 C>T (p.S2118F) mutation who was only mildly symptomatic, 
had a completely normal fundus appearance. Macular oedema was 
observed in four out of seven patients (IV.2, V.10, V.11, V.12) of GC171 
and two out of four patients (III.2 and III.3) in GC16352 and seems to 
occur with higher frequency in patients with a PRPF8 mutation than 
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other forms of adRP (van Lith-Verhoeven et al., 2002, Tarttelin et al., 
1996, Testa et al., 2006, Walia et al., 2008). AF imaging in symptomatic 
patients with relative preservation of visual acuity, when available, 
revealed a ring of increased autofluorescence surrounding the central 
macula (Figure 3-33). Hyperfluorescent rings of various types are 
observed in RP or Leber’s congenital amaurosis (usually surrounding 
healthy macula) and cone or cone-rod dystrophy or X-linked 
retinoschisis (usually surrounding dystrophic macula)(Robson et al., 
2008). However, in primary RPE retinal dystrophies, such as those 
caused by mutations in MERTK or RPE65, such rings have not been 
described (Mackay et al., 2010, Lorenz et al., 2008). Furthermore, SD-
OCT images in affected patients demonstrate an intact hyper-reflective 
layer at the junction of dystrophic retina and choroid which might 
represent intact RPE-Bruch’s membrane complex. However, in the 
mouse model there is evidence of defective RPE function (Graziotto et 
al., 2011). It is possible that human PRPF8 retinopathy may have thus 
different pathophysiology with relative late demise of RPE. 
The ERG in the mildly symptomatic obligate carrier showed a DA 0.01 
rod ERG within the normal range but a subnormal DA 11.0 bright flash 
ERG a-wave. Cone full-field ERGs and pattern ERGs were normal. The 
consequences of this mutation, which in other family members caused 
legal blindness, were those of minor rod photoreceptor function. 
Affected status was not evident from fundus examination or perimetry. 
This suggests caution in reassuring members of families with PRPF8- 
related disease of their unaffected status and confirms the importance 
of electroretinography in the detection of subclinical disease. 
There is a history of incomplete penetrance in two individuals in the 
second family, but neither was available for examination. The mutations 
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p.R2310K (McKie et al., 2001, van Lith-Verhoeven et al., 2002) and 
p.R2310G (McKie et al., 2001, Martinez-Gimeno et al., 2003) have 
previously been reported and suggests that c.6930G>C (R2310S) in 
exon 42 is a hot spot for mutation. PRPF8, PRPF3, and PRPF31 genes 
are involved in the assembly and function of the spliceosome, which 
clips introns out of pre-mRNA (Smith et al., 2008). The gene PRPF8 
encodes a large and highly conserved nuclear protein (Grainger and 
Beggs, 2005) which stimulates a helicase, Brr2, required for activation 
of the spliceosome (Maeder and Guthrie, 2008). PRPF8 mutations which 
cause adRP inhibit this function. More than 15 different mutations, most 
situated within exon 42 of PRPF8, are associated with RP and 
presumably inhibit the interaction of the PRPF8 protein with Brr2. The 
only detected mutation in PRPF8 outside exon 42 is p.S2118F, which 
was reported occurring in GC16352 (Towns et al., 2010). This non-
conservative amino acid change is predicted to cause significant 
alteration to the structure and function of the PRPF8 protein. 
The function of the C-terminal of PRPF8 protein has been investigated 
using various methods by different laboratories. Grainger and Beggs 
(Grainger and Beggs, 2005) suggested that the nine RP13 missense 
mutations reported in exon 42 of PRPF8 affect seven very highly 
conserved amino acid residues indicating that those residues have a 
conserved function which is altered in case of mutation. Those nine 
amino acids belong to the region of yPrp8p that interacts with Brr2p, 
one of the spliceosomal RNA helicases, and is close to the prp8–1 
(G2347D) mutation, which ablates the binding of C-terminal yPrp8 
peptides by yBrr2p in vitro (van Nues and Beggs, 2001). By yeast two-
hybrid, Fan et al. (Fan et al., 2004) have demonstrated that C-terminal 
94-amino acid region of hPRPF8 interacts with the multifunctional 
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plasminogen activator inhibitor type-2 protein (PAI-2). Therefore, it is 
reasonable to assume that the interaction PRPF8/PAI-2 could also be 
altered in RP13 patients. 
Two different groups have established independently the crystal 
structure of PRPF8 (Reyes et al., 1999, Pena et al., 2007). Both groups 
proposed that the C-terminal domain of PRPF8 including the MPN (Mpr-
1, Pad-1, N-terminal) domain is an interaction domain. They suggest 
that the reported residues mutated in RP13 constitute a binding surface 
between PRPF8 and other partner(s) and the disruption of this 
interaction provides a plausible molecular mechanism for RP13. It is 
notable that exon 38 encodes a part of the MPN domain of PRPF8 and 
S2118 is part of a α1 helix which may be altered by the mutation in the 
present report. 
To conclude, this is the first report of marked intrafamilial variation and 
nonpenetrance associated with two PRPF8 mutations: c.6353 C>T (p. 
S2118F) in exon 38 and c.6930G>C (p.R2310S) in exon 42. The data 
suggest that all exons of PRPF8 should be screened in families with 
adRP and incomplete penetrance. The important role of 
electrophysiological assessment is noted. The findings extend the range 
of phenotypes seen in association with PRPF8 gene mutations and 
provide important information to assist the management of families in 
whom this form of adRP is suspected.  
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3.4 EVALUATION OF THE PHENOTYPES OF RETINAL DYSTROPHIES CAUSED BY 
DE NOVO MUTATIONS 
 
3.4.1 A DETAILED PHENOTYPIC DESCRIPTION OF AUTOSOMAL DOMINANT CONE 
DYSTROPHY DUE TO A DE NOVO MUTATION IN THE GUCY2D GENE 
 
3.4.1.1 Introduction 
 
The cone dystrophies and cone–rod dystrophies (CORD) are a 
heterogeneous group of progressive genetically determined retinal 
disorders, which may be inherited as an autosomal dominant, 
autosomal recessive, or X-linked trait (RetNet). They are characterised 
clinically by a loss of visual acuity, abnormal colour vision, photophobia, 
and visual field loss. Many will develop macular atrophy. 
Electroretinography demonstrates generalised cone system dysfunction 
with either no or mild rod system involvement (Michaelides et al., 
2006). The gene ‘Guanylate cyclase 2D, membrane (retina-specific)’ 
(GUCY2D, MIM ID*600179) accounts for up to 35% of patients with 
autosomal dominant cone dystrophy or CORD (Kitiratschky et al., 2008, 
Payne et al., 2001, Hunt et al., 2010). It was also the first gene to be 
implicated in Leber’s congenital amaurosis, a major cause of blindness 
in children (Perrault et al., 1996). The protein translated by GUCY2D, 
retinal guanylate cyclase 1, is expressed in both rod and cone 
photoreceptors (Yang et al., 1995). Two mutation sites in GUCY2D, the 
codons 575 and 838, have been reported to cause autosomal dominant 
cone dystrophy or CORD (Hunt et al., 2010, Small et al., 2008). The 
mutation p.V933A has also been described in GUCY2D in association 
with the phenotype of autosomal dominant central areolar choroidal 
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dystrophy, a condition similar to CORD (Hughes et al., 2012). The 
importance of identifying this condition is paramount as, using a gene 
therapy technique, a partial restoration of visual function has been 
demonstrated in GUCY2D knockout mouse model increasing the 
likelihood of eventual treatment in humans (Boye et al., 2010). The 
section describes a family with autosomal dominant cone dystrophy due 
to a de novo mutation in the codon 838 in the GUCY2D gene 
(Mukherjee et al., 2014).  
 
3.4.1.2 Methods 
 
All affected patients underwent clinical examination and imaging. 
Electrophysiological assessment was performed in the three affected 
patients using techniques that incorporated the ISCEV standards 
(McCulloch et al., 2015). Additional On–Off ERGs were performed using 
an orange stimulus (560 cd/m2, duration 200 ms) superimposed on a 
constant green background (150 cd/m2). S-cone ERGs were performed 
using a blue stimulus (445 nm, duration 5ms, 80 cd/m2) superimposed 
on a constant orange background (620nm, 560 cd/m2) (Arden et al., 
1999). 
 
3.4.1.3 Results 
 
3.4.1.3.1 Molecular genetics 
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The GUCY2D gene was screened for disease-causing mutations using 
methods described above. The coding region and the intron–exon 
boundaries of 20 published exons (NM_000180.3) were amplified. Four 
microsatellite markers (D17S1828, D17S1876, D17S1791, and 
D17S799) were used to determine the haplotypes of a 9.4-Mb region 
in chromosome 17p surrounding the GUCY2D gene.  
 
3.4.1.3.2 Clinical phenotype 
 
The pedigree of the family is illustrated in Figure 3-37. The clinical data 
on the subjects are summarised in Table 3-13 and illustrated in Figure 
3-36.  
The earliest symptom experienced by the affected subjects was 
reduced central vision. The youngest subject (21-year old) noticed 
deterioration of her visual acuity at 11 years of age. There was a 
discordance in onset of symptoms in the monozygotic twins (44-year 
old) with III:3 noticing problems a decade earlier than III:2. Later in 
the disorder, photoaversion and a difficulty in colour vision developed. 
No subject reported nyctalopia.  
The best-corrected visual acuity of subject IV:1 was 6/18 while vision 
was less than 6/60 in subjects III:2 and III:3. The reduction of vision 
in the right eye of subject II:1 was from an advanced cataract. He had 
undergone retinal reattachment surgery in his left eye. Visual acuity 
was normal in subject II:2. Colour vision (Ishihara) was very poor in 
subjects III:2, III:3, and IV:1.  
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Fundus examination of IV:1 showed mild pigmentary changes in the 
macula. The fundi of the monozygotic twins showed symmetrical well-
demarcated perifoveal retinal thinning. The retina of the right eye of 
II:1 was difficult to examine due to dense cataract. The left eye showed 
peripapillary atrophy and an abnormal foveal reflex. Subject II:2 
showed no abnormality on fundus examination.  
FAF of IV:1 showed a small area of mild hypo-autofluorescence in the 
perifoveal region surrounded by a ring of hyperautofluorescence. 
Subjects III:2 and III:3 both show a larger central area of speckled 
hypo-autofluorescence, reflecting patchy atrophic changes in the retinal 
pigment epithelium (RPE), surrounded by a ring of increased 
autofluorescence. Subject II:2 had normal FAF. FAF could not be 
performed reliably in II:1 due to cataracts.  
OCT was performed in subject IV:1, aged 21 years, and showed abrupt 
disruption of the inner–outer segment junction layer in the subfoveal 
photoreceptors. In her mother and aunt (III:2 and III:3), there is 
thinning of the inner retina with irregular disruption of photoreceptor–
RPE complex. The junction between normal and abnormal outer retina 
corresponded to the hyper-autofluorescent ring referred to above. The 
OCT was within normal limits in II:2 and was not performed in II:1.  
In one of the monozygotic twins III:2, the areas of speckled hypo-
autofluorescence were 6.99 and 6.33mm2 in the right and left eye, 
respectively, while in case of her twin sister the areas were 6.89 and 
6.83mm2 in the right and left eye, respectively. 
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Table 3-13: Clinical phenotype of the family with GUCY2D mutation. (BCVA – Best-corrected visual acuity, OD – Right 
eye, OS – Left eye, N/A – not available) 
Subject 
ID 
Age  Onset  Earliest 
symptom 
Current 
symptoms 
BCVA Refractive 
error 
Colour 
vision - 
Ishihara 
Fundus 
changes 
OD OS 
IV:1 21 
years 
11 years Reduced central 
vision 
Photoaversion 6/18 6/18 Myopia 0/17 Mild macular 
mottling 
III:2 44 
years 
23 years Reduced central 
vision 
Photoaversion 2/60 3/60 None 0/17 Perifoveal 
retinal thinning 
III:3 44 
years 
12 years Reduced central 
vision 
Loss of colour 
and central 
vision, 
Photoaversion 
3/60 1/60 Myopia 0/17 Perifoveal 
retinal thinning 
II:1 68 
years 
No 
symptoms 
Never None 2/60 6/18 Myopia N/A Peripapillary 
atrophy 
II:2 65 
years 
No 
symptoms 
Never None 6/6 6/6 None 17/17 None 
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Figure 3-36: Phenotype of affected subjects IV:1 (A), III:2 (B), III:3 (C), and unaffected subject II:2 (D). The fundus 
photographs show central macular atrophy in III:2 and III:3 (44-year olds) and a normal macula in subjects IV:1 aged 
21 years and II:2 (unaffected; 65 years old). FAF shows a hyper-autofluorescent ring surrounding the central macular 
atrophy in all the affected subjects. The OCT reveals absence of outer retinal layers in the central macula in III:2 and 
III:3 and absence of outer segments in the young IV:1. 
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Figure 3-37: Pedigree of the family of cone dystrophy with p.R838H 
mutation in GUCY2D. The electropherograms demonstrating the gene 
sequence in forward and reverse are demonstrated. The chromosomes of 
individuals are demonstrated using microsatellite markers and are coded. 
 
The b-wave amplitudes of photopic cone ERG in III:2 was 65% on the 
right and 75% on the left eye in comparison to the lower limit of normal 
while the amplitudes were 68 and 72% of the lower limit of normal on the 
right and left eye, respectively, in her monozygotic twin III:3. 
 
3.4.1.3.3 Functional phenotype 
 
Dark-adapted full-field ERGs (DA 0.01, DA11.0) were normal in III:2, III:3, 
and IV:1, in keeping with preserved rod system function (Figure 2a). 
Photopic 30Hz flicker ERGs (LA 3.0 30Hz) showed mild delay (1–4 ms 
above the upper limit of normal) and amplitude reduction. Single flash 
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cone ERGs (LA 3.0 2Hz) showed borderline delay with a subnormal b-
wave:a-wave ratio in all subjects, suggesting generalised system 
dysfunction at an inner retinal level. This was confirmed by On–Off ERGs, 
which showed electronegative On-responses (reduced b-waves); Off- 
response d-waves were of borderline timing and, although of normal 
amplitude, showed an abnormal positive ‘plateau’ following the d-wave. S-
cone ERGs were markedly subnormal. Pattern ERGs were undetectable in 
all the three cases in keeping with severe macular involvement. 
Figure 3-38: Full-field electroretinograms (ERGs) from one eye of subjects 
IV:1 (A), III:2 (B) and III:3 (C) and representative normal traces (bottom 
row). 
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3.4.1.3.4 Molecular genetics 
 
Sanger sequencing of the GUCY2D gene was performed in all the five 
subjects. Three out of the five (IV:1, III:2, and III:3) carried heterozygous 
mutation c.2513G>A p.R838H. The parents (II:1 and II:2) did not carry 
the mutation. Microsatellite markers surrounding the GUCY2D gene 
showed that the mutation segregated with the markers derived from the 
mother (II:2) (Figure 3-37). 
 
3.4.1.4 Discussion 
 
This section describes the detailed phenotype of patients suffering from 
autosomal dominant cone dystrophy consequent upon a de novo mutation 
in GUCY2D, reports the first de novo mutation in the gene, compares the 
phenotype in the monozygotic twins, and expands our knowledge of the 
clinical, electrophysiological, and psychophysical phenotypes of the 
disorder. Onset of the disease as evidenced by a decrease in the visual 
acuity was variable between early teens to early twenties. There was 
relative concordance among the monozygotic twins when the areas of 
speckled hypofluorescence and the b-wave amplitudes of the photopic 
cone ERG were compared. However, there was a discordance of onset 
between the two monozygotic twins of more than a decade although the 
final visual acuity was similar at 44 years of age. Similar variability in the 
age on onset has been described in patients with CORD consequent upon 
GUCY2D mutations (Gregory-Evans et al., 2000, Smith et al., 2007, 
Downes et al., 2001, Ito et al., 2004). All three affected patients in our 
family had generalised cone dysfunction with severe macular involvement, 
but unlike the majority of previous cases, (Ito et al., 2004, Downes et al., 
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2001, Smith et al., 2007, Gregory-Evans et al., 2000) there was no ERG 
evidence of rod system dysfunction. The possibility that rod dysfunction 
will develop later in life cannot be excluded, but there is no evidence of 
scotopic ERG reduction with increasing age in this small cohort. An 
electronegative dark-adapted ERG (b:a ratio < 1.0) has been reported in 
GUCY2D CORD, (Gregory-Evans et al., 2000) but in our family, only the 
light-adapted ERG had a low b:a ratio. The combination of a flicker ERG 
delay, an electronegative On- response and the unusual shape of the Off- 
ERG waveform distinguishes these cases from those with autosomal 
dominant cone dystrophy due to GUCA1A mutation, often associated with 
a reduced cone ERG of normal timing with subnormal On- and Off- ERG 
components (Downes et al., 2001). The latter study speculated that these 
abnormalities could result from impaired transduction kinetics, but there 
is also evidence of weak RetGC expression in the outer plexiform layer (Liu 
et al., 1994) and histological evidence of synaptic disruption in cases of 
CORD (Gregory-Evans et al., 1998). Generalised cone dysfunction was 
accompanied by perifoveal photoreceptor–RPE disruption in the 
monozygotic twins. This structural loss of the central cones may result 
from the high cone density. 
In the phototransduction cascade, exposure to a photon results in a 
decrease in the photoreceptor intracellular Ca2+ concentration. This is 
because light leads to sequential isomerisation of rhodopsin and activation 
of transducin and phosphodiesterase (PDE). PDE hydrolyses cGMP closing 
cGMP-gated cation channels ceasing the calcium influx. RetGC-1, the 
protein translated by GUCY2D is involved in the regeneration of cGMP in 
the photoreceptors. This is achieved in response to lowering of Ca2+ 
concentration under the influence of guanylate cyclase activating proteins 
(GCAP). The mutation in this report, p.R838H, is believed to cause a gain 
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of function increasing the affinity of RetGC-1 for GCAP even in high Ca2+ 
concentrations (Wilkie et al., 2000). The cone photoreceptor death in this 
disorder is believed to be caused by the high cGMP concentration keeping 
cGMPgated cation channels open, resulting in increased Ca2+ 
concentration in the cell (Tucker et al., 1999). Decreasing the cGMP 
concentration may be therapeutic for these individuals. This can 
potentially be achieved by increasing photopic exposure of the 
photoreceptors resulting in stimulation of PDE (Liu et al., 2009) or can be 
directly achieved by administration of PDE agonists. Interestingly, PDE6C 
recessive mutations abrogating the PDE function have been described to 
cause a phenotype of early-onset cone photoreceptor dystrophy (Thiadens 
et al., 2009). 
Haplotype analysis of our family confirmed a de novo mutation in GUCY2D 
transmitted from the unaffected mother. However, de novo mutations 
more commonly derive from the paternal germline (Ellegren, 2007). 
Ascertainment of a family showing a de novo mutation in any inherited 
disease affects the counselling advice given to a person presenting with 
the disorder. The diagnosis of the disorder in an individual without a family 
history would usually suggest a recessive inheritance. The recurrence risk 
to future siblings in such a pedigree is extremely low but might occur if 
the de novo mutation involved the parent’s germ-cells, the so called 
germline mosaicism. Given the findings in this family, the possibility of a 
de novo mutation causing a dominant allele in GUCY2D needs to be 
considered as this would dramatically change the risks of recurrence in 
children from a population risk to 50%. The prevalence of families 
presenting this way is not known but will become clearer with the 
implementation of high-throughput sequencing. Alternatively, in cone 
dystrophy, specific tests for dominant alleles in GUCY2D and/or GUCA1A 
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should be considered when seeking a molecular diagnosis even in the 
absence of a family history.  
To conclude, this report expands and refines the phenotypic description of 
patients with the cone dystrophy associated with mutations in GUCY2D 
gene. The existence of a de novo germline mutation herein described 
should alert the physician to its possibility in a family with cone dystrophy 
and has implications for counselling. 
 
 
3.4.2 DE NOVO AND GERMLINE MUTATIONS IN CHM CAUSING CHOROIDEREMIA 
 
3.4.2.1 Introduction 
 
Choroideremia, is an X-linked retinal dystrophy predominantly affecting 
men with early onset night blindness, progressive visual field loss and 
eventual loss of central vision (Sorsby et al., 1952). Although variable in 
onset and progression (Renner et al., 2006), this disorder presents with 
mid-peripheral mottling of retinal pigment epithelium (RPE) which leads to 
patchy atrophy of RPE and choroid. The atrophy usually progresses both 
peripherally and centrally until it involves the fovea. 
The gene CHM (MIM *300390), translates Rab escort protein (REP-1), a 
protein involved in post-translational modification of Rab GTPases, which 
are regulators of phagosome function and vesicular trafficking (Preising 
and Ayuso, 2004, Seabra et al., 2002). Among the mutations reported in 
CHM, all but two (p.L550P (Sergeev et al., 2009) and p.H507R (Esposito 
et al., 2011)) cause premature truncation of the protein resulting in the 
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affected hemizygous males to lack REP-1 function (MacDonald et al., 
1998). The mutation p.L550P causes destabilisation of the tertiary 
structure of the REP-1 protein (Sergeev et al., 2009) while p.H507R results 
in the generation of functionally inactive variant (Esposito et al., 2011) 
effectively causing a deficiency in REP-1 activity.  
In this section, three families are described where choroideremia is caused 
by a de novo germline mutation in CHM in females with normal phenotype. 
This report makes it even more important to confirm the carrier status in 
a mother of an affected male prior to genetic counselling advice. 
 
3.4.2.2 Methods 
 
Three families were ascertained from the inherited eye disease clinic of 
Moorfields eye hospital (MEH). All three affected males and their 
unaffected mothers underwent complete ophthalmic examination and 
imaging. PCR and Sanger sequencing of the coding region and intron-exon 
boundaries of the fifteen published exons of CHM (NM_000390.2) was 
performed. Multiplex ligation-dependent probe analysis (MLPA) was 
performed to detect large deletions or insertions in the CHM, RP2 and 
RPGR genes on the X-chromosome. Four microsatellite markers (DXS1216, 
DXS986, DXS1196 and DXS8077) were used to determine the haplotypes 
spanning approximately 2.7 Mb region on Chromosome Xq surrounding 
CHM. 
Splice site prediction tools, Automated splice site analysis (Nalla and 
Rogan, 2005), Human splicing finder version 2.4.1 (Desmet et al., 2009), 
NetGene 2 (Brunak et al., 1991) and NNSPLICE 0.9 (Reese et al., 1997) 
were used to identify the effects of the intronic nucleotide substitutions  
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3.4.2.3 Results  
 
3.4.2.3.1 Clinical phenotype 
 
The clinical features of the affected individuals are illustrated in Figure 
3-39 and described in Table 3-14. 
The affected males of the three families presented with an early symptom 
of night blindness which manifested between 6 to 15 years of age. All the 
patients complained of visual field loss. None of the patients had significant 
general medical disorders. Pedigree analysis of all three families showed 
no other affected relatives (Figure 3-40). 
The best-corrected Snellen visual acuities of all patients ranged from 6/6 
to 6/9. Slit-lamp examination revealed normal anterior segments with 
intraocular pressures within normal range. Dilated fundoscopy showed 
variable amount of atrophy in the mid-peripheral retina with sparing of 
central macula in both eyes (Figure 3-39). The areas of atrophy became 
more clearly delineated and increased in size with age. There were variable 
amounts of intra-retinal pigmentation. In all cases, the optic discs were 
pink in colour and the retinal blood vessels retained normal calibre.  
Autofluorescence imaging delineated the areas of preserved retina in the 
central macula (Figure 3-39). Optical coherence tomography of both eyes 
showed preserved retina and choroid in the areas of retained 
autofluorescence while the areas of atrophy showed complete absence of 
outer layers of the retina and severe thinning of the choroid (Figure 3-39). 
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Figure 3-39: Clinical characteristics of the affected males with de novo 
CHM mutations. In all cases, the fundus photographs, FAF images and 
OCT scans of the left eyes are demonstrated. Panel A: V:1, GC18470; 
Panel B: IV:5, GC15975; Panel C: IV:2, GC15155. The fundus photographs 
clearly delineate the areas of extensive chororioretinal atrophy. In the FAF 
images, the areas of atrophy are shown as dark regions which surround a 
central area of perimacular sparing. In the areas of normal 
autofluorescence, OCT shows normal retinal morphology while in other 
areas there is extensive atrophy and some tubule formation. 
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Table 3-14: Clinical features of the affected patients with choroideremia. 
Subject 
ID 
Mutation Age Age 
of 
onset  
Earliest 
symptom 
Other 
symptoms 
BCVA  Fundus 
changes 
OD OS 
V:1 – 
GC18470 
c.49+3_49+16 
delins 
GCTTCCTGGTG 
CTTCCTGGAC 
21 
years 
15 
years 
Night 
blindness 
Peripheral 
visual field 
loss 
6/9 6/12 Mid-
peripheral 
patchy 
chorioretinal 
atrophy. 
Intra-retinal 
pigment  
IV:5 – 
GC15975 
c.1-
?_1413+?del 
18 
years 
6 
years 
Night 
blindness 
Peripheral 
visual field 
loss 
6/6 6/6 Mid-
peripheral 
patchy 
chorioretinal 
atrophy. 
Minor intra-
retinal 
pigment  
IV:2 – 
GC15155 
c.941-2 A>G 31 
years 
10 
years 
Night 
blindness 
Peripheral 
visual field 
loss 
6/6 6/6 Large areas 
of 
chorioretinal 
atrophy. 
Minor intra-
retinal 
pigment 
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Figure 3-40: The pedigrees of the three CHM families. In two families, 
alleles identified on microsatellite analysis are demonstrated by the bars 
 
Choroideremia was diagnosed in the affected males on the basis of the 
clinical observations. The asymptomatic mothers of the probands had no 
significant ocular or medical history. Ophthalmic examination showed 
normal anterior and posterior segments with no evidence of carrier signs 
of choroideremia. A detailed family history showed the presence of many 
ostensibly unaffected male relatives (Figure 3-40) with either a 1 in 2, or 
1 in 4 prior risk of being affected. 
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3.4.2.3.2 Molecular genetics 
 
Bi-directional Sanger sequencing of CHM in DNA derived from leukocytes 
of the proband and the mother showed the mutations shown in Table 
3-14. In all three families, the mother was homozygous for the wild-type 
sequence. In-silico analysis of the intronic mutations predicted disruption 
of the splice sites. 
Haplotype analysis using four microsatellite markers surrounding CHM was 
performed in two families as illustrated in Figure 3-40. In both cases 
maternity was confirmed. These data strongly suggest the occurrence of 
the CHM mutation de novo in the mother, including the cell producing the 
gamete of the affected son. Analysis of the unaffected brother (IV:1) of 
the proband of family 15155 showed the wild type CHM allele, and 
inheritance of the other maternal X chromosome to that of his brother. 
 
3.4.2.4 Discussion 
 
In this section, three families showing de novo mutations in CHM causing 
choroideremia are presented. This significant incidence of de novo 
mutations in CHM makes it important to genetically screen the mother of 
the affected male. Absence of the mutation in the female significantly 
alters the risk of having another affected male child from 50% to 
negligible. 
In our cohort of 52 families with genetically confirmed choroideremia, 3 
families presented with de novo mutations in females with no clinical signs. 
Our report suggests the incidence of a de novo mutation in CHM to be 
5.77% in the British cohort. The first suggestion of a de novo mutation in 
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CHM was reported in one patient in a screen of 35 patients (2.8%) (van 
den Hurk et al., 2003). This implies large screens of CHM should identify 
more cases of de novo mutations.  
Recent studies have suggested a prevalence of between 28-49 de novo 
germline mutations per meiosis in humans (Roach et al., 2010, Durbin et 
al., 2010). de novo germline mutations are more common in paternal germ 
cells presumably due to the greater number of cell divisions prior to 
gametogenesis of sperm compared to ova (Ellegren, 2007). In this 
respect, these families are unusual in there being a maternal origin of the 
de novo mutation.  
Deleterious mutations usually decrease the biological fitness of the trait 
resulting in negative selection. One of the mechanisms of maintenance of 
the disorder in the population is high frequency of de novo mutations. 
Although rare de novo mutations have been described in retinal 
dystrophies (Gehrig et al., 1999, Schwartz et al., 2003, Chang et al., 2007), 
these are mainly in the regions of mutational hotspots of the respective 
genes. In our families, the mutations are novel and are distributed along 
the whole gene (Table 3-14). 
Description of a de novo mutation in any inherited disease affects the 
counselling advice given to families. The diagnosis of the disorder in a 
male, would usually suggest a 1 in 2 prior risk to brothers, and the same 
risk of carrier status to sisters. Given the findings in these families, the 
possibility of a de novo mutation has to be considered, particularly if there 
is no clear maternal history of affected males, and if the mother is 
unavailable for examination for carrier signs. Moreover, when young, 
female carrier signs can be subtle and difficult to interpret. This report 
makes it more important to confirm carrier status in the mother of an 
affected male prior to genetic counselling advice.  
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3.5  A PHENOTYPIC DESCRIPTION OF PATIENTS WITH MONO-ALLELIC MUTATIONS 
IN THE RPE65 GENE 
 
3.5.1 INTRODUCTION 
 
Retinal dystrophies are a group of inherited disorders characterised by 
impairment in retinal function. Mutations in the visual cycle genes are 
responsible for a significant proportion of these disorders. One such gene 
is RPE65, mutations in which are associated with three distinct 
phenotypes. The phenotype first associated with bi-allelic mutations in 
RPE65, was that of Leber’s congenital amaurosis (LCA) (Marlhens et al., 
1997, Gu et al., 1997). Since, patients with phenotype similar to LCA have 
been observed with RPE65 mutations. These patients presented in infancy, 
frequently suffered from nystagmus, night blindness and a tendency to 
fixate on light (Thompson et al., 2000). Fundus examination showed pale 
retina with retinal pigment epithelium (RPE) atrophy in the periphery. Rod 
electroretinograms (ERGs) were undetectable and cone ERGs were 
extinguished late in the first decade. However, unlike classic description 
by Theodore Leber in 1869 (Leber, 1869), many of these patients retained 
useful vision until the second decade of their lives (Walia et al., 2010). 
These patients have been documented variously as juvenile and early-
onset retinitis pigmentosa (Foxman et al., 1985, Lorenz et al., 2000), 
childhood-onset severe retinal dystrophy (Gu et al., 1997), early onset 
severe retinal dystrophy (Lorenz et al., 2000), and severe early childhood 
onset retinal dystrophy (Weleber et al., 2011). 
The second phenotype described recently was that of fundus albipunctatus 
(Schatz et al., 2011). The only subject described had compound 
heterozygous mutations in RPE65. She was night blind from birth, had 
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relatively good visual acuity at 18-years of age and had scattered 
homogeneous yellow-white dots in the outer retina.  
The third distinct phenotype associated with a mono-allelic mutation was 
identified in an Irish family (Bowne et al., 2011). These patients presented 
in 2nd to 5th decade with impaired dark adaptation. Although there was 
variability within the family, the severely affected individuals exhibited 
extensive diffuse chorioretinal atrophy and variable intra-retinal 
pigmentation. 
In this section, two families with dominant RPE65 mutation have been 
described where two distinct phenotypes are expressed, one of which has 
never been associated with RPE65. 
 
3.5.2 METHODS 
 
Patients underwent detailed ophthalmic examination and imaging. 
Electrophysiological assessments were performed according to ISCEV 
standards. Sanger sequencing of the coding region and intron-exon 
boundaries of the published exons of the RPE65 gene was undertaken. 
 
3.5.3 RESULTS  
 
Two families GC11527 and GC16236 were included in the study. Molecular 
analysis of the RPE65 gene in both the families identified the same 
c.1430A>G, p.Asp477Gly mutation.  
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3.5.3.1 GC11527: 
 
The pedigree of the family is illustrated in Figure 3-41.  
Figure 3-41: Pedigrees of RPE65 families – A: GC11527, B: GC16236 
 
3/5 affected individuals in the family were phenotyped. The proband, 
subject III:1 presented at 36-years-age with a distortion of reading vision 
in the left eye. His best-corrected-visual acuities were 6/5 in the right eye 
and 6/9 in the left eye. Patchy chorioretinal atrophy and intraretinal 
pigmentation were observed on fundoscopy. Goldmann kinetic visual fields 
were full in both eyes. At 50-years-age, he complained of night blindness 
and significant reduction in visual field. At 71-years-age, the subject’s 
best-corrected visual acuities were hand movements in the right eye and 
6/48 in the left eye. Retinal examination revealed extensive chorioretinal 
atrophy involving large parts of retina in both eyes. Autofluorescence 
imaging and OCT examination showed extensive atrophy of the retina and 
the choroid in both eyes. He had retained a small part of his mid-peripheral 
visual field in his left eye.  
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His deceased mother, subject II:1 was phenotyped at 87-years-age. Her 
presenting symptom was decreased reading vision at 45 years of age. She 
had hand movements vision in the right eye and perception of light vision 
in the left eye. Ophthalmic examination showed extensive chorioretinal 
atrophy involving large parts of her retina in both eyes. 
Examination of subject III:3 showed a completely different phenotype. He 
presented with distortion of reading vision at 46-years-age. On dilated 
fundoscopy, a yellowish-white sub-retinal deposit was observed in his 
fovea bilaterally. On fundus autofluorescence imaging, the deposit was 
markedly hyper-autofluorescent. On OCT examination, there was a distinct 
hyper-reflective dome-shaped sub-retinal lesion in both eyes. Subject II:2 
was asymptomatic and could not be phenotyped. 
The DNA of the proband, subject III:1 was analysed for mutations in the 
C1QTNF5, the PRPH2 and the CHM gene which failed to detect any 
pathogenic mutations. Molecular analysis of the RPE65 gene identified 
p.Asp477Gly mutation in all the symptomatic individuals as well as 
asymptomatic subject II:2. The subject III:3 was also screened for 
mutations in the PRPH2 gene which did not reveal any pathogenic 
mutations. 
 
3.5.3.2 GC16236: 
 
The pedigree of the family is illustrated in Figure 3-41. The proband, 
subject III:1, presented with difficulty in reading at 33-years-age. At the 
time his best-corrected visual acuities were 6/36 in the right eye and 6/18 
in the left eye. Retinal examination showed presence of patchy 
chorioretinal atrophy in both eyes. He developed night vision difficulties at 
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38-years-age while his visual acuities worsened with time. At 46 years of 
age, his best-corrected visual acuities were hand movements in both eyes. 
Fundoscopy showed extensive chorio-retinal atrophy in both eyes 
involving the fovea. OCT examination and fluorescein angiography 
demonstrated the same areas of atrophy. Electrophysiology at 33-years-
age showed severely abnormal rod-specific ERG, delayed and subnormal 
cone function and markedly subnormal pattern ERG. EOG light rise was 
abolished. 
Figure 3-42: Variability in the phenotypes of patients with p.D477G 
mutation in the RPE65 gene. A – Patient III:1 of GC11527 and B – Patient 
III:1 of GC16236 showing similar phenotype of extensive chorioretinal 
atrophy. C- Patient III:3 of GC11527 showing a much milder phenotype of 
adult-vitelliform macular dystrophy 
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Subject II:1 was examined once at 74-years-age before her demise. At 
the time, her best-corrected visual acuities were 6/60 right eye and 6/24 
left eye. She presented with loss of central vision in her thirties although 
developed night blindness later. Retinal examination showed extensive 
chorioretinal atrophy and large loss of visual fields with preservation of 
some mid-peripheral areas.  
 
3.5.4 DISCUSSION 
 
This section explores and further expands the phenotype of dominant-
acting p.Asp477Gly mutation in the RPE65 gene. It associates the 
phenotype of adult-onset vitelliform macular dystrophy with this mutation 
for the first time. 
The presenting symptom in  all of the affected individuals of both families 
was difficulty in near vision between 33-46 years of age. Although all the 
individuals eventually became symptomatic of night vision abnormalities, 
none of them presented with night blindness as the presenting symptom. 
Subject II:2 of family 11527 carried the mutation and felt asymptomatic 
from history although he was not available for phenotyping. Similar 
phenomenon of non-penetrance has been described in the individual #47 
of the original Irish family (Bowne et al., 2011). 
The individual III:3 of family 11527 carrying a mutation in the RPE65 gene 
expressed a phenotype of adult-onset vitelliform macular dystrophy. This 
has not been observed before. This phenotype is associated with 
mutations in the PRPH2 gene in 15-20% of cases (Felbor et al., 1997, 
Meunier et al., 2011). Recently, mutations in IMPG1 gene has been 
observed in some families with adult-onset vitelliform macular dystrophy 
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(Manes et al., 2013). It is established that genetic heterogeneity underlies 
this phenotype (Sohocki et al., 1997) and thus, we speculate that RPE65 
mutations could be responsible for at least some of these patients. 
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4 GENERAL DISCUSSION 
 
Retinal dystrophies are a group of widely-varied retinal pathologies which 
are linked by the common mechanism of inherited genetic defects. Among 
the sub-group of retinitis pigmentosa (RP), characterised by rod 
photoreceptor demise preceding the cone photoreceptor death, Mendelian 
modes of inheritance are the predominant routes of disease transmission. 
In general, autosomal dominant (ad) inheritance pattern contributes to 
about 30-40% of the disease load of RP (Hartong et al., 2006). This study 
concentrated on studying the inherited retinal dystrophies transmitted by 
the autosomal dominant route.  
Data was collected on phenotypes of retinitis pigmentosa caused by 
several different genes (Section 3.1) while the phenotypic variability was 
explored on disease caused by RP1, PRPF8, GUCY2D and RPE65 genes 
(Sections 3.2-3.5). Families with novel and de novo mutations were 
identified (Sections 3.1, 3.2 and 3.4) and new phenotype was associated 
with the RPE65 gene (Section 3.5). In several families with retinitis 
pigmentosa, asymptomatic patients were identified (Sections 3.2, 3.3 and 
3.5) suggesting the non-penetrance which had implications on the genetic 
counselling of these families.  
The theme underpinning this thesis is the demonstration of extreme 
phenotypic variability within disorders having the same molecular 
diagnosis. This has been demonstrated in each sections of the Result 
chapter with identification of non-penetrance and new phenotypes. At the 
time of writing of this thesis, no clear explanations have been put forward 
to explain this phenomenon. Several hypotheses can be examined. From 
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the geneticist’s point of view, there can be several molecular mechanisms 
which govern the expression of a phenotype. The genes, mutations in 
which cause the disease do not work in isolation. They function in synergy 
as well as against genes participant in similar or even the same pathway. 
This is evident in the splice factors which together form a spliceosome to 
effect the deletion of introns from the primary transcript. It is conceivable 
that splice factors influence the expression of each other governing the 
final phenotype. Similar explanations can be speculated regarding 
transcription factors and the genes forming the primary cilium. It is also 
possible that modifier genes are expressed which govern the final protein 
expression of several genes as a part of their function. Such genes may 
exist among the several thousand already discovered by Human Genome 
Project or may exist in the intronic and/or inter-genic regions of the human 
genome remaining to be identified. It has already been determined that 
differential expression of the wild-type allele results in an all-or-none 
disease expression in PRPF31 retinitis pigmentosa. It is feasible that similar 
differential expression of the wild-type alleles is one to the factors of the 
phenotypic variability.  
The role of the environment in determining the final disease phenotype 
has been suggested previously. It is well known that photopic damage of 
the posterior pole of the retina accelerates the disease process of retinal 
dystrophies. Lack of anti-oxidants in the diet and smoking show clear link 
with progression of the disease phenotype. Hence, it is feasible that 
environment plays a major role in the variability shown in the disease 
expression. It is likely that a single factor is not responsible for all the 
variability shown. It is probable that a combination of environmental and 
genetic influences shape the final disease outcome. 
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Currently, the molecular diagnosis of about 70% of the families with adRP 
can be determined in the known genes following a combination of several 
methods, some of which are expensive and time consuming (Daiger et al., 
2014). Section 3.1 showed the usage of one particular algorithm to try and 
elucidate the genetic causes of a large cohort of families with 63.8% 
accuracy. This method is considerably quicker and less expensive. This 
algorithm could be used as a screening tool to eliminate the commonly 
implicated genes so that resources can be concentrated on the families 
with no molecular diagnosis. One disadvantage of the method followed in 
this study is the inability to identify mutations in regions of the gene not 
considered as hot-spots. This has been shown to be the case in one family 
with PRPF8 mutation (Section 3.3). 
Detailed phenotyping on patients with RP1 retinitis pigmentosa helped in 
characterising the natural history of the disease. Although this was limited 
by the cross-sectional nature of the study, survival analysis was attempted 
to increase the plausibility of the conclusions drawn. This had direct impact 
on patient care as more informed advice could be given to the affected 
families in the clinic. 
Approach to identifying the molecular diagnosis in autosomal dominant 
disease is limited by the mono-allelic nature of the pathogenesis. The 
uncertainty on the causality of an amino acid substitution was partially 
answered in this study using bioinformatic techniques (Section 3.1). The 
true identification of a mutation can only be achieved using functional 
studies. One of the limitations of this study is that most of the missense 
changes identified have not been functionally assessed. This makes it 
uncertain although plausible to characterise the changes as true 
mutations. 
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Identification of the molecular diagnosis in an autosomal dominant family 
requires usage of linkage strategies even with the prevalence and 
widespread acceptance of next-generation sequencing. Although whole 
genome or whole exome sequencing is a significant advance over PCR 
based strategies, it is vitally important to identify the affected individuals 
in a pedigree underlying the importance of phenotyping. With the usage 
and relentless advances in imaging techniques, patients identified as 
hitherto unaffected may be discovered to carry mutations. As there is 
expansion of phenotypes associated with a single gene defect (Section 
3.5), new mechanisms of disease are being identified and need exploring. 
It is likely that in future, current phenotype-based nomenclature of the 
disease would have to be replaced by genotype-based description. 
Molecular diagnosis is rapidly becoming important not only into rare 
monogenetic disorders but also into disorders following non-Mendelian 
patterns of inheritance. There is a definite expansion of knowledge and 
interest into susceptibility factors for common disorders like age-related 
macular degeneration and diabetes. The gap between the laboratory and 
the clinic has become considerably narrow with increasing knowledge of 
the influence of genes in most chronic diseases.  
As we understand the pathogenesis of the disorders where molecular 
diagnosis play a major role either by being directly causative or by 
increasing susceptibility, opportunities for novel therapies like gene 
supplementation become available. Novel approaches to treating 
autosomal dominant conditions like repairing mRNA transcript of the 
defective allele or gene augmentation have been attempted with variable 
degrees of success (Berger et al., 2015, Lewin et al., 2014, Rossmiller et 
al., 2012). In this era of exciting new therapies, obtaining a definitive 
molecular diagnosis has become imperative. 
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Currently, there is a rapid advancement and consequent explosion in 
phenotyping, genotyping and functional analytical techniques. Thus, it is 
inevitable that clinical medicine of the future will be transformed by the 
influences of genetics and genomics. The holy grail of “genomic medicine” 
is achievable although there is a need of substantial amount of clinical and 
basic laboratory research.  
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5 APPENDIX 
 
Table 5-1: The list of genes screened and the mutations identified in our cohort. 
Gene Mutation Number of 
families 
Reference Mutation 
type 
RHO c.344C>T, p.Thr17Met 2 (Dryja et al., 1991) Missense 
 c.116T>G, p.Met39Arg 5 (Davies et al., 2012) Missense 
 c.119T>G, p.Leu40Arg 1 (al-Maghtheh et al., 1994) Missense 
 c.165C>A, p.Asn55Lys 3 (Ramon et al., 2014) Missense 
 c.173C>G, p.Thr58Arg 6 (Dryja et al., 1990a) Missense 
 c.202_213delCTGCGCACGCCT, p.Leu68_Pro71del 1 (Keen et al., 1991) In-frame 
deletion 
 c.266G>A, p.Gly89Asp 2 (Sung et al., 1991) Missense 
 c.316G>A, p.Gly106Arg 5 (Inglehearn et al., 1992) Missense 
 c.328T>C, p.Cys110Arg 1 (To et al., 2000) Missense 
 c.403C>T, p.Arg135Trp 2 (Sung et al., 1991) Missense 
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 c.511C>A, p.Pro171Thr 1 Novel Missense 
 c.512C>T, p.Pro171Leu 2 (Dryja et al., 1991) Missense 
 c.512C>G, p.Pro171Arg 1 Novel Missense 
 c.533A>G, p.Tyr178Cys 3 (Sung et al., 1991) Missense 
 c.541G>A, p.Glu181Lys 4 (Dryja et al., 1991) Missense 
 c.553T>C, p.Cys185Arg 1 (Liu et al., 2010) Missense 
 c.568G>A, p.Asp190Asn 3 (Dryja et al., 1991) Missense 
 c.632A>C, p.His211Pro 1 (Keen et al., 1991) Missense 
 c.763_765delATC, p.Ile256del 1 (Inglehearn et al., 1991) In-frame 
deletion 
 c.886A>G, p.Lys296Glu 3 (Keen et al., 1991) Missense 
 c.888G>C, p.Lys296Asn 2 (Sohocki et al., 2001) Missense 
 c.937-1 G>T 2 (Reig et al., 1996) Splice site 
mutation 
 c.1032G>A, p.Val345Met 2 (Dryja et al., 1991) Missense 
 c.1039C>T, p.Pro347Ser 1 (Dryja et al., 1990a) Missense 
 c.1040C>T, p.Pro347Leu 10 (Dryja et al., 1990b) Missense 
RP1 c.2017delA, p.Lys673Argfs*9 1 Novel Nonsense 
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 c.2029C>T, p.Arg677* 19 (Pierce et al., 1999, Sullivan et 
al., 1999) 
Nonsense 
 c.2035C>T, p.Gln679* 3 (Berson et al., 2001, Sullivan 
et al., 1999) 
Nonsense 
 c.2055T>A, p.Tyr685* 1 Novel Nonsense 
 c.2098G>T, p.Glu700* 3 (Bowne et al., 1999) Nonsense 
 c.2115delA, p.Gly706Valfs*7 1 (Gamundi et al., 2006) Nonsense 
 c.2143C>T, p.Gln715* 1 Novel Nonsense 
 c.2168_2181delGAGGGATACTTTGT or 
c.2172_2185delGATACTTTGTGAGG, 
p.Ile725Argfs*6 
11 (Payne et al., 2000) Nonsense 
 c.2205_2206insA, p.Thr736Asnfs*4 3 Novel Nonsense 
 c.2232C>A, p.Cys744* 1 (Payne et al., 2000) Nonsense 
 c.2285_2289delTAAAT, p.Leu762Tyrfs*17 2 (Payne et al., 2000) Nonsense 
 c.2596_2597delTT, p.Leu866Lysfs*7 8 Novel Nonsense 
 c.2607_2608insA, p.Arg872Thrfs*2 3 (Payne et al., 2000) Nonsense 
PRPF31 c.79G>T, p.Glu27* 1 (Waseem et al., 2007) Nonsense 
 c.202G>T, p.Glu68* 1 Novel Nonsense 
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 c.238+2T>C 1 Novel Splice site 
mutation 
 c.412C>A, p.Thr138Lys 1 (Martinez-Gimeno et al., 2003) Missense 
 c.528 -3 to -45 del 1 (Vithana et al., 2001) Splice site 
mutation 
 c.527+1 G>T 1 (Chakarova et al., 2006) Splice site 
mutation 
 c.528-1 G>A 1 (Waseem et al., 2007) Splice site 
mutation 
 c.527+3 A>G 7 (Vithana et al., 2001) Splice site 
mutation 
 c.529C>T, p.Gln177* 1 Novel Nonsense 
 c.580_581 dup 33bp, p.Glu183_Met193dup 1 (Vithana et al., 2001) In-frame 
insertion 
 c.584T>A, p.Leu195Pro 1 Novel Missense 
 c.646G>A, p.Ala216Pro 1 (Vithana et al., 2001) Missense 
 c.808delC, p.His270Thrfs*51 1 Novel Nonsense 
 c.877delC, p.Arg293Glyfs*28 1 Novel Nonsense 
Appendix 
214 
 
 c.973G>T, p.Glu325* 1 (Vithana et al., 2001) Nonsense 
 c.1087A>T, p.Lys363* 1 Novel Nonsense 
 c.1115_1125delGGAAGCAGGCC, 
p.Arg372Glnfs*99 
1 (Vithana et al., 2001) Nonsense 
 c.1146+2 T>C 1 Novel Splice site 
mutation 
 30 kb del 1 (Abu-Safieh et al., 2006) Nonsense 
 112 kb del 1 (Rose et al., 2011) Nonsense 
PRPH2 c.136C>T, p.Arg46* 1 (Meins et al., 1993) Nonsense 
 c.356_358delGCT, p.Cys119del 1 (Farrar et al., 1991) In-frame 
deletion 
 c.618_626delGGACGGCGT, p.Asp207_V209del 1 (Kalyanasundaram et al., 
2009) 
In-frame 
deletion 
 c.634A>G, p.Ser212Gly 1 (Farrar et al., 1992) Missense 
 c.646C>T, p.Pro216Ser 1 (Fishman et al., 1994) Missense 
 c.647C>T, p.Pro216Leu 1 (Kajiwara et al., 1991) Missense 
 c.653C>T, p.Ser218Leu 1 Novel Missense 
PRPF3 c.1482C>T, p.Thr494Met 3 (Chakarova et al., 2002) Missense 
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PRPF8 c.6353C>T, p.Ser2118Phe 1 (Towns et al., 2010) Missense 
 c.6926A>C, p.His2309Pro 2 (McKie et al., 2001) Missense 
 c.6928A>G, p.Arg2310Gly 1 (McKie et al., 2001) Missense 
 c.6930G>C, p.Arg2310Ser 2 (Towns et al., 2010) Missense 
 c.6942C>A, p.Phe2314Leu 1 (McKie et al., 2001) Missense 
 c.7000T>A, p.Tyr2334Asn 1 (Towns et al., 2010) Missense 
IMPDH1 c.676G>A, p.Asp226Asn 1 (Bowne et al., 2002) Missense 
 c.680T>C, p.Leu227Pro 1 (Wada et al., 2005a) Missense 
 c.713A>G, p.Lys238Arg 2 (Wada et al., 2005b) Missense 
 c.928A>C, p.Thr310Pro 1 Novel Missense 
 c.952T>G, p.Tyr318Asp 1 Novel Missense 
 c.968A>G, p.Lys323Arg 1 Novel Missense 
NR2E3 c.166G>A, p.Gly56Arg 2 (Coppieters et al., 2007) Missense 
 c.170A>G, p.Lys57Arg 1 Novel Missense 
NRL c.148T>A, p.Ser50Thr 2 (Bessant et al., 1999) Missense 
RP9 c.410A>T, p.His137Leu 3 (Keen et al., 2002) Missense 
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Table 5-2: Clinical features of affected adRP patients with RP1 mutations. Pt- Patient, FAF – Fundus autofluorescence, OCT 
– Optical Coherence Tomogram, CMO – Cystoid macular oedema, N/A – Not available, A/S - Asymptomatic 
Family Mutation Pt Onset Age at 
diagnosis 
(years) 
Follow 
up  
Visual 
acuity 
Fundus FAF Visual 
fields 
degree2 
OCT CMO 
MCL903 p.Lys673 
Argfs*9 
1929 34 
years 
35 33 years 6/18 
(OD), 
6/12 
(OS) 
Extensive 
intra-retinal 
pigmentation 
and atrophy 
Extensive hypo-
autofluorescence 
involving the 
macula 
 Thinning of the 
retina and 
absence of 
photoreceptor 
layer 
Absent 
MCL903 p.Lys673 
Argfs*9 
28375 50 
years 
50 3 years 6/5 
(OD), 
6/5 
(OS) 
Moderate 
intra-retinal 
pigmentation 
mainly 
nasally 
N/A  N/A Absent 
MCL903 p.Lys673 
Argfs*9 
28271  60 4 years 6/9 
(OD), 
6/9 
(OS) 
Moderate 
intra-retinal 
pigmentation 
Hyper-
autofluorescent 
ring 
7434.28, 
8465.13 
Normal 
photoreceptor 
layer within the 
hyper-
autofluorescent 
ring 
Absent 
MCL903 p.Lys673Ar
gfs*9 
28376  61 7 years 6/9 
(OD), 
6/9 
(OS) 
Moderate 
intra-retinal 
pigmentation 
N/A 154.11, 
30.52 
N/A Absent 
C18881 p.Arg677* 29289 55 
years 
70 1 year HM 
(OD), 
HM 
(OS) 
Extensive 
intra-retinal 
pigmentation 
and atrophy 
Patchy hypo-
autofluorescence 
involving the 
macula 
 Disrupted 
photoreceptor 
layer 
Absent 
CG16126 p.Arg677* 22992 23 
years 
25 Single 
visit 
6/6 
(OD), 
Little intra-
retinal 
pigmentation 
N/A  N/A Absent 
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6/5 
(OS) 
CG16126 p.Arg677* 22993  54 Single 
visit 
6/9 
(OD), 
6/12 
(OS) 
Very little 
intra-retinal 
pigmentation 
N/A 13419.52, 
13908.62 
N/A N/A 
CG16126 p.Arg677* 25967 A/S 50 Single 
visit 
6/9 
(OD), 
6/9 
(OS) 
Very little 
intra-retinal 
pigmentation 
Normal posterior 
pole 
 N/A Absent 
DB2879 p.Arg677* 28026 A/S 60 Single 
visit 
6/9 
(OD), 
6/12 
(OS) 
Very little 
intra-retinal 
pigmentation 
in the right 
eye 
unilaterally 
Normal left eye. 
Hyper-
autofluorescent 
ring in the right 
eye 
12865.28, 
16744.83 
Normal 
posterior pole 
both eyes. 
Peripheral 
photoreceptor 
layer disrupted 
right eye 
Absent 
DB2879 p.Arg677* 28029  61 Single 
visit 
6/5 
(OD), 
6/5 
(OS) 
Very little 
intra-retinal 
pigmentation 
Normal posterior 
pole 
11277.82, 
10806.15 
N/A Absent 
F17215 p.Arg677* 26394 A/S 34 1 year 6/5 
(OD), 
6/6 
(OS) 
Intra-retinal 
pigmentation 
in the nasal 
quadrant 
N/A  N/A Absent 
F1841 p.Arg677* 1276  72 5 years 6/24 
(OD), 
6/36 
(OS) 
Moderate 
intra-retinal 
pigmentation 
N/A  N/A Absent 
G3315 p.Arg677* 1381  52 7 years 6/6 
(OD), 
6/6 
(OS) 
Moderate 
intra-retinal 
pigmentation 
N/A  N/A Absent 
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and patchy 
atrophy 
M1048 p.Arg677* 1938 15 
years 
56 Single 
visit 
6/9 
(OD), 
6/12 
(OS) 
Moderate 
mid-
peripheral 
intra-retinal 
pigmentation 
N/A  N/A Absent 
PE3651 p.Arg677* 2305 42 
years 
57 17 years 6/9 
(OD), 
6/9 
(OS) 
Moderate 
intra-retinal 
pigmentation 
Small hyper-
autofluorescent 
ring 
 Normal 
photoreceptor 
layer within 
hyper-
autofluorescent 
ring 
Absent 
PE3651 p.Arg677* 18792  37 5 years 6/18 
(OD), 
6/18 
(OS) 
Little intra-
retinal 
pigmentation 
N/A  Normal 
laminations in 
posterior pole 
Present 
R18036 p.Arg677* 27892 15 
years 
42 Single 
visit 
6/9 
(OD), 
6/9 
(OS) 
Very little 
intra-retinal 
pigmentation 
Normal posterior 
pole 
 N/A Absent 
RC14 p.Arg677* 15050  70 6 years 6/12 
(OD), 
6/60 
(OS) 
Very little 
intra-retinal 
pigmentation
. Perifoveal 
atrophy 
Poor  Thin retina Absent 
RC14 p.Arg677* 1 47 
years 
30 34 years 6/12 
(OS) 
Moderate 
mid-
peripheral 
intra-retinal 
pigmentation 
N/A 182.08 N/A N/A 
RC14 p.Arg677* 2  50 11 years   N/A  N/A N/A 
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RC14 p.Arg677* 3 25 
years 
28 32 years 6/9 
(OD), 
6/12 
(OS) 
Moderate 
mid-
peripheral 
intra-retinal 
pigmentation 
N/A 26.39, 
21.24 
N/A N/A 
RC14 p.Arg677* 4  33 3 years   N/A  N/A N/A 
RC14 p.Arg677* 5  17 25 years   N/A  N/A N/A 
S1348 p.Arg677* 2733 28 
years 
37 23 years 6/12 
(OD), 
6/9 
(OS) 
Very little 
intra-retinal 
pigmentation 
N/A  N/A Absent 
T19413 p.Arg677* 30119  38 Single 
visit 
6/5 
(OD), 
6/5 
(OS) 
Little intra-
retinal 
pigmentation 
N/A  N/A Absent 
TW1890 p.Arg677* 2831 35 
years 
50 3 years 6/12 
(OD), 
6/12 
(OS) 
Very little 
intra-retinal 
pigmentation 
N/A  N/A Present 
TW1890 p.Arg677* 22949 A/S 23 1 year  Normal 
looking 
fundus 
N/A  N/A Absent 
TW1890 p.Arg677* 28971 31 
years 
30 1 year 6/6 
(OD), 
6/6 
(OS) 
Very little 
intra-retinal 
pigmentation 
in the infero-
nasal 
quadrant 
Normal posterior 
pole 
12332.6, 
13925.01 
Normal 
posterior pole 
Absent 
W16317 p.Arg677* 23421  41 8 years 6/5 
(OD), 
6/5 
(OS) 
Moderate 
intra-retinal 
pigmentation
, more 
nasally 
Small hyper-
autofluorescent 
ring 
 Normal 
photoreceptor 
layer within 
hyper-
Absent 
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autofluorescent 
ring 
W18260 p.Arg677* 28228 23 
years 
26 12 years 6/6 
(OD), 
6/6 
(OS) 
Moderate 
intra-retinal 
pigmentation 
N/A 262.71, 
295.83 
N/A Absent 
W18999 p.Arg677* 29473 45 
years 
46 2 years 6/6 
(OD), 
6/9 
(OS) 
Moderate 
intra-retinal 
pigmentation
, mainly 
infero-nasally 
Small hyper-
autofluorescent 
ring in the 
posterior pole. 
Hyper-
autofluorescent 
line outlining 
infero-nasal 
dystrophy 
 Normal 
photoreceptor 
layer within 
hyper-
autofluorescent 
ring 
Absent 
WB27 p.Arg677* 20911 A/S 55 8 years 6/6 
(OD), 
6/6 
(OS) 
Intra-retinal 
pigmentation 
limited to 
nasal 
quadrants 
Normal in 
posterior pole 
9195.79, 
10094.73 
Normal 
posterior pole 
Absent 
WB27 p.Arg677* 3078 39 
years 
44 28 years 6/18 
(OD), 
6/18 
(OS) 
Little intra-
retinal 
pigmentation 
N/A  N/A Absent 
WB27 p.Arg677* 28991 A/S 40 Single 
visit 
6/6 
(OD), 
6/5 
(OS) 
Very little 
intra-retinal 
pigmentation 
inferiorly 
Infero-nasal 
hyper-
autofluorescent 
line 
 Normal 
posterior pole 
Absent 
WB27 p.Arg677* 23370 A/S 36 Single 
visit 
6/6 
(OD), 
6/6 
(OS) 
Moderate 
intra-retinal 
pigmentation 
in the nasal 
sector 
N/A 12524.46, 
11308.8, 
15055.71, 
15084.78 
N/A Absent 
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B15890 p.Gln679* 22578  33 8 years 6/9 
(OD), 
6/6 
(OS) 
Very little 
intra-retinal 
pigmentation 
Normal posterior 
pole 
 Normal 
posterior pole 
Absent 
B3001 p.Gln679* 23877  26 3 years 6/5 
(OD), 
6/6 
(OS) 
Little intra-
retinal 
pigmentation 
Large hyper-
autofluorescent 
ring 
 N/A Absent 
M18163 p.Gln679* 28084  46 Single 
visit 
6/9 
(OD), 
6/9 
(OS) 
Little 
nummular 
intra-retinal 
pigmentation 
with patchy 
atrophy 
Small hyper-
autofluorescent 
 Normal 
photoreceptor 
layer within 
hyper-
autofluorescent 
ring 
Absent 
MF15448 p.Tyr685* 21798 26 
years 
56 9 years 6/12 
(OD), 
6/12 
(OS) 
No intra-
retinal 
pigmentation 
Hyper-
autofluorescent 
ring which later 
disappeared 
 Normal 
photoreceptor 
layer within the 
hyper-
autofluorescent 
ring, Macular 
oedema 
Present 
MF15448 p.Tyr685* 23977  35 1 year 6/5 
(OD), 
6/5 
(OS) 
No intra-
retinal 
pigmentation 
Normal posterior 
pole 
11869.88, 
12745.86 
Normal 
posterior pole 
Absent 
H16907 p.Glu700* 25890 45 
years 
69 5 years 6/12 
(OD), 
6/12 
(OS) 
Moderate 
intra-retinal 
pigmentation 
Small hyper-
autofluorescent 
ring 
 Normal 
photoreceptor 
layer within the 
ring 
Present 
SP45 p.Glu700* 2671 A/S 29 15 years 6/5 
(OD), 
6/5 
(OS) 
Very little 
intra-retinal 
pigmentation 
Small hyper-
autofluorescent 
ring 
46.9, 58.32 N/A Absent 
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SP45 p.Glu700* 2327 45 
years 
84 Single 
visit 
 Mild intra-
retinal 
pigmentation 
N/A  N/A N/A 
TA1154 p.Glu700* 10474  61 10 years 6/12 
(OD), 
6/12 
(OS) 
Moderate 
intra-retinal 
pigmentation 
and patchy 
atrophy 
Small hyper-
autofluorescent 
ring 
22, 31.66 Normal 
photoreceptor 
layer within the 
hyper-
autofluorescent 
ring 
Absent 
TA1154 p.Glu700* 14110  64 10 years 6/18 
(OD), 
6/12 
(OS) 
Moderate 
intra-retinal 
pigmentation 
and patchy 
atrophy 
Small hyper-
autofluorescent 
ring 
1300.68, 
1403.21 
Disrupted 
photoreceptor 
layer within the 
posterior pole 
Present 
M18228 p.Gly706Va
lfs*7 
28177 25 
years 
57 2 years 6/18 
(OD), 
6/18 
(OS) 
Extensive 
intra-retinal 
pigmentation 
Patchy hypo-
autofluorescence 
with small peri-
foveal area of 
retained 
autofluorescence 
 Normal 
photoreceptor 
layer peri-
foveally 
Absent 
H18297 p.Gln715* 28282 56 
years 
73 10 years 6/9 
(OD), 
6/18 
(OS) 
Moderate 
intra-retinal 
pigmentation 
N/A 354.14, 
57.93, 
218.3, 
161.2 
N/A Absent 
B2481 p.Ile725Ar
gfs*6 
21051 15 
years 
66 10 years 6/30 
(OD), 
6/38 
(OS) 
Moderate 
intra-retinal 
pigmentation 
Normal posterior 
pole 
1742.64, 
3237.61 
N/A Present 
BO675 p.Ile725Ar
gfs*6 
756  70 1 year 6/6 
(OD), 
6/12 
(OS) 
Moderate 
intra-retinal 
pigmentation 
N/A  N/A Absent 
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BO675 p.Ile725Ar
gfs*6 
29588 51 
years 
53 Single 
visit 
6/12 
(OD), 
6/9 
(OS) 
Moderate 
intra-retinal 
pigmentation 
Hyper-
autofluorescent 
ring, more 
prominent in the 
left eye 
 Photoreceptor 
layer preserved 
within the 
hyper-
autofluorescent 
ring 
Present 
C17534 p.Ile725Ar
gfs*6 
26917 30 
years 
45 3 years 6/6 
(OD), 
6/9 
(OS) 
Very little 
intra-retinal 
pigmentation 
Hyper-
autofluorescent 
line in the 
peripheral macula 
 N/A Absent 
C932 p.Ile725Ar
gfs*6 
8694 26 
years 
28 33 years 3/60 
(OD), 
HM 
(OS) 
Very little 
intra-retinal 
pigmentation 
Extensive hypo-
autofluorescence 
involving the 
macula 
3247.52, 
1166.52 
Disruption of 
the 
photoreceptor 
layer in the 
posterior pole 
Absent 
C932 p.Ile725Ar
gfs*6 
27438  31 3 years 6/24 
(OD), 
6/18 
(OS) 
Little intra-
retinal 
pigmentation 
Small hyper-
autofluorescent 
ring 
 Normal 
photoreceptor 
layer within 
hyper-
autofluorescent 
ring 
Present 
CS134 p.Ile725Ar
gfs*6 
22551 25 
years 
61 8 years 6/18 
(OD), 
6/36 
(OS) 
Moderate 
mid-
peripheral 
intra-retinal 
pigmentation 
N/A  N/A Present 
CS134 p.Ile725Ar
gfs*6 
910 22 
years 
25 25 years 6/6 
(OD), 
6/18 
(OS) 
Moderate 
mid-
peripheral 
intra-retinal 
pigmentation 
Small hyper-
autofluorescent 
ring 
 Normal 
photoreceptor 
layer within 
hyper-
autofluorescent 
ring 
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CS134 p.Ile725Ar
gfs*6 
981 20 
years 
28 18 years 6/7.5 
(OD), 
3/38 
(OS) 
Moderate 
mid-
peripheral 
intra-retinal 
pigmentation
. Left 
macular 
atrophy 
Small hyper-
autofluorescent 
ring right eye. 
Macular hypo-
autofluorescence 
left eye 
 Normal 
photoreceptor 
layer within 
hyper-
autofluorescent 
ring right eye 
Absent 
CS134 p.Ile725Ar
gfs*6 
2569  70 7 years 6/18 
(OD), 
6/18 
(OS) 
Moderate 
mid-
peripheral 
intra-retinal 
pigmentation 
N/A 2067.57, 
1275.59 
Lamellar hole 
left eye. Normal 
photoreceptor 
layer in peri-
foveal region 
Absent 
H17866 p.Ile725Ar
gfs*6 
27628 32 
years 
33 3 years 6/5 
(OD), 
6/5 
(OS) 
Normal 
central 
macular 
Normal posterior 
pole 
 N/A Absent 
PKC3650 p.Ile725Ar
gfs*6 
2322 A/S 34 17 years 6/6 
(OD), 
6/6 
(OS) 
Moderate 
intra-retinal 
pigmentation 
infero-nasally 
N/A 2051.45, 
2670.86 
N/A Absent 
PKC3650 p.Ile725Ar
gfs*6 
27551 35 
years 
38 18 years 6/7.5 
(OD), 
1/60 
(OS) 
Very little 
intra-retinal 
pigmentation 
Extensive hypo-
autofluorescence 
involving the 
macula 
 Disruption of 
the 
photoreceptor 
layer in the 
posterior pole 
Absent 
PKC3650 p.Ile725Ar
gfs*6 
1 45 
years 
47 3 years 6/9 
(OD), 
6/9 
(OS) 
Moderate 
intra-retinal 
pigmentation 
N/A  N/A Absent 
PKC3650 p.Ile725Ar
gfs*6 
15236 31 
years 
62 4 years 6/6 
(OD), 
Little intra-
retinal 
pigmentation 
N/A  N/A Absent 
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6/6 
(OS) 
with marked 
pigment 
epithelial 
atrophy 
S17697 p.Ile725Ar
gfs*6 
27228 50 
years 
51 4 years 6/6 
(OD), 
6/6 
(OS) 
No intra-
retinal 
pigmentation 
N/A 7912.45, 
7458.12 
N/A Absent 
S4315 p.Ile725Ar
gfs*6 
27512 38 
years 
52 4 years 6/6 
(OD), 
6/6 
(OS) 
Little intra-
retinal 
pigmentation 
with atrophic 
patches 
Small hyper-
autofluorescent 
ring 
 Normal 
photoreceptor 
layer within the 
hyper-
autofluorescent 
ring. 
Absent 
S4315 p.Ile725Ar
gfs*6 
28284 29 
years 
27 4 years 6/9 
(OD), 
6/6 
(OS) 
No intra-
retinal 
pigmentation 
Hyper-
autofluorescent 
line in the 
temporal 
periphery of left 
eye 
4468.21, 
3472.22 
N/A Absent 
T1560 p.Ile725Ar
gfs*6 
2869 34 
years 
49 8 years 6/18 
(OD), 
6/12 
(OS) 
Moderate 
intra-retinal 
pigmentation 
N/A  N/A Absent 
W139 p.Ile725Ar
gfs*6 
2923  66 8 years 6/12 
(OD), 
1/60 
(OS) 
Little mid-
peripheral 
intra-retinal 
pigmentation
. Extensive 
pigment 
epithelial 
atrophy 
N/A  Disruption of 
the lamellar 
structure in the 
periphery. 
Interrupted 
photoreceptor 
layer in fovea 
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P18453 p.Thr736As
nfs*4 
28513 A/S 26 2 years 6/5 
(OD), 
6/5 
(OS) 
Very little 
intra-retinal 
pigmentation 
Hyper-
autofluorescent 
line outlining 
infero-nasal 
dystrophy 
 Normal 
posterior pole 
Absent 
P18591 p.Thr736As
nfs*4 
28719 A/S 40 1 year 6/9 
(OD), 
6/9 
(OS) 
Little intra-
retinal 
pigmentation 
limited to 
infero-nasal 
quadrant 
Normal 
autofluorescence 
except infero-
nasally 
 Normal 
posterior pole 
Absent 
P128 p.Cys744* 10002 15 
years 
57 3 years 6/9 
(OD), 
6/9 
(OS) 
Extensive 
intra-retinal 
pigmentation 
N/A  N/A N/A 
P128 p.Cys744* 1 27 
years 
27 Single 
visit 
  N/A  N/A N/A 
D3543 p.Leu762T
yrfs*17 
15750 26 
years 
54 6 years 6/60 
(OD), 
HM 
(OS) 
Moderate 
intra-retinal 
pigmentation 
Extensive hypo-
autofluorescence 
involving the 
macula 
 Disruption of 
the 
photoreceptor 
layer 
Present 
D3543 p.Leu762T
yrfs*17 
1 35 
years 
35 2 years  No intra-
retinal 
pigmentation 
Normal posterior 
pole 
13888.22, 
15689.76 
N/A Absent 
LP16218 p.Leu762T
yrfs*17 
23241 72 
years 
73 3 years 6/9 
(OD), 
6/18 
(OS) 
Moderate 
mid-
peripheral 
intra-retinal 
pigmentation 
N/A  N/A Absent 
LP16218 p.Leu762T
yrfs*17 
23240  47 8 years 6/12 
(OD), 
6/12 
(OS) 
Very little 
intra-retinal 
pigmentation 
Broad hyper-
autofluorescent 
ring 
11602.01, 
12753.52 
Retention of 
photoreceptor 
layer within the 
hyper-
Present 
Appendix 
227 
 
autofluorescent 
ring 
GW3902 p.Leu866L
ysfs*7 
10567 50 
years 
65 1 year 6/18 
(OD), 
6/9 
(OS) 
Extensive 
intra-retinal 
pigmentation 
Small hyper-
autofluorescent 
ring 
 N/A Absent 
GW3902 p.Leu866L
ysfs*7 
23752 30 
years 
31 6 years 6/9 
(OD), 
6/9 
(OS) 
Little intra-
retinal 
pigmentation 
Normal posterior 
pole 
 N/A Absent 
JC15253 p.Leu866L
ysfs*7 
21698  47 7 years 6/5 
(OD), 
6/6 
(OS) 
Little intra-
retinal 
pigmentation 
infero-nasally 
Normal posterior 
pole 
 N/A Absent 
JC15253 p.Leu866L
ysfs*7 
22067  74 Single 
visit 
6/6 
(OD), 
6/6 
(OS) 
Little intra-
retinal 
pigmentation 
infero-nasally 
N/A  N/A Absent 
L5231 p.Leu866L
ysfs*7 
20978 40 
years 
81 9 years HM 
(OD), 
HM 
(OS) 
Extensive 
intra-retinal 
pigmentation 
and atrophy 
N/A  N/A Absent 
N3837 p.Leu866L
ysfs*7 
2196  35 16 years 6/36 
(OD), 
6/12 
(OS) 
Moderate 
intra-retinal 
pigmentation 
Centrally 
preserved 
autofluorescence 
 Peripheral 
disruption of 
layers 
Present 
N3837 p.Leu866L
ysfs*7 
2195 50 
years 
65 Single 
visit 
6/9 
(OD), 
6/9 
(OS) 
Little intra-
retinal 
pigmentation 
N/A  N/A Absent 
R15153 p.Leu866L
ysfs*7 
21538  56 6 years 6/18 
(OD), 
Moderate 
intra-retinal 
pigmentation 
Small hyper-
autofluorescent 
ring 
1791.18, 
1372.1 
N/A Absent 
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6/9 
(OS) 
RK4589 p.Leu866L
ysfs*7 
10106  65 4 years 6/36 
(OD), 
6/24 
(OS) 
Extensive 
intra-retinal 
pigmentation 
and atrophy 
Patchy hypo- 
autofluorescence 
in the posterior 
pole 
 Disruption of 
the laminations 
and 
photoreceptor 
layer 
Absent 
RK4589 p.Leu866L
ysfs*7 
28733 A/S 36 3 years 6/5 
(OD), 
6/5 
(OS) 
Little intra-
retinal 
pigmentation 
in the nasal 
quadrant 
Hyper-
autofluorescent 
line outlining 
nasal dystrophy 
 Normal in 
posterior pole 
Absent 
RK4589 p.Leu866L
ysfs*7 
28849 A/S 28 3 years 6/5 
(OD), 
6/5 
(OS) 
Intra-retinal 
pigmentation 
in the nasal 
quadrant 
Normal posterior 
pole 
 N/A Absent 
RK4589 p.Leu866L
ysfs*7 
1 A/S 37 Single 
visit 
6/6 
(OD), 
6/6 
(OS) 
Intra-retinal 
pigmentation 
in the infero-
nasal 
quadrants 
Normal posterior 
pole 
 Normal 
posterior pole 
Absent 
SBM754 p.Leu866L
ysfs*7 
2677 50 
years 
50 14 years 6/12 
(OD), 
6/12 
(OS) 
Little mid-
peripheral 
intra-retinal 
pigmentation 
Distinct hyper-
autofluorescent 
ring 
 Normal 
laminations and 
IS/OS junction 
within the ring 
Absent 
SBM754 p.Leu866L
ysfs*7 
28378 32 
years 
63 1 year 6/9 
(OD), 
6/9 
(OS) 
Moderate 
mid-
peripheral 
intra-retinal 
pigmentation 
N/A  Thin and 
without outer 
retinal 
laminations in 
periphery 
Present 
SBM754 p.Leu866L
ysfs*7 
28379 A/S 34 1 year 6/5 
(OD), 
No 
pigmentation 
N/A  Normal Absent 
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6/5 
(OS) 
SBM754 p.Leu866L
ysfs*7 
1 22 
years 
51 Single 
visit 
6/9 
(OD), 
6/12 
(OS) 
Very little 
intra-retinal 
pigmentation
. Peripheral 
atrophy 
Small hyper-
autofluorescent 
ring 
 Normal 
laminations 
within the ring, 
thinning outside 
Absent 
SBM754 p.Leu866L
ysfs*7 
2  52 Single 
visit 
 No 
pigmentation 
Normal in the 
posterior pole 
 Normal in the 
posterior pole 
Absent 
SBM754 p.Leu866L
ysfs*7 
3 A/S 61 Single 
visit 
6/5 
(OD), 
6/5 
(OS) 
Very little 
intra-retinal 
pigmentation 
Hyper-
autofluorescent 
line inferiorly 
 Normal in the 
posterior pole 
Absent 
B1438 p.Arg872T
hrfs*2 
679  66 1 year 6/12 
(OD), 
6/12 
(OS) 
Moderate 
intra-retinal 
pigmentation 
N/A  N/A Present 
K16588 p.Arg872T
hrfs*2 
23911 39 
years 
42 10 years 6/12 
(OD), 
6/18 
(OS) 
Very little 
intra-retinal 
pigmentation 
Broad hyper-
autofluorescent 
ring 
4604.58, 
4038.3 
Normal 
photoreceptor 
layer within 
hyper-
autofluorescent 
ring 
Present 
R4301 p.Arg872T
hrfs*2 
24544  58 8 years 6/24 
(OD), 
6/18 
(OS) 
Little intra-
retinal 
pigmentation
, more in 
nasal 
quadrants 
Small hyper-
autofluorescent 
more evident in 
left eye 
 Disrupted 
photoreceptor 
layer in right 
eye. Normal 
photoreceptor 
layer within 
hyper-
autofluorescent 
ring in left eye 
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TW3662 p.Arg872T
hrfs2 
2812 28 
years 
28 17 years 6/5 
(OD), 
6/5 
(OS) 
Moderate 
intra-retinal 
pigmentation 
infero-nasally 
Small hyper-
autofluorescent 
ring 
 Normal 
photoreceptor 
layer within 
hyper-
autofluorescent 
ring 
Absent 
TW3662 p.Arg872T
hrfs*2 
2933 A/S 52 Single 
visit 
6/6 
(OD), 
6/6 
(OS) 
Intra-retinal 
pigmentation 
in infero-
nasal sector 
N/A 12425.6, 
13003.3 
N/A N/A 
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